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Summary 
Growth hormone (GH) is the major regulator of postnatal somatic growth and 
exhibits profound effects on cell growth, differentiation and metabolism. GH 
predominantly exerts its functions through stimulation of multiple signaling pathways 
leading to activation of gene transcription. GH-stimulated activation of signal 
transducers and activators of transcription (Stats), mitogen activated protein (MAP) 
kinase and phosphatidylinositol 3 kinase (PI3K) cascades have been shown to 
regulate the transcription of GH-responsive genes. The small GTPase Ras is the major 
regulator for GH stimulated activation of p44/42 MAP kinase and subsequent Elk-1 
mediated transcription. The Ras superfamily of small GTPases exhibit diverse 
functions and have been regarded as important mediators in cell signaling. The aim of 
this project was to investigate the role of small GTPases Rap1 and RhoA in GH signal 
transduction. 
Rap1, a close relative of Ras, shares common effectors with Ras and exhibits 
an antagonistic effect on Ras activated p44/42 MAP kinase activity. In the first study, 
we demonstrated that GH stimulated the activation of Rap1 and Rap2 in NIH-3T3 
cells. Full activation of Rap1 and Rap2 by GH required the combined activity of both 
JAK2 and c-Src kinases. GH stimulated tyrosine phosphorylation of C3G, a Rap1 
specific GEF, which again required the combined activity of JAK2 and c-Src. The 
tyrosine residue 504 of C3G was the target of phosphorylation and a CrkII-C3G 
pathway was required for GH stimulated Rap activation. Activated Rap1 inhibited GH 
stimulated activation of RalA and subsequent p44/42 MAP kinase activity and Elk-1 
mediated transcription which were negatively regulated by CrkII through Rap1. We 
also demonstrated that C3G-Rap1 mediated CrkII enhancement of GH stimulated 
   viii
JNK/SAPK activity. Therefore a linear JAK2 independent pathway was identified 
switching GH stimulated p44/42 MAP kinase and JNK/SAPK activities. 
We also demonstrated that GH stimulated the activation of another small 
GTPase RhoA and its substrate, serine/threonine kinase ROCK, in NIH-3T3 cells. GH 
stimulated activation of RhoA required JAK2 dependent dissociation of RhoA from 
its negative regulator p190RhoGAP. Although RhoA was reported to regulate p44/42 
MAP kinase activity, it did not affect GH stimulated JAK2 tyrosine phosphorylation 
or p44/42 MAP kinase activity. However, RhoA and ROCK activity were required for 
GH stimulated Stat5 mediated transcription. GH stimulated RhoA activity was not 
required for the initial activation and DNA binding of Stat5 or degradation of Stat5 
molecules. Instead, RhoA dependent enhancement of GH stimulated Stat5 mediated 
transcription was due to repression of the recruitment of HDAC6 by transcription 
cofactor p300. The results also demonstrated that RhoA was the pivot for PKA 
inhibition of GH stimulated Stat5 mediated transcription as a consequence of 
inactivation of RhoA through PKA induced phosphorylation on serine residue 188.  
Therefore, the small GTPases Rap1 and RhoA are two important regulators for 
GH stimulated signal transduction pathways leading to activation of gene 
transcription. Combined with the previous demonstration of GH stimulated activation 
of Ras, Ral and Rac, the pivotal role of Ras-related small GTPases in GH signaling 
has been established.   
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Growth hormone (GH) is a peptide hormone secreted from the pituitary 
gland under the control of the hypothalamus. It belongs to a large family of 
evolutionarily conserved hormones including prolactin and placental lactogens 
(Kopchick and Andry, 2000). GH is the primary regulator of postnatal somatic growth 
and metabolism (Herrington and Carter-Su, 2001). GH acts as an autocrine and 
paracrine growth factor to regulate the proliferation (Baixeras et al., 2001; Kaulsay et 
al., 1999; Nielsen et al., 1999), apoptosis (Baixeras et al., 2001), differentiation 
(Hansen et al., 1998; Nielsen et al., 1999; Shang and Waters, 2003) and chemotaxis 
(Lal et al., 2000; Ohlsson et al., 1998) in various cell types. GH exerts its cellular 
effects through binding to its specific membrane-bound receptor termed as growth 
hormone receptor (GHR), followed by initiation of the activation of sequential 
signaling molecules and transcription factors, leading to the transcription of 
corresponding genes. In addition to regulation of gene transcription, GH also 
participates in the regulation of cytoskeleton reorganization, Ca2+ influx and glucose 
transport (Goh et al., 1997; Gaur et al., 1996; Yokota et al., 1998).  
1.1 The growth hormone molecule 
1.1.1 Growth hormone gene and protein structure 
In human, growth hormone is expressed in the pituitary by the hGH-N gene 
that is part of a gene cluster composed of five structurally and functionally related 




long arm of human chromosome 17 at bands q22-24 (Miller and Eberhardt, 1983) and 
is arranged from 5' to 3' as hGH-N (N for normal), hPL-1 (also known as hCS-L, L 
for like), hPL-2 (also known as hCS-A), hGH-V (V for variant) and hPL-3 (also 
known as hCS-B), respectively (Okada and Kopchick, 2001; Lewis et al., 2000). 
These genes share more than 92 % identity in the coding and flanking sequences 
(Miller and Eberhardt, 1983). 
 
 
Fig.1.1 Schematic representation of the human GH gene cluster The five genes 
comprising approximately 8 kb of structural sequences are spread over 50 kb of DNA 






The proximal promoter of the hGH-N gene, which is 500 bp in length, 
contains the TATA box and two bindings sites for the pituitary-specific transcription 
factor (Pit-1) GHF-1 (Karin et al., 1990). Pit-1 plays a major role in the pituitary 
specific expression of the hGH-N gene (Karin et al., 1990). In addition to mediating 
tissue specific expression, this promoter regulates transcription in response to 
hormonal signals through the cis-acting elements (Bodner et al., 1988). The remote 
sequences of hGH-N promoter, which are 15 kb upstream of the transcription 
initiation site, are also required for efficient gene expression (Edens and Talamantes, 
1998).  
The hGH-N gene is expressed in the pituitary gland as two isoforms of 
product, 22 kDa and 20 kDa hGH, generated by alternate splicing (Kopchick and 
Andry, 2000; Lewis et al., 2000). The 22 kDa hGH-N is the predominant form and its 
transcript comprises 90 % of pituitary gland mRNA (Lewis et al., 1994). The 20 kDa 
hGH-N is produced by deletion of amino acid residues 32-46 and constitutes up to 15 
% of secreted GH in human (Lewis et al., 2000). There also exists a 17 kDa hGH-N in 
circulation which exhibits the diabetogenic action (Sinha and Jacobsen, 1994). The 
mature 22 kDa isoform of hGH-N is a 191 amino acid polypeptide and also the major 
form of circulating hGH (85 %) (Kopchick and Andry, 2000). The half-life of hGH is 
approximately 25 minutes (Zeisel et al., 1992; Li et al., 2001). The three-dimensional 
structure of hGH has been determined. It contains four α-helices arranged in a 




bridges at four cystine residues (de Vos et al., 1992). The cystine residues form two 
loops with different length within GH molecule and the larger one is required for GH 
activity (Kopchick and Andry, 2000).  
The nucleotide and amino acid sequence of GH from several species has 
been determined (Kopchick and Andry, 2000). The nucleotide sequence identity 
among human, rat and bovine GH is approximately 75-77 %. The amino acid 
sequence of bovine GH shares higher identity with that of ovine GH (99 %) than hGH 
(75 %). Rat and mouse GH exhibit 95 % and 92 % similarity in amino acid sequence, 
respectively, to that of ruminants (Kopchick and Andry, 2000). Among the studied 
species, only primate GH binds to the hGH receptor (Souza et al., 1995). Under 
certain conditions hGH also binds and activates the PRL receptor (Fuh and Wells, 
1995). 
1.1.2 Regulation of growth hormone synthesis and secretion 
GH is produced by somatotrophs located in the anterior pituitary gland (Le 
Roith et al., 2001). GH is also expressed in the central nervous system (Gossard et al., 
1987), bone marrow and thymus (Binder et al., 1994), mammary gland (Selman et al., 
1994; Mertani et al., 2001), gonads from both sexes (Izadyar et al., 1999; Untergasser 





The physiological synthesis and secretion of GH from the anterior pituitary 
gland are controlled mainly by two hypothalamic neuropeptides, GH releasing 
hormone (GHRH) and somatostatin (SRIF) (Muller et al., 1999). GHRH produced 
from the hypothalamus binds to and activates a specific GHRH receptor which is a 
G-protein coupled receptor on the somatotrophs and increases the level of 
intracellular cAMP, which in turn increases the concentration of the pituitary specific 
factor, Pit-1 (Shim and Cohen, 1999; Sekkali et al., 1999).  Pit-1 belongs to POU 
homeodomain family of transcription factors and binds to multiple binding sites in the 
proximal promoter region of the hGH-N gene to stimulate transcription (Shewchuk et 
al., 1999). It has been reported that mutations in the Pit-1 gene are clinically 
associated with severe deficiencies of hGH and hypothyroidism (Pfaffle et al., 1999). 
GHRH also increases intracellular Ca2+, which in turn stimulates the release of GH 
(Morishita et al., 2003). Hypothalamic derived somatostatin inhibits GH release 
through reduction of cAMP concentration and/or hyperpolarization of the cells via 
SRIF receptors (Morishita et al., 2003; Gaylinn et al., 1999). It has recently 
demonstrated that the effect of both GHRH and SRIF on GH gene transcription is 
mediated through pertussis toxin-sensitive G protein (Morishita et al., 2003).   
GH releasing peptides (GHRPs) is a class of synthetic molecules that can 
stimulate GH release via stimulation of the GH secretagogue receptor (GHS-R), a 
seven-transmembrane G-protein coupled receptor expressed in the pituitary (Howard 




from stomach extracts, is the endogenous ligand that binds and activates the GHS-R 
(Kojima et al., 1999). Another ligand for GHS-R is des-Gln14-Ghrelin that is formed 
by alternative splicing of the Ghrelin gene and also promotes GH release (Kojima et 
al., 1999).  
GH release is also regulated by free fatty acid, leptin and neuropeptide Y 
(Smith et al., 1996; Howard et al., 1996; Butler and Le Roith, 2001). The direct action 
of free fatty acid on the pituitary is to inhibit GH release and is postulated to form a 
feedback loop since GH stimulates lipid mobilization (Butler and Le Roith, 2001). In 
rodents, leptin stimulates GH production by regulating GHRH and somatostatin 
activity (Vuagnat et al., 1998; Carro et al., 1997; Tannenbaum et al., 1998). It has 
also been suggested that the effect of leptin on GH secretion may be achieved through 
inhibition of neuropeptide Y expression by leptin (Chan et al., 1996). GH release is 
also regulated by behaviors. It has been reported that stress, sleep and exercise can 
elevate GH level via stimulation of GHRH production (Kopchick and Andry, 2000). 
1.2 Growth hormone receptor and growth hormone binding protein (GHBP) 
GH exerts cellular effects through binding to the transmembrane GH 
receptor (GHR) (Fig. 1.2), which is present on the surface of most cells (Kelly et al., 
1993). GHR was the first identified member of type I cytokine receptor superfamily 
which includes prolactin (PRL) receptor, erythropoietin (EPO) receptor, 




(GM-CSF) receptor, leptin receptor, leukemia inhibitor factor (LIF) receptor, ciliary 
neurotrophic factor receptor, as well as several of the interleukin (IL-2-7, IL-9, IL-11, 
IL-12 and IL-18) receptors (Carter-Su et al., 1996). Type I cytokine receptors possess 
the following characteristics: 1) a single polypeptide chain with one putative 
membrane-spanning domain, 2) limited amino acid homology (14-44 %) in two 
tandem fibronectin III-like region spanning approximately 210 amino acids in the 
extracellular domain, 3) a conserved pairs of cysteine residues in the extracellular 
domain and a conserved tryptophan residue adjacent to the second cysteine in the 
N-terminal fibronectin domain, 4) a WSXWS-like motif in the C-terminal fibronectin 
domain (YXXFS in the mammalian GHR), 5) absence of a canonical tyrosine kinase 
consensus sequence and 6) a proline-rich domain named Box 1 and a 
hydrophobic/acidic domain referred to as Box 2 in the intracellular domain (Zhu et 
al., 2001). Box 1 composed of 8 residues is essential for the association of GHR with 
JAK2 and is critical for most GH stimulated cellular effects (Frank et al., 1994), while 
Box 2 is less well defined. Box 2 consists of approximately 15 residues and is located 
30 residues distal to Box 1 (Carter-Su et al., 1996). Deletion or mutation of these 
boxes abrogates JAK2 activation and subsequent proliferative signaling (Ihle, 1995; 
Carter-Su et al., 1996).  
Expression of the GHR has been observed in both differentiated and 
non-differentiated cells in the gastrointestinal tract, reproductive systems, 




systems, central nervous system, the integument, renal and urinary systems and the 
endocrine system (Edens and Talamantes, 1998; Lobie et al., 2000). The level of 
GHR mRNA is regulated by hormones (including GH itself) and nutrition factors 
(Schwartzbauer and Menon, 1998).  
GHR is modified post-translationally by ubiquitinylation or glycosylation. 
GHR contains 19 potential ubiquitinylation sites and polyubiquitinylation of GHR is 
increased upon GH binding (Strous et al., 1996). The short half-life of GHR is 
probably due to ubiquitinylation that is known to target proteins for degradation (van 
Kerkhof and Strous, 2001). GHR has a predicted molecular weight of 70 kDa, 
however, the observed molecular weight in SDS-PAGE is 110-120 kDa (Leung et al., 
1987). This discrepancy can be largely attributed to N-linked glycosylation at the five 


















Fig. 1.2 Schematic structure of the GH receptor The regions of the GHR important 
for signal transduction. Potential N-linked glycosylation sites (N) and extracellular 
cysteines (C) with three pairs of disulfide bonds are indicated. Ten intracellular 
tyrosine (Y) residues important in rat GHR are shown. This figure has been modified 
































Growth hormone binding protein (GHBP) comprising the extracellular 
ligand-binding domain of GHR is generated by two separate mechanisms dependent 
of the species: proteolytic shedding in human and rabbits; alternative splicing of the 
GHR mRNA in rat and mice (Baumann, 2001; Wang et al., 2002). It has also been 
reported that in primates, both alternate splicing and proteolysis are used to generate 
GHBP (Martini et al., 1997). Up to 60 % of circulating GH is bound to the GHBP and 
the GHBP modulates GH action either positively or negatively. It can inhibit GHR 
signaling through competition for ligand or formation of unproductive GHR/GHBP 
dimer (Mannor et al., 1991; Ross et al., 1997). In vivo, GHBP can also promote the 
effects of GH through prolongation of the half-life of GH in the serum by decreasing 
the rate of clearance and subsequent degradation (Clark et al., 1996). GHBP is also 
located in the nucleus and the nuclear localized GHBP acts as a potent enhancer of 
Stat5 mediated transcription stimulated by GH, prolactin and erythropoietin (Graichen 
et al., 2003).  
1.3 Biological effects of growth hormone 
GH exhibits pleiotropic effects on multiple organs and systems. The 
predominant phenotypic function of GH is to promote postnatal longitudinal bone 
growth (Martinez et al., 1996; Kelly et al., 2001). This is achieved through direct 
stimulation of prechondrocytes in the growth plate by GH followed by a clonal 




been observed that hypersecretion of GH leads to giantism and acromegaly in adults 
while hyposecretion of GH results in dwarfism (Colao et al., 1997). Furthermore, GH 
deficient children grow taller after treatment with GH (Blethen et al., 1997).  
GH has been demonstrated to exert a mitogenic effect on various cells. It 
can stimulate proliferation of insulinoma cells (Friedrichsen et al., 2001), 
chondrocytes (Siebler et al., 2001), UMR 106 osteoblasts (Morales et al., 2004) and 
several GHR cDNA transfected cell lines (Colosi et al., 1993; Kaulsay et al., 1999). 
GH also regulates the differentiation of adipocytes, either positively in established cell 
lines or negatively in the primary cell cultures (Richter et al., 2003; Shang and 
Waters, 2003).  
GH is also a key regulator of the lipid, carbohydrate, nitrogen and mineral 
metabolism (Kopchick and Andry, 2000). In mature adipocytes, GH reduces body fat 
by increasing the hydrolysis of triglycerides and preventing re-esterification of free 
fatty acid, which is termed as lipolytic effect of GH (Okada and Kopchick, 2001). GH 
also increases the lean muscle mass through acceleration of amino acid uptake and 
nitrogen retention (Butler and Le Roith, 2001). GH exhibits an early insulin-like 
effect and a late insulin antagonistic effect on carbohydrate metabolism. The 
insulin-like effect involves lipogenesis and elevated glucose conversion into 
glycogen, while the insulin antagonistic effect results in lipolysis, hyperglycemia and 




GH is also implicated in the development of mammary gland and lactation 
(Walden et al., 1998; Kelly et al., 2002). It is essential for normal puberty mammary 
development and an intact pituitary gland plays an important role for mammary 
development in rats (Ruan and Kleinberg, 1999; Walden et al., 1998). It has also been 
demonstrated that GH has growth-promoting effect on human mammary cancer cells 
in vitro (Kaulsay et al., 1999). GH is also required for sexual differentiation and 
pubertal maturation (Sharara and Giudice, 1997; Kelly et al., 2001).  
In human, GHR is widely distributed throughout the central nervous system 
(CNS) (Lobie et al., 1993). Circulating GH can pass through the blood-brain barrier to 
exert its functions; GH can also be produced in the brain and thus acts via 
autocrine/paracrine mechanisms (Schneider et al., 2003). GH regulates the size, 
morphology and cognitive function of the CNS during development and has 
protective properties in dementia and in traumatic or ischemic injury of the CNS 
(Lobie et al., 2000; Schneider et al., 2003). GH is important for mood improvement 
and well-being (Schneider et al., 2003). It can also increase rapid eye movement 
(REM) sleep with a concomitant decrease in slow wave sleep (SWS) (Lobie et al., 
2000). 
GH also affects functions of immune system through regulation of the 




modulation of the activity of neutrophils, macrophages and natural killer cells 
(Yu-Lee et al., 1998). 
1.4 Cellular mechanism of growth hormone signal transduction 
1.4.1 Growth hormone receptor (GHR) and protein tyrosine kinase JAK2 
The cellular effects of GH are initiated by the binding of GH to the 
extracellular region of the transmembrane GHR (Zhu et al., 2001). GH contains a 
high affinity receptor-binding site termed as “site 1” and another one with lower 
affinity called “site 2” (Fuh et al., 1992). Therefore, one GH molecule interacts with 
two receptor molecules and the unliganded GHR may exist as a preformed dimer that 
undergoes a GH-induced conformational change to achieve activation (Cunningham 
et al., 1991; He et al., 2003). Cytokine receptors have no intrinsic kinase activity and 
thus they utilize cytoplasmic tyrosine kinases to transduce their signals (Liu et al., 
1998). The kinases essential for initiation of cytokine receptors signaling are Janus 
family nonreceptor tyrosine kinases, including JAK1, JAK2 and Tyk2 which are 
widely expressed as well as JAK3 which is primarily found in haematopoietic cells 
(Ihle, 1995). JAKs are composed of seven conserved JH regions (Fig. 1.3) devoid of 
SH2 or SH3 domains. The C-terminal JH1 domain possesses kinase activity, while 
JH2 pseudokinase domain, which is just N-terminal to JH1 domain, is kinase-like but 
catalytically inactive and negatively regulates the catalytic activity presumably via 




of JAKs containing FERM domain motifs is involved in protein interaction, kinase 






Fig. 1.3 Schematic structure of JAKs The seven JAK homology domains (JH) are 
indicated as boxes with different colors.  
 
Although GH stimulated tyrosine phosphorylation of JAK1 and JAK3 and 
association of GHR with Tyk2 have been observed (Smit et al., 1996; Johnston et al., 
1994; Hellgren et al., 1999), JAK2 is the major mediator of GH signal transduction 
and most identified GH initiated signaling pathways are JAK2 activity dependent, 
except GH stimulated Ca2+ influx through L-type channels and activation of c-Src 
kinase (Frank et al., 1995; Billestrup et al., 1995; Zhu et al., 2002).  
The membrane proximal proline-rich Box 1 domain in GHR is responsible 
for the interaction of GHR with JAK2. Although Box 1 is sufficient for interaction 
and activation of JAK2, the distal sequences are also required for maximal activation 
through stabilization of the association of GHR with JAK2 (Carter-Su et al., 2000). 
The N-terminal region of JAK2 is required for the interaction of JAK2 with GHR and 
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the FERM motifs play an important role in this event (He et al., 2003). Upon GH 
stimulation, GHR-associated JAK2 is spatially positioned and/or conformationally 
modified, with a resultant increase of its affinity for the receptor (Zhu et al., 2001). 
Thereafter, JAK2 is transphosphorylated and activated, which in turn phosphorylates 
GHR (Argetsinger et al., 1993). The tyrosyl-phosphorylated GHR and JAK2 recruit 
numerous SH2 and other phosphotyrosine-binding domain containing proteins and 
initiate several signaling pathways to regulate gene transcription, metabolic enzymes 
and actin cytoskeleton, ultimately leading to GH stimulation of body growth and 
metabolic effects (Carter-Su et al., 2000).  
Until now, a number of molecules have been demonstrated to involve in GH 
stimulated cellular signaling (Fig 1.4). They are: 1) Src family non-receptor tyrosine 
kinases c-Src and c-Fyn, 2) non-receptor tyrosine kinase FAK; 3) receptor tyrosine 
kinases EGFRs; 4) adaptor proteins SHC and Grb2; 5) SH2-Bβ and APS; 6) Ras-like 
small GTPases family members Ras, Ral and Rac; 7) members of insulin receptor 
substrate (IRS) group including IRS-1, -2 and –3 and phosphatidylinositol 3-kinase; 
8) members of MAP kinase family including p44/42 MAP kinase, p38 MAP kinase 
and JNK/SAPK; 9) Stat family members Stat1, 3, 5A and 5B; etc (Zhu et al., 2001; 
Diakonova et al., 2002; Zhu et al., 2002). Many of the above molecules become 
tyrosyl-phosphorylated upon GH stimulation, presumably by JAK2, such as FAK, 



























































1.4.2 Protein tyrosine kinases c-Src, FAK and EGFRs 
The Src family non-receptor tyrosine kinases consists of Src, Lyn, Fyn, Lck, 
Hck, Fgr, Blk and Yes (Schlessinger, 2000). It has been demonstrated that GH 
stimulates activation of c-Src which does not require JAK2 activity (Zhu et al., 2002). 
This is the first identified kinase utilized by GH independent of JAK2. c-Fyn , another 
Src family kinase, is also phosphorylated upon GH stimulation (Zhu et al., 1998a), 
however, the dependence of its phosphorylation on JAK2 has not been decided. JAK2 
independent activation of Src family kinases is also observed upon cellular 
stimulation by other cytokines, such as prolactin, interleukin-3 and erythropoietin 
(Zhu et al., 2001). The GH stimulated c-Src activity is utilized to regulate RalA 
dependent activation of p44/42 MAP kinase pathway (Zhu et al., 2002). GH 
stimulated activation of Ral also requires JAK2, but c-Src is the kinase apparently 
exerting predominant effect here (Zhu et al., 2002). The dependence of Ral activation 
on c-Src has also been reported previously in neutrophils stimulated by fMet-Leu-Phe 
and PDGF (M'Rabet et al., 1999).  
Both c-Src and c-Fyn are components of a multiprotein complex centered 
around CrkII and p130Cas formed upon GH stimulation (Zhu et al., 1998a). It has 
been demonstrated that GH stimulates a time-dependent association between c-Src 
and FAK or c-Cbl (Zhu et al., 1998a). FAK has been previously reported to be the 




al., 1998b). The tyrosine residue 925 of FAK is phosphorylated upon activation to 
create a Grb2 binding site and initiate the p44/42 MAP kinase cascade as a 
consequence (Abbi and Guan, 2002). Therefore, it can be postulated that 
c-Src-FAK-Grb2 complex may participate in the regulation of GH stimulated p44/42 
MAP kinase activity. Finally, c-Src-RalA-PLD pathway is likely subject to 
inactivation by Csk (Src-inactivating kinase) in GH signaling, thus providing an 
explanation for the observation that Csk inhibits GH stimulated p44/42 MAP kinase 
activity (Gu et al., 2001).  
Another Src substate, c-Cbl, is the negative regulator of GH stimulated 
Stat5 mediated transcription and activated Src have been demonstrated to associate 
with and activate Stat1, 3 and 5 (Tanaka et al., 1996; Zhu et al., 1998a; Chin et al., 
1998; Tanaka et al., 1996; Goh et al., 2002). Therefore, Src may be involved in the 
regulation of GH stimulated Stat5 mediated transcription. However, in BRL-GHR 
cells Src does not affect GH stimulated Stat5 mediated transcription (Graichen and 
Lobie, unpublished). Therefore, further studies are required for full understanding of 
contribution of Src signaling pathways to cellular effects of GH. Analysis of the 
genetic targets by cDNA microarray will provide clues in this regard. 
Focal adhesion kinase (FAK) is another non-receptor tyrosine kinase 
utilized by GH to induce phosphorylation of paxillin and tenin (Zhu et al., 1998b; Ryu 




factors to mediate cell motility, proliferation, survival and apoptosis (Abbi and Guan, 
2002; Parsons, 2003). It interacts with various other signaling molecules, such as Src, 
PI-3 kinase, Grb2, SHC, Nck-2 and PLC-γ (Abbi and Guan, 2002). It has been 
reported that GH stimulated tyrosine phosphorylation of FAK is JAK2 dependent but 
FAK does not affect GH stimulated Stat5 mediated transcription (Zhu et al., 1998b). 
Since both FAK and IRS-1 interact with PI-3 kinase, it has been postulated that IRS-1 
associated PI-3 kinase activity may be utilized by GH to regulate metabolism, while 
FAK dependent PI-3 kinase activity modulates GH stimulated cytoskeleton 
reorganization (Ridderstrale and Tornqvist, 1994; Goh et al., 1997). The association 
of FAK with SHC and Grb2 also suggests a role of FAK in GH stimulated activation 
of p44/42 MAP kinase pathway (Schlaepfer and Hunter, 1997).   
EGFR subfamily of receptor tyrosine kinase (RTK) consists of EGFR 
(ErbB1), ErbB2 (HER2/Neu), ErbB3 (HER3) and ErbB4 (HER4) (Zhu et al., 2001). 
GH does not affect kinase activity of EGFR. However, EGFR is tyrosine 
phosphorylated by JAK2 and serves as the docking sites for Grb2 to facilitate GH 
stimulated activation of p44/42 MAP kinase pathway (Yamauchi et al., 1997). Thus 
EGFR may participate in GH stimulated cellular proliferation. In addition to EGFR, it 
has been observed that GH can stimulate both phosphorylation and dephosphorylation 
of tyrosine residues of ErbB2 in a cell-type dependent manner (Kim et al., 1999; Zhu 




et al., 1999). The involvement of EGFR family in GH signaling indicates that 
cytokine receptors and RTKs crosstalk with each other at the receptor level.  
1.4.3 Multiprotein complexes 
Another signaling event upon GH stimulation is the formation of 
multiprotein complex. The assembly of multiprotein signaling complexes is a 
common mechanism for various receptors signaling (Pawson, 1995). Several 
complexes have been observed induced by GH, including one containing GHR, 
JAK2, SHP-2 and glycoprotein (Kim et al., 1998), one containing Stat5, p42 MAP 
kinase, SHC and an Akt-1 like protein (Dinerstein-Cali et al., 2000), and one large 
complex centered around adaptor CrkII and p130Cas (Fig. 1.5) (Zhu et al., 1998a). 
The formation of these complexes, with the potential activation of multiple 
downstream signaling pathways, may be essential for the pleiotropic effects of GH, 
including cytoskeleton reorganization, cell migration, chemotaxis, mitogenesis, and 
gene transcription.  
Crk family adaptor proteins consisting of CrkI and CrkII are widely 
expressed and mediate the formation of signaling protein complexes upon stimulation 
of extracellular stimuli (Feller, 2001). CrkII, containing one SH2 and two SH3 
domains, is the more abundant species of Crk in normal cells (Matsuda et al., 1992). 
CrkII associates with a variety of molecules in response of GH stimulation, including 




SHC, Grb2 and Sos (Zhu et al., 1998a). CrkII has been demonstrated to enhance GH 
stimulated PI-3 kinase activity and subsequent actin cytoskeleton reorganization and 
JNK/SAPK activity (Goh et al., 2000). CrkII dependent PI-3 kinase activity is also 
utilized to inhibit GH stimulated Stat5 mediated transcription (Goh et al., 2000). 
However, the inhibitory effect of CrkII on GH stimulated activation of p44/42 MAP 
kinase is independent of PI-3 kinase activity (Goh et al., 2000). It has been reported 
that CrkII-p130Cas is implicated in cell invasion and survival through regulation of 
Rho and Rac (Zhu et al., 2001). Although GH stimulates Rac activity to regulate cell 
motility, SH2-Bβ is the adaptor to recruit Rac in this event (Diakonova et al., 2002); 
therefore the relationship between CrkII and Rho GTPases in GH signaling requires 
further studies.  
Cbl is an adaptor protein with ubiquitin ligase activity and is composed of 
one PTB domain, one RING finger domain and one proline-rich region (Dikic et al., 
2003). c-Cbl is a negative regulator of various signaling pathways through 
endocytotic internalization or ubiquitin-dependent degradation of the corresponding 
receptor or tyrosine kinases (Dikic et al., 2003). Upon GH stimulation, c-Cbl 
associates with CrkII and PI-3 kinase (Zhu et al., 1998a). c-Cbl does not induce GHR 
internalization, however, it attenuates GH stimulated Stat5 mediated transcription 













Fig. 1.5 Multiprotein complex centered around CrkII and p130Cas stimulated by 
GH This figure has been modified from Zhu et al., 2001.  
 
1.4.4 IRS and PI-3 kinase  
The family of insulin receptor substrate (IRS) proteins consists of at least 
four mammalian members. IRS-1 and IRS-2 are the best characterized and 
ubiquitously expressed, IRS-3 is exclusively expressed in adipose tissue and β cells, 
and IRS-4 is expressed in thymus, brain and kidney (Dominici and Turyn, 2002). GH 
has been demonstrated to stimulate the tyrosine phosphorylation of all the four IRS 
proteins presumably through JAK2 (Zhu et al., 2001; Urso et al., 2003). Neither GHR 























Yenush and White, 1997), therefore other intermediate signaling molecules should 
involve in the interaction and activation of IRS upon GH stimulation. Since IRS-1 has 
been identified in the multiprotein complex centered around CrkII induced by GH 
(Zhu et al., 1998a), it is possible that the adaptor protein CrkII or Grb2 links IRS to 
JAK2 to facilitate JAK2 dependent phosphorylation of IRS. GH may also utilize FAK 
and associated Src kinase to phosphorylate IRS. Tyrosyl-phosphorylated IRS 
associates with SH2 domain of a variety of other signaling molecules, such as p85 
subunit of PI-3 kinase, Fyn, SHP-2, Grb2, CrkII, etc (Zhu et al., 2001).  
Among these effector proteins, the lipid kinase PI-3 kinase plays an important 
part in GH signaling. GH stimulates the association of PI-3 kinase with IRS and this 
association increases the enzymatic activity of PI-3 kinase (Carter-Su et al., 2000). In 
certain cell types, GH stimulated activation of PI-3 kinase is also mediated by 
IRS-independent pathways (Zhu et al., 2001). It has been observed that 
overexpression of either CrkII or CrkII interacting protein c-Cbl results in enhanced 
GH stimulation of PI-3 kinase activity (Goh et al., 2000; Goh et al., 2002). 
Furthermore, the direct association of p85 subunit of PI-3 kinase with GHR and Tec 
tyrosine kinase bridging JAKs with PI-3 kinase may provide alternative mechanism 
for PI-3 kinase activation by GH (Moutoussamy et al., 1998; Takahashi-Tezuka et al., 
1997). PI-3 kinase catalyzes the conversion of the plasma membrane lipid PI(4,5)P2 to 
PI(3,4,5)P3 and the latter polyphosphoinositide recruits Akt/PKB, PKD-1, p70S6K, 




demonstrated to utilize PI-3 kinase/Akt pathway to regulate apoptosis, GLUT4 
transport and c-fos transcription (Zhu et al., 2001). PI-3 kinase mediates GH 
stimulated p44/42 MAP kinase activity and this effect of PI-3 kinase is presumably 
restricted to IRS dependent activation of p44/42 MAP kinase (Liang et al., 2000; Goh 
et al., 2000). PI-3 kinase activity is also required for GH stimulated lipogenesis and 
actin cytoskeleton reorganization (Goh et al., 1997; Ridderstrale and Tornqvist, 1994). 
Furthermore, it has been demonstrated that PI-3 kinase mediates CrkII induced 
diminution of GH stimulated Stat5 transactivation (Goh et al., 2000). 
1.4.5 Mitogen-activated protein (MAP) kinase pathway 
The mitogen-activated protein (MAP) kinases are serine/threonine protein 
kinases essential for gene transcription, cellular proliferation and survival in response 
to a variety of extracellular stimuli (English et al., 1999; Lewis et al., 1998). MAP 
kinase signalling cascades are evolutionarily conserved and are typically composed of 
three hierarchical kinases including MAPKK kinase (MAPKKK), MAPK kinase 
(MAPKK) and MAP kinase (MAPK) (Cobb, 1999). To date, more than 20 
mammalian members of the MAP kinase family have been identified (Cobb, 1999; 
English et al., 1999). Among them, p44/42 MAP kinase (ERK), c-jun N-terminal 
kinase (JNK or SAPK) and p38 MAP kinase are best characterized and GH stimulates 
the activation of all above three MAP kinases and subsequent gene transcription 




It has been reported that the membrane proximal part of GHR cytoplasmic 
domain including Box1 is sufficient for GH stimulated p44/42 MAP kinase activity 
(Sotiropoulos et al., 1994). JAK2, the major protein tyrosine kinase utilized to initiate 
GH signaling, is required for this process (Winston and Hunter, 1995). One common 
mechanism to activate p44/42 MAP kinase is via a well-established sequential 
cascade involving SHC, Grb2, Sos, Ras, Raf and MEK (Cobb, 1999). GH also utilizes 
the above cascade and the GHR/JAK2 mediated activation of p44/42 MAP kinase is 
dependent on both Ras and Raf (Vanderkuur et al., 1997). It has recently been 
demonstrated that the Ras-like small GTPase RalA and its substrate enzyme PLD 
which catalyzes the formation of phosphatidic acid, downstream of JAK2 and Ras, are 
required for activation of p44/42 MAP kinase by GH (Zhu et al., 2002). Furthermore, 
a JAK2-independent pathway regulating GH stimulated p44/42 MAP kinase activity 
has also been identified, which is mediated by tyrosine kinase c-Src dependent 
activation of the above-mentioned RalA-PLD pathway (Zhu et al., 2002). Other 
pathways also mediate the activation of p44/42 MAP kinase in GH signaling. PI-3 
kinase activity and PKC (specifically PKCδ) activity are both required for full 
activation of p44/42 MAP kinase stimulated by GH (Kilgour et al., 1996; MacKenzie 
et al., 1997). Interestingly, PKC-ζ, a mediator of PI-3 kinase signaling, has been 
reported to phosphorylate and activate Raf-1 and MEK (Schonwasser et al., 1998). 
One recent study suggests that GH stimulated p44/42 MAP kinase activity could be 




for SHC and Grb2 (Yamauchi et al., 1998). The activation of p44/42 MAP kinase by 
GH is cell type specific as it is not observed in IM-9 cells (Love et al., 1998). 
Therefore, in certain cell types or under certain cellular contexts, GH may utilize 
other MAP kinases to substitute the role of p44/42 MAP kinase.     
Upon activation, p44/42 MAP kinase activates a variety of proteins 
including p70S6K, p90RSK, Sap-1a, phospholipase A2 (PLA2), c-Raf-1, c-jun, 
ternary complex factor (p62TCF/Elk1) and Stats (David et al., 1995; Treisman, 1996). 
GH has been demonstrated to utilize all of these downstream proteins to mediate its 
signal transduction (Argetsinger and Carter-Su, 1996; Thomas, 1998; Finidori, 2000). 
p90RSK phosphorylates the serum response factor (SRF) that binds to the serum 
response element (SRE) of the c-fos gene promoter (Rivera et al., 1993). Binding of 
both SRF and Elk-1 to the SRE contributes to the induction of c-fos gene transcription 
by GH (Liao et al., 1997; Rivera et al., 1993). GH has been demonstrated to stimulate 
the phosphorylation and subsequent transcriptional activity of Elk-1 (Hodge et al., 
1998). GH also utilizes Elk-1 to mediate the transcription of egr-1 gene (Clarkson et 
al., 1999). MEK1 is required for GH stimulated phosphorylation of Elk-1 as well as 
SRE mediated transcription of c-fos, egr-1 and junB (Hodge et al., 1998). p44/42 
MAP kinase has also been demonstrated to regulate Stat mediated transcription 
through serine phosphorylation of Stat molecules (Horvath and Darnell, 1997). 
Furthermore, the MEK1 kinase inhibitor decreases GH stimulated Stat5A mediated 




has been demonstrated that phosphorylation by p44/42 MAP kinase markedly 
stabilizes c-fos and enhances its transforming efficiency of NIH-3T3 cells, therefore 
p44/42 MAP kinase possibly regulates the activity of transcription factors through 
phosphorylation dependent alteration of protein stability (Okazaki and Sagata, 1995). 
However, further studies are required to determine whether p44/42 MAP kinase also 
utilizes such mechanism to regulate GH stimulated transcriptional activation.  
GH activates JNK/SAPK through the formation of a multiprotein signaling 
complex centered around p130Cas¯CrkII (Zhu et al., 1998a). In addition, 
overexpression of CrkII enhances GH stimulated JNK/SAPK activity (Goh et al., 
2000). Similar to p44/42 MAP kinase, GH stimulated activation of JNK/SAPK is also 
PI-3 kinase dependent (Goh et al., 2000). JNK/SAPK is activated by adverse stimuli, 
such as heat, UV irradiation and osmotic stress; it also acts as an important mediator 
in response to cytokines and growth factors (Weston and Davis, 2002). A major target 
of JNK/SAPK signaling is AP-1 transcription factors, such as c-Jun and related 
molecules, which are phosphorylated and activated by JNK/SAPK (Davis, 2000). 
JNK/SAPK and subsequent c-Jun mediated transcription provides another potential 
pathway for GH to exert its cellular function. 
It has been demonstrated that GH stimulates phosphorylation and activation 
of p38 MAP kinase dependent of JAK2 activity (Zhu and Lobie, 2000). GH 




transcription, actin cytoskeleton reorganization and mitogenesis (Zhu and Lobie, 
2000). Interestingly, autocrine production of GH by human mammary carcinoma cells 
results in the up-regulation of CHOP expression at the transcription level and 
subsequent enhancement of CHOP mediated transactivation (Mertani et al., 2001). 
The increased CHOP mediated transcription is utilized by GH to prevent apoptosis of 
mammary carcinoma cells (Mertani et al., 2001). p38 MAP kinase is therefore an 
important regulator to coordinate the pleiotropic effects of GH.  
1.4.6 Stat pathway 
Stats are a family of important transcription factors, utilized by many 
cytokines, including GH, prolactin, erythropoietin, interleukins and numerous growth 
factors, such as EGF and PDGF, to regulate cell growth, differentiation and survival 
(Bowman et al., 2000; Kisseleva et al., 2002). Though GH has been demonstrated to 
stimulate the binding of Stat1 and Stat3 to the SIE of the c-fos gene promoter 
(Campbell et al., 1995; Meyer et al., 1994), Stat5, existing as two forms 5A and 5B 
encoded by different genes (Mui et al., 1995), is the key mediator of GH dependent 
transcription (Herrington et al., 2000). Stat5A and 5B are highly (90 %) identical to 
each other in the coding sequence (Shuai, 1999; Herrington et al., 2000). Stat5 has 
been demonstrated to be required for GH stimulated proliferation of islet β cells and 
differentiation of adipocytes (Friedrichsen et al., 2001; Shang and Waters, 2003). 




action in the liver. Stat5B deficiency in male mice leads to the loss of GH 
pulse-regulated male specific liver gene expression and the overall pattern of sexually 
dimorphic liver gene expression becomes feminized (Udy et al., 1997). Disruption of 
Stat5B also results in abolishment of the male pubertal growth spurt (Udy et al., 1997).  
Stat5A/5B double knock-out mice also exhibit impaired male-characteristic body 
growth rates and male-specific liver gene expression, however, the above striking 
phenotypes are not observed in Stat5B-deficient female mice or mice only with 
Stat5A disruption (Udy et al., 1997; Teglund et al., 1998; Park et al., 1999). In 
addition to hepatic cells, it has been reported that GH stimulates Stat5 DNA binding 
ability in normal human fibroblasts but not in cells from Laron Syndrome patients 
(Freeth et al., 1998). GH stimulated activation of Stat5 is also observed in human 
IM-9 lymphocytes, mouse CHO-GHR epithelial cells, NIH-3T3 fibroblasts and 
preadipocytes (Han et al., 1996; Silva et al., 1996; Goh et al., 1997; Goh et al., 2000).  
Stats are the only known family of transcription factors whose activity is 
regulated by tyrosine phosphorylation (Shuai, 1999). Upon GH stimulation of cells, 
JAK2 activity is required for recruitment and subsequent tyrosine phosphorylation of 
Stat5 (Herrington et al., 2000). The intracellular domain of the GHR has been 
demonstrated to regulate the full activity of Stat5 (Hansen et al., 1996). Stat5 is 
phosphorylated by JAK2 on a single tyrosine residue (tyrosine 694 of Stat5A and 
tyrosine 699 of Stat5B) and dissociate from GHR as either homo- or hetero-dimers 




molecules are translocated into the nucleus, bind to the specific DNA elements and 
regulate transcription (Ihle, 1996).  
Activation of Stat5 is also regulated by serine phosphorylation (Beadling et 
al., 1996). The phosphorylation of Stat5B serine residue 730 and Stat5A serine 
residues 725 and 779 regulates GH stimulated Stat5 mediated transcriptional activity 
either positively or negatively dependent of promoter type (Park et al., 2001). One of 
the serine kinases responsible for Stat5 phosphorylation is p44/42 MAP kinase. It has 
been reported that inactivation of MEK blocks GH stimulated Stat5A mediated 
transcription but does not affect nuclear translocation of Stat5A (Pircher et al., 1997). 
Interestingly, though upon GH stimulation, p44/42 MAP kinase induces serine 
phosphorylation of Stat5A by direct intermolecular interaction and increases GH 
stimulated Stat5A mediated transcription, it does not affect Stat5B activity (Pircher et 
al., 1997; Pircher et al., 1999). The mechanism of serine phosphorylation of Stat5 to 
regulate transcriptional activity still requires further elucidation.  
Some negative regulatory pathways required for termination of GH 
stimulated Stat5 signaling have been described. One such pathway involves tyrosine 
phosphatase SHP-1 and SHP-2, which associate with tyrosine-phosphorylated JAK2 
and Stat5B, may contribute to the dephosphorylation leading to deactivation of Stat5B 
(Ram and Waxman, 1997; Yu et al., 2000). SOCS/CIS proteins can also inhibit GH 




and Waxman, 1999). SOCS proteins constitute a negative feedback loop because their 
expression is induced by GH and they in turn inhibit GH signaling (Chen et al., 2000). 
It has been demonstrated that overexpression of CrkII diminishes GH stimulated Stat5 
mediated transcription in a PI-3 kinase dependent manner without alteration of 
tyrosine phosphorylation of Stat5 (Goh et al., 2000). Interestingly, c-Cbl, a CrkII 
interacting protein, also increases PI-3 kinase activity and inhibits GH stimulated 
Stat5 mediated transcription through ubiquitilation and subsequent proteosomal 
degradation of Stat5 proteins (Goh et al., 2002).  
Upon activation by GH, Stat5 binds to IFNγ activated sequence (GAS)-like 
elements (GLE) in the promoter of several genes, such as the serine protease inhibitor 
Spi 2.1, insulin, cytochrome P450 3A 6 and 10, acid labile subunit, IGF-1 and 
β-casein genes (Herrington et al., 2000; Schwartz et al., 2002). The role of Stat5 in 
GH stimulated gene transcription has been studied in particular detail by analysis of 
the Spi 2.1 gene promoter. The regulation of the expression of Spi 2.1 by GH is 
complex, involving Stat5 as well as other transcription factors, such as glucocorticoid 
receptor and YY1 that are associated with Stat5 in the Spi 2.1 promoter (Bergad et al., 
2000). Recently, chromatin remodeling has also been proposed to regulate GH 
stimulated Spi 2.1 gene expression (Simar-Blanchet et al., 1998). 
The roles of Stats in GH regulated cellular effects have not been fully 




regulate cell proliferation, differentiation and apoptosis (Shuai, 1999). Stats play a 
pivotal role in proliferation or apoptosis stimulated by other cytokines, such as EPO 
and IL-2 (Bittorf et al., 2000; Fung et al., 2003); however, this has not yet been 
reported for GH. Instead, JAK2 mediated activation of the p44/42 MAP kinase and 
p38 MAP kinase pathways have been demonstrated to be required for the propagation 
of GH initiated mitogenic signals (Kaulsay et al., 1999). Furthermore, Stat5 has been 
reported to be essential for GH stimulated differentiation of 3T3-F442A preadipocytes 
but does not affect GH stimulated p44/42 MAP kinase and p70S6K activity (Yarwood 
et al., 1999). Thus, the activation of MAP kinases and Stats by GH appear to be two 
independent but related events dictating two separate biological outcomes, and the 
combination of them results in proliferation, survival and differentiation of cells.  
1.5 Transcription cofactors p300/CBP 
p300 and its closely related protein CBP are ubiquitous and versatile 
regulators of transcription and were originally identified by their ability to interact 
with the adenoviral E1A and the cAMP-response-element-binding protein (CREB), 
respectively (Janknecht, 2002). The p300/CBP genes are conserved from worms to 
human and the proteins share several conserved regions including the bromodomain 
which recognizes acetylated residues, three cysteine-histidine (CH)-rich domains 
(CH1, CH2 and CH3), a KIX domain and an ADA2-homology domain (Chan and La 




exert important functions in protein-protein interaction (Chan and La Thangue, 2001). 
The N- and C-terminal regions of p300 and CBP can activate transcription and the 
central HAT domain performs histone acetyltransferase activity (Goodman and 
Smolik, 2000).  
p300 and CBP perform overlapping roles in embryonic development, 
however, they also have unique functions in certain physiological processes, such as 
retinoic acid mediated transcription and haematopoietic differentiation (Chan and La 
Thangue, 2001). Recent studies indicate that p300/CBP possess tumor suppressing 
characteristics and have been regarded as potential therapeutic targets for viral 
infections and neurogenerative diseases (Janknecht, 2002). p300 and CBP are 
important in cell cycle regulation and involved in cell proliferation, differentiation and 
p53-dependent apoptosis (Goodman and Smolik, 2000). They exert these functions by 
acting as transcriptional co-regulators in multiple transcription events.    
Transcriptional activation is generally correlated with histone acetylation by 
histone acetyltransferase (HAT) complexes, and repression is correlated with 
deacetylation by HDAC complexes (Armstrong and Emerson, 1998). p300 and CBP 
can activate transcription through histone acetylation dependent chromatin 
remodeling or acetylation of transcription activators, general transcription factors and 
chromatin-associated proteins (Janknecht, 2002). Alternatively, they serve as adaptors 




TFIIB to facilitate transcriptional initiation (Chan and La Thangue, 2001). 
Accumulating evidence has shown that p300/CBP participate in the regulation of 
Stat5 mediated transcription in cytokine signaling and the direct binding of p300 to 
transactivation domain of Stat5 has been observed upon prolactin stimulation 
(Pfitzner et al., 1998; Boer et al., 2003). It has also been demonstrated that RhoGDI, 
the inactivator of RhoA, requires CBP/p300 to regulate certain transcriptional event 
(Su et al., 2002). p300 can also repress transcription. It has been reported that p300 
downregulates c-Myc and subsequent cell cycle arrest at G1/S transition (Baluchamy 
et al., 2003). p300 is also required for E1A induced suppresion of Stat5 mediated 
transcription (Pfitzner et al., 1998). Furthermore, one recent study has demonstrated 
that a transcriptional repression domain in p300 termed as cell cycle regulatory 
domain 1 (CRD1) is required for the repression of p53 mediated transcription through 
recruitment of HDAC6 to the transcription complex (Girdwood et al., 2003).  
1.6 Ras-related small GTPases 
1.6.1 Ras superfamily small GTPases 
The Ras superfamily of small GTPases are monomeric G proteins with 
molecular masses of 20-40 kDa and comprise more than 100 members that have been 
identified in eukaryotes from yeast to human (Takai et al., 2001). One common 
mechanism utilized by small GTPases to regulate cellular function is to cycle between 




by distinct classes of regulatory proteins (Boguski and McCormick, 1993). Activation 
of small GTPases is mediated by guanine nucleotide exchange factors (GEFs) that 
facilitate GDP dissociation and allow the more abundant GTP to bind, while GTPase 
activating proteins (GAPs) accelerate GTP hydrolysis resulting in rapid conversion to 
the inactive state (Bos, 1998). Upon activation, the small GTPases associate with 
effectors which in turn regulate diverse biological functions. Based on structural and 
functional characteristics, the Ras superfamily is divided into five subfamilies: Ras, 
Rho, Rab, Arf and Ran (Takai et al., 1992). Ras-like subfamily members mainly 
regulate cell proliferation and differentiation; Rho proteins regulate actin cytoskeleton 
dynamics and gene expression; Rab and Arf regulate intracellular vesicle trafficking; 
Ran subfamily regulates nucleocytoplasmic transport during the G1, S and G2 phases 
and microtubule organization during the M phase of cell cycle (Takai et al., 2001).  
1.6.2 Ras 
Ras-like subfamily of small GTPases consist of at least 13 members, 
including Ras, RalA and B, Rap1 and 2, R-Ras, TC21, M-Ras and Rheb (Bos et al., 
2001). In this family, Ras has been extensively studied and three forms of proteins, 
Ha-ras, Ki-ras and N-ras, have been identified (Bos, 1989). Ras proteins are regarded 
as oncoproteins due to their ability to transform mammalian cells when activated by 
point mutations and the presence of mutated Ras in about 15% of all human tumors 




Ras can be stimulated by various extracelluar ligands which activate 
receptors with intrinsic or associated tyrosine kinases activity (Bos, 1998). 
Phosphotyrosines serve as docking sites for the adaptor proteins, such as Grb2 and 
SHC/Grb2 complex, which recruit Sos, the Ras specific GEF, from the cytosol to the 
plasma membrane to stimulate Ras that is located at the cytoplasmic face of the 
plasma membrane (Bos, 1998). p140RasGRF is also a GEF for Ras, mediating 
Ca2+-induced Ras activation (Farnsworth et al., 1995). It is characterized with an 
IQ-motif and expressed predominantly in neural tissues (Shou et al., 1992). RasGRP, 
another RasGEF, has been reported to regulate diacylglycerol stimulated Ras activity 
(Ebinu et al., 1998).  
Upon activation, the GTP-bound Ras interacts with distinct downstream 
effectors and initiates multiple signaling cascades, including at least three downstream 
signaling cascades mediated by the Ser/Thr protein kinase Raf (A-Raf, B-Raf, and 
Raf-1), RalGEFs (RalGDS, Rlf, Rgl and Rsc), and phosphatidylinositol-3 (PI-3) 
kinases (Bos, 1998; Ebinu et al., 1998). The most significant consequence of 
activation of Raf is the initiation of p44/42 MAP kinase pathway (Burgering and Bos, 
1995; Marshall, 1996). PI-3 kinase contains a p85 regulatory subunit and a p110 
catalytic subunit and is activated by direct binding of Ras to p110 subunit 
(Rodriguez-Viciana et al., 1996). RalGEFs are major mediators to connect the 




Ras possesses an important role in cell growth and differentiation as it is 
required for activation of p44/42 MAP kinase by a number of growth factors 
including GH (Winston and Hunter, 1995; Burgering and Bos, 1995; Marshall, 1996). 
Ras has been demonstrated to mediate JAK2 dependent activation of p44/42 MAP 
kinase stimulated by GH (Winston and Hunter, 1995; Hodge et al., 1998). GH 
stimulation of cells results in the assembly of the SHC¯Grb2¯Sos complex and the 
recruitment of Sos activates Ras and subsequent Raf-MEK-MAP kinase pathway 
(Vanderkuur et al., 1997). IRS-1 associated PI-3 kinase activity is also utilized by GH 
to stimulate Ras activation (Liang et al., 2000). Whether other pathways are involved 
in the regulation of GH stimulated Ras activity remains to be determined.  
1.6.3 Ral 
RalA and RalB, two members of the Ral subfamily small GTPase, possess 
important roles in the regulation of various cellular processes, such as vesicular 
transport, receptor endocytosis, cytoskeletal organization, gene expression, cell 
proliferation and transformation (Bos, 1998; Takai et al., 2001). Ral can be activated 
through direct binding of GTP-bound Ras to Ral specific GEFs, such as RalGDS, Rgl 
and Rlf (Hofer et al., 1994). Several studies have suggested that RalA is downstream 
of Ras (Wolthuis et al., 1998; Urano et al., 1996). However, there also exists the Ras 
independent mechanism of Ral activation. RalA can be activated by direct interaction 




Park, 2001). Moreover, PI-3 kinase and Src family kinases are also implicated in the 
activation of Ral (M'Rabet et al., 1999; de Ruiter et al., 2000).  
Once activated, Ral interacts with and activates its downstream effectors 
RalBP1, filamin and phospholipase D1 (PLD1). RalBP1 (or RLIP76) exhibits GAP 
activity for Rac and Cdc42 but not for RhoA (Feig et al., 1996). Ral participates in the 
endocytosis of the growth factor receptors probably through RalBP1 (Nakashima et 
al., 1999). Filamin mediates the effect of RalA on Cdc42 induced filopodium 
formation (Ohta et al., 1999). RalA has been demonstrated to interact directly with 
PLD1 and coordinates with Arf, another PLD1 interacting small GTPase, to activate 
PLD1 activity (Luo et al., 1998). It has been reported that RalA activity is required for 
v-Src and v-Ras induced activation of PLD (Jiang et al., 1995). PLD1 and PLD2 are 
widely expressed phospholipid-specific phosphodiesterases that hydrolyze 
phosphatidylcholine, a major phospholipid in the cell membrane, to produce 
phosphatidic acid (PA) and choline (Frohman et al., 1999; Liscovitch et al., 2000). 
PA can be further converted to two second messengers, lyso-PA (LPA) and 
diacylglycerol (DAG) (Liscovitch et al., 2000; Cockcroft, 2001).  
Both RalA and RalB have been demonstrated to be activated by GH 
dependent on combined activity of JAK2 and c-Src (Zhu et al., 2002). Ras also 
participates in the activation of Ral by GH, though there also exists Ras independent 




might also be mediated by Rap1 (Zhu et al., 2002). RalA is utilized by GH to increase 
the production of phosphatidic acid through stimulation of phospholipase D, which in 
turn activates p44/42 MAP kinase cascade and subsequent Elk-1 mediated 
transcription (Zhu et al., 2002). The cellular effect of RalA dependent activation of 
p44/42 MAP kinase pathway in response to GH remains to be elucidated. Although 
Ral has been implicated in the regulation of cell proliferation and Ras-mediated 
oncogenic transformation, GH stimulated RalA activity is not expected to be involved 
in these processes in NIH-3T3 cells since GH induces little increase in cell number in 
this cell type (Zhu et al., 2002). However, in mammary carcinoma cells, RalA may be 
required for p44/42 MAP kinase dependent mitogenesis and the invasive phenotype 
induced by autocrine GH production and/or exogenous GH (Zhu et al., 2002).   
1.6.4 Rap1 and Rap2 
Rap1 is closely related to Ras and was initially identified in a screen for 
cDNAs that revert the morphology of Ki-Ras transformed NIH-3T3 fibroblasts 
(Kitayama et al., 1989). Structurally, Rap1 shares striking similarity with Ras in the 
effector domain. Several studies have demonstrated that both Rap1 and Ras can bind 
the same effectors, such as Raf-1 and RalGDS (Okada et al., 1998). In addition, it has 
been suggested that Rap1 antagonizes Ras activity by sequestrating its target, Raf-1, 
in the inactive form (Bos, 1998). Rap2 exhibits 60 % identity to Rap1 and shares most 




function of Rap2 is more limited compared to that of Rap1, although an antagonistic 
effect of Rap2 on Ras mediated transcription has been reported (Ohba et al., 2000).   
Rap1 is ubiquitously expressed and particularly abundant in platelets, 
neutrophils and brain (Bos et al., 2001). In cells, Rap1 is located both in plasma 
membrane and in intracellular member systems (Bos et al., 1997). Rap can be 
activated through stimulation of various transmembrane receptors, including receptor 
tyrosine kinases, heterotrimeric G-protein coupled receptors, cytokine receptors and 
cell adhesion molecules (Bos et al., 1997). The activity of Rap is controlled by GEFs 
and GAPs. C3G is the first identified Rap specific GEF and it predominantly 
catalyzes guanine nucleotide exchange reaction for Rap1 and Rap2 (Gotoh et al., 
1995). C3G was originally identified as a major protein bound to the SH3 domain of 
c-Crk (Zhai et al., 2001). There are three proline-rich sequences that bind to the SH3 
domain of c-Crk in the central region of C3G and one C-terminal CDC25 homology 
domain catalyzing guanine nucleotide exchanging (GEF) reaction of Rap (Matsuda 
and Kurata, 1996). The function of the C3G N-terminus remains unknown but recent 
studies have reported the association of p130Cas to this region (Kirsch et al., 1998). 
C3G is activated by c-Crk mediated membrane recruitment. Two isoforms of c-Crk 
protein are generated by alternative mRNA splicing. The larger form is CrkII, 
containing one SH2 domain and two SH3 domains, while the smaller form is CrkI 
lacking the C-terminal SH3 domain and one negative regulatory tyrosine residue 




major adaptor for C3G (Matsuda et al., 1992). A number of growth factors and 
cytokines stimulate the recruitment of the Crk-C3G complex to the membrane where 
tyrosine kinases are located such that C3G tyrosine residue 504 is phosphorylated 
with a resultant increase in its GEF activity (Kiyokawa et al., 1997; Ichiba et al., 
1999). Many other RapGEFs have been identified, including Epac which mainly 
mediates cAMP dependent Rap1 activation and CD-GEF which is the main regulator 
of Rap1 activation by Ca2+ and DAG (de Rooij et al., 1998; Yamashita et al., 2000), 
etc. Unlike other small GTPases, Rap1 has a very low intrinsic GTPase activity due to 
absence of a conserved glutamine residue at position 61 (Noda, 1993). Therefore, 
GAPs, such as Rap1GAP and Spa-1, are important regulators in the activation cycle 
of Rap1 through facilitation of GTP hydrolysis (Polakis et al., 1991; Kurachi et al., 
1997).  
Upon binding to GTP, Rap1 is activated and interacts with effectors to 
initiate downstream signaling. Rap1 regulates p44/42 MAP kinase activity either 
positively or negatively through Raf-1 or B-Raf kinase depending on cellular context 
(Bos et al., 2001). RalGEFs, including RalGDS, Rlf and Rgl, are putative effectors of 
Rap1 and may be the mediators for the crosstalk between Ral and Rap (Spaargaren 
and Bischoff, 1994; Wolthuis et al., 1996). Another potential effector is Krit1, an 
ankyrin repeat-containing protein that specifically interacts with activated Rap1 




In mammalian cells, Rap1 is implicated in various cellular processes. 
Several studies have shown that Rap1 is crucial for integrin mediated cell adhesion 
(Bos et al., 2001). It involves in cAMP stimulated neurite outgrowth (York et al., 
1998). It has been reported that Rap1 is implicated in the activation of cell 
proliferation and transformation (Altschuler and Ribeiro-Neto, 1998). Rap1 is also 
found to associate with secretory vesicles and may play a role in exocytosis (Bos et 
al., 2001). Rap1 functions in a general process in signal transduction.  
1.6.5 RhoA 
RhoA belongs to the Rho subfamily of the Ras-related small GTPases 
superfamily (Takai et al., 2001). Twenty mammalian Rho family members have been 
identified, including Rho (A, B, C), Rac (1, 2, 3), Cdc42, TC10, TCL, Chp (1, 2), 
RhoG, Rnd (1, 2), RhoBTB (1, 2), RhoD, Rif and TTF (Etienne-Manneville and Hall, 
2002). Among them, RhoA, Rac and Cdc42 have been extensively studied. The first 
identified cellular effect of Rho GTPases was to regulate actin cytoskeleton. Briefly, 
RhoA induces the formation of stress fibers and focal adhesions, Rac regulates the 
formation of lamellipodia and membrane ruffles while Cdc42 mediates the formation 
of filopodia (Nobes and Hall, 1995). In addition to regulation of cytoskeleton 
organization, RhoA has been demonstrated to participate in diverse cellular processes, 
including gene transcription, hormone secretion, cell cycle progression, and cell 




The activity of RhoA is regulated by three classes of proteins: guanine 
nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs) and GDP 
dissociation inhibitors (GDIs) (Etienne-Manneville and Hall, 2002). Numerous RhoA 
GEFs have been reported, including Lfc, Lsc, Lbc, Net1, Dbl, Vav, and a newly 
identified GEFs family consisting of PDZ-RhoGEF, p115 RhoGEF and LARG (van 
Aelst and D'Souza-Schorey, 1997; Chikumi et al., 2002; Cheng et al., 2002). 
p190RhoGAP is the best characterized GAP for RhoA, containing a N-terminal GTP 
binding domain and a C-terminal domain possessing the GAP activity (Settleman et 
al., 1992). p190RhoGAP is pivotal for RhoA inactivation in several signaling 
pathways (Tatsis et al., 1998; Arthur et al., 2000; Chen et al., 2003). RhoGDIs 
negatively regulate RhoGTPases activity by extraction of them from plasma 
membrane and subsequent formation of inactive cytosolic complexes with them 
(Olofsson, 1999). 
RhoA activity can be modulated by tyrosine kinases or serine kinases. 
Tyrosine kinase Src negatively regulates RhoA by activation of p190RhoGAP (Arthur 
et al., 2000). Another kinase modulating RhoA activity is the serine kinase PKA 
which has been reported to inactivate RhoA through phosphorylation of RhoA on 
serine residue 188 (Forget et al., 2002). Upon activation, RhoA interacts with and 
stimulates effector proteins, including Rho kinase (ROCK), mDia, protein kinase N 
and phosphoatidylinositol 4-phosphate 5-kinase (Aspenstrom, 1999). As the most 




of RhoA, such as smooth muscle contraction, actin cytoskeleton organization in 
nonmuscle cells, transformation of fibroblastic cells and regulation of transcription 
(Aspenstrom, 1999; Aznar et al., 2003).  
The first demonstrated transcriptional event regulated by RhoA was LPA 
and serum induced SRF mediated transcription of c-fos promoter in NIH-3T3 cells 
(Hill et al., 1995). By now, several other RhoA regulated transcription factors have 
been identified, such as NF-κB, Stat3, Stat5, ATF2, Max and CHOP (Aznar et al., 
2001). Stats are important regulators in cytokine signaling and responsible for 
transcriptional activation of target genes that control proliferation, differentiation and 
survival (Bromberg and Darnell, Jr., 2000). RhoA triggers simultaneous 
phosphorylation at both tyrosine and serine residues of Stat3 and subsequent 
activation of Stat3 essential for oncogenic RhoA mediated transformation of human 
HEK cells (Aznar et al., 2001). RhoA also promotes tyrosine phosphorylation and 
serine dephosphorylation of Stat5A with a concomitant increase in Stat5A activity to 
mediate the transition from the epithelial to mesenchymal morphology induced by 
oncogenic RhoA (Benitah et al., 2003). Though the mechanism for RhoA to regulate 
gene expression remains unclear, recent studies suggest that it is possibly achieved 
through the modulation of transcriptional cofactor p300/CBP by RhoA. It has been 
reported that RhoA inhibits iNOS expression via negative regulation of 
NF-κB-CBP/p300 pathway (Rattan et al., 2003). The antagonistic relationship 




with the previous findings that RhoA inhibited while RhoGDI stimulated CBP/p300 
mediated ER dependent transactivation (Su et al., 2002).  
1.7 Rationale and objectives of research 
Growth hormone is the major regulator of somatic growth and implicated in 
many other physiological and pathological processes. Several pathways and many 
molecules mediating GH signal transduction have been identified. GH stimulated 
activation of transcription is one predominant mechanism of GH induced cellular 
effects. Activation of MAP kinases and subsequent transcription factors and JAK2 
dependent activation of Stat5 mediated transcription are important pathways in GH 
signaling. Though many molecules have been identified to regulate the above 
pathways in response to GH stimulation, the understanding of the complex 
mechanisms is still far from satisfactory. The Ras superfamily of small GTPases 
exhibit diverse functions and have been regarded as pivotal mediators in cell 
signaling. However, their roles in GH signal transduction are largely unknown. 
 The small GTPase Ras is known as one important activator of GH 
stimulated p44/42 MAP kinase pathway. Rap1, a small GTPase closely related to Ras, 
antagonizes Ras dependent p44/42 MAP kinase activity in other systems. 
Furthermore, Rap1 is the specific substrate of CrkII-C3G complex and CrkII 
overexpression has been demonstrated to diminish p44/42 MAP kinase activity but 




objective of this project is to investigate whether Rap1 involves in the CrkII 
dependent switch of p44/42 MAP kinase and JNK/SAPK activities in GH signaling. 
Among the small GTPases family, RhoA is one exhibiting a predominant effect on 
regulation of gene transcription. The activity of numerous transcription factors, 
including Stat3 and Stat5, can be modulated by RhoA and/or its major effector 
serine/threonine kinase ROCK. The second objective of this project is to explore the 
role of RhoA in GH stimulated Stat5 mediated transcription. This work also provides 
an insight of the mechanism of GH stimulated activation of these small GTPases and 



















2.1 Chemicals and reagents 
Recombinant human growth hormone (hGH) was a generous gift of Novo 
Nordisk (Singapore). The p44/42 MAP kinase assay kit and the SAPK/JNK assay kit 
were purchased from New England Biolabs (Beverly, MA). The PKA activity assay 
kit was obtained from Upstate Biotechnology (Lake Placid, NY). The Biotin DNA 
labeling kit was from Pierce (Milwaukee, WI). The transfection reagent Effectene™ 
was from Qiagen (Hilden, Germany). The Complete™ protease inhibitor cocktail 
tablets were purchased from Roche Diagnostics (Mannheim, Germany). The 
enhanced chemiluminescence (ECL) kit were purchased from Amersham Pharmacia 
Biotech (Buckinghamshire, UK). The QuikChange® site-directed mutagenesis kit 
was purchased from Stratagene (La Jolla, CA). The β-gal enzyme activity assay 
system was from Promega (Madison, WI). Myristoylated PKA inhibitor was from 
Calbiochem (La Jolla, CA), trichostatin A (TSA) was from Sigma (St. Louis, MO), 
forskolin and 8-Br-cAMP were from Merck (Whitehouse Station, NJ). DAPI was 
from Molecular Probes (Eugene, OR). The [3H] acetyl CoA and [32P] ATP were from 
NEN® Life Science Products Inc (Boston, MA). P81 phosphocellulose paper squares 
were purchased from Upstate Biotechnology (Lake Placid, NY).  All other chemicals 




2.2 DNA constructs   
pET15b-GST-RalGDS-RBD construct  encoding the 97 amino acids 
spanning RBD of RalGDS, pGEX4T3-GST-RalBD construct for GST-RLIP-RBD 
containing amino acids 397 to 518 of human RLIP76 and pGEX2T-RBD construct for 
GST-Raf1-RBD containing amino acids 51-131 of Raf-1 were the generous gifts of 
Dr. Johannes L. Bos (Utrecht, Netherlands). The wild type and dominant negative 
form Rap1A plasmids were kindly provided by Dr. Alfred Wittinghofer (Dortmund, 
Germany). The kinase defective mutant DNA constructs for c-Src and JAK2 were 
generously provided by Dr. Joan S. Brugge (Boston, MA) and Dr. Olli Silvennoinen 
(Tampere, Finland), respectively. The wild type CrkII expression vector and the wild 
type and Y504F mutant form of C3G were generous gifts from Dr. Michiyuki 
Matsuda (Tokyo, Japan). The dominant negative form of Ras cDNA and the wild type 
RhoA cDNA were purchased from Upstate Biotechnology (Lake Placid, NY). RhoA 
S188A mutant DNA was generated by the QuikChange® site-directed mutagenesis kit 
(Stratagene). pGEX-3X-C21 construct containing the RBD of Rhotekin, the 
pCAG-Myc-ROCK construct and the GFP-C3 exoenzyme expression vector were 
generous gifts of Dr. Shuh Narumiya (Kyoto, Japan). The wild type p190RhoGAP 
expression vector and the GAP defective mutant R1283A were obtained from Dr. Ian 
Macara (Virginia, USA). The p300 wild type vector and HAT defective mutant 
p300MutAT2 were from Dr. Hendrik Stunnenberg (Nijmegen, Netherlands). The 




(Dundee, UK). The HDAC6 expression vector with Myc tag was kindly provided by 
Dr. Tony Kouzarides (Cambridge, UK). The trans-activator plasmid pFA2-Elk-1, 
pFA2-c-Jun and pFA2-CREB consisting of the DNA binding domain of Gal4 (residue 
1-147) fused with the transactivation domain of Elk-1 (residue 307-427), c-Jun 
(residue 1-223) or CREB (residue 1-280), respectively, and the pFR-Luc plasmid 
containing luciferase reporter gene were purchased from Stratagene (La Jolla, CA). 
The Spi-GLE1-Luc plasmid was from Dr Haldosen (Karolinska, Sweden). All 
plasmids were prepared with the plasmid maxiprep kit from Qiagen (Hilden, 
Germany). 
2.3 Antibodies   
The monoclonal antibodies against CrkII, Ras, RalA, phospho-tyrosine 
PY20, p190RhoGAP and ROCK were obtained from Transduction Laboratories 
(Lexington, KY). The polyclonal antibodies against JAK2, C3G, Rap1, Rap2, ROCK, 
PKA or Stat5A/B, the monoclonal antibody against RhoA, and protein A/G plus 
agarose were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). GFP 
monoclonal antibody was purchased from Clonetech (Palo Alto, CA). The 
monoclonal antibodies against c-Src, p300, phospho-Stat5A/B (Y694/Y699), or 
phospho-tyrosine (4G10) and the polyclonal antibody against phospho-MYPT (Thr 
696) were purchased from Upstate Biotechnology (Lake Placid, NY). Anti-mouse IgG 




(St. Louis, MO). Anti-mouse or anti-rabbit IgG conjugated to HRP were purchased 
from Amersham Pharmacia Biotech (Buckinghamshire, UK).  
2.4 Cell culture and treatment 
NIH-3T3 cells were grown at 37 ˚C in 5 % CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10 % heat-inactivated fetal bovine serum 
(FBS), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine. 
NIH-3T3 cells were grown on coverslips or culture flasks in medium containing 10 % 
fetal bovine serum before deprival of serum for 14-16 h. Quiescent cells were treated 
with 50 nM hGH unless otherwise indicated, or pretreated with chemicals as indicated 
prior to hGH stimulation. 50 nM of hGH is within the physiological range for 
circulating rodent GH (Gaur et al., 1996). 
2.5 Site-directed mutagenesis and polymerase chain reaction (PCR)  
RhoA mutation (S188A) was generated by PCR mutagenesis using the 
QuikChange® site-directed mutagenesis kit (Stratagene) according to the 
manufacturer’s instructions.  
The primers were synthesized by BioAsia Inc, China. The primer pairs are: 
5’-primer, 5’-CGTGGGAAGAAAAAAGCTGGTTGCCTTGTCT-3’; and 3’-primer, 
5’-AGACAAGGCAACCAGCTTTTTTCTTCCCACG-3’.  
To amplify DNA, 50 ng of cDNA template was mixed with the PCR 




MgSO4, 0.1 % Triton X-100, 0.1 mg/ml nuclease-free BSA], 200 µM each of the 
deoxy-adenine, deoxy-cytosine, deoxy-guanine and deoxy-thymidine nucleotides 
(New England Biolabs), 125 ng each of the sense and anti-sense primers and 2.5 units 
of PfuTurbo DNA polymerase. The reaction was carried out by predenaturation at 95 
oC for 30 sec followed by 16 cycles of denaturation at 95 oC for 30 sec, annealing at 
55 oC for 1 min and extension at 68 oC for 10 min. After PCR, the samples were 
cooled down to 37 oC and 10 units of DpnI enzyme were added to digest the parental 
supercoiled dsDNA at 37 oC for 1h. 2 µl of the DpnI treated DNA was used to 
transform 50 µl of DH5α E. coli competent cells. 
2.6 Preparation of E. coli competent cells 
DH5α E. coli strain was streaked onto an LB (pH 7.5) agar plate (1 % 
bacto-tryptone, 0.5 % bacto-yeast extract, 1 % NaCl and 1.5 % agar) without 
antibiotics and incubated at 37 ˚C overnight. A single colony was inoculated into 2 ml 
of LB and grown at 37 ˚C with shaking. The culture was added into 400 ml of LB 
(OD600 < 0.1) and grown for approximately 3-4 h at 37 ˚C to reach OD600 0.3-0.6. The 
cells were harvested by centrifugation at 4000 rpm for 5 min at 4 ˚C. The pellet was 
resuspended on ice in 1/20 volume of TSS buffer (LB broth, pH 6.1, 10 % PEG, MW 
3350 or 8000, 5 % DMSO, 10 mM MgCl2, 10 mM MgSO4, pH 6.5-6.8), followed by 
incubation on ice for 10 min. The competent cells were aliquoted and stored at -80 ˚C.




2.7 DNA transformation 
The plasmid DNA (0.1-0.5 µg) was mixed with 50 µl of competent cells 
and incubated on ice for 30 min. The cells were subjected to heat-shock at 42 ˚C for 
90 sec allowing the DNA to enter the cells. After another 5 min of incubation on ice, 
the cells were grown in nonselective medium for 1 h and then spread on the LB agar 
plates containing the appropriate antibiotics.       
2.8 DNA preparation 
Small-scale plasmid DNA preparation was carried out using the Qiagen 
Minipreps Kit (Qiagen, Germany) according to the manufacturer’s instructions. The 5 
ml overnight bateria culture was harvested by centrifugation at 14,000 rpm for 15 
min. The cell pellet was resuspended in Resuspension Solution (50 mM Tris-HCl, pH 
7.5, 10 mM EDTA, pH 8.0, and 100 µg/ml RNase A), followed by the addition of 
Lysis Solution (0.2 M NaOH and 1 % SDS) and Neutralization Solution (4.09 M 
guanidine hydrochloride, 0.759 M potassium acetate and 2.12 M glacia acetic acid, 
pH 4.2). The lysate was centrifuged at 14,000 rpm for 10 min at room temperature, 
and the supernatant was transferred to the Spin Column. After spin for 1 min, the 
column was washed by Washing Solution diluted with 95 % ethanol (162.8 mM 
potassium acetate and 27.1 mM Tris-HCl, pH 7.5). The plasmid DNA was eluted in 




Large-scale plasmid DNA preparation was carried out using QIAGEN 
Plasmid Maxi Kit (QIAGEN, Germany) according to the manufacter’s instructions. 
Similar to the process of minipreps, large volume (200 ml) of bacteria culture was 
harvested and incubated with Resuspension, Lysis and Neutralization Solution 
sequentially. After centrifugation, the supernatant was subjected to the 
pre-equilibrated QIAGEN-tip 500 column, followed by washing with Buffer QC (1 M 
NaCl, 50 mM MOPS, pH 7.0 and 15 % isopropanol). The plasmid DNA was eluted 
by Buffer QF (1.25 M NaCl, 50 mM Tris-HCl, pH 8.5 and 15 % isopropanol) and 
precipitated by 0.7 volume of isopropanol. The DNA pellet was washed with 70 % 
ethanol, air-dried and dissolved in nuclease-free water.       
2.9 Agarose gel electrophoresis 
0.8 % agarose (w/v) gels were prepared in 1 x TAE buffer (40 mM 
Tris-acetate and 2 mM EDTA) supplemented with ethidium bromide (1 µg/ml). The 
samples were loaded into the agarose gel after mixed with DNA loading buffer (0.25 
% bromophenol blue and xylene cyanol in 25 % Ficoll type 400) and electrophoresed 
in 1x TAE buffer. The DNA bands were visualized by a UV-transilluminator with the 
wavelength at 300 nm or 366 nm.       
2.10 Purification of GST fusion proteins 
E. coli strain BL-21 cells transformed with the plasmid with the GST-fusion 




reach OD600 0.6-1.0 and induced by 1 mM IPTG at 37 ˚C for 3 h.  Cells were then 
harvested and sonicated in the sonication buffer (50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 % Triton X-100, 1 mM DTT, 1 tablet of Complete™ protease 
inhibitor mixture per 50 ml) on ice for 10 cycles of 1 min. After centrifugation, the 
supernatants were incubated with 1 ml of glutathione-agarose beads at 4 ˚C for 1 h.  
The beads were washed two times by high salt buffer (50 mM Tris-HCl, pH 7.5, 500 
mM NaCl, 1 mM EDTA, 0.5 % Triton X-100, 1 mM DTT, 1 tablet of Complete™ 
protease inhibitor mixture per 50 ml) and two times by low salt buffer (50 mM 
Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 tablet of Complete™ 
protease inhibitor mixture per 50 ml). The purified GST-fusion protein was eluted by 
50 mM glutathione and dialysis was performed overnight in the dialysis buffer (50 
mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT). The yield of the 
protein was analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue. The 
purified protein was aliquoted and stored in –80 ˚C.  
2.11 Transient transfection of mammalian cells   
Cells were cultured to 50 % confluence in medium supplemented with 10 % 
fetal bovine serum. Transient transfection was performed using Effectene™ according 
to the manufacturer's instructions. The DNA (µg) to Effectene (µl) ratio was 1: 20. 
Cells were incubated with the transfection complex for 6-18 h before change of 




2.12 Nuclear extraction  
Cells were rinsed once with ice-cold PBS and incubated with 500 µl buffer 
A (10 mM Tris-HCl, pH 7.4, 10 mM KCl, 2 mM MgCl2, 1mM dithiothreitol, 0.1 mM 
PMSF, 1 tablet of Complete™ protease inhibitor mini mixture per 10 ml) at 4 ˚C for 
30 or 60 min until intact nuclei were isolated completely observed by microscopy. 
The nuclei were collected by centrifugation at 4,000 rpm at 4 ˚C for 10 min, and then 
lysed in 40 µl buffer B (20 mM HEPES, pH 8.0, 400 mM NaCl, 1 mM EGTA, 10 % 
glycerol, 1mM DTT, 0.5 mM PMSF, 1 tablet of Complete™ protease inhibitor mini 
mixture per 10 ml) at 4 ˚C for 60 min. After that, the samples were centrifuged and 
the supernatants were the nuclear extracts. The protein concentration were measured 
and diluted as required. 
2.13 Immunoprecipitation  
After treatment as indicated, cells were lysed at 4 ˚C for 20 min in 1 % 
Nonidet P-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 1 % Nonidet P-40, 150 mM 
NaCl, 1 mM EDTA, 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
Na3VO4, 1 tablet of Complete™ protease inhibitor mixture per 50 ml). Cell lysates 
were centrifuged at 14,000 rpm for 15 min and the supernatants were precleared by 
the protein A/G plus agarose. The agarose beads were removed by centrifugation and 
then the protein concentrations of the supernatants were determined. For each 




corresponding antibody for 4 h or overnight at 4 ˚C. Immunocomplexes were 
incubated with 40 µl protein A/G plus agarose for 1 h or overnight. 
Immunoprecipitates were washed three times with PBS or lysis buffer. The bound 
proteins were eluted in laemmli sample buffer and then resolved by SDS-PAGE.  
2.14 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)  
The Laemmli SDS-polyacrylamide gel was cast using the Bio-Rad 
Mini-PROTEAN II system. The separating gel was composed of 6-12 % acrylamide 
(37.5: 1), 0.375 M Tris-HCl, pH 8.8 and 0.1 % SDS.  The stacking gel was 
composed of 4 % acrylamide, 0.125 M Tris-HCl, pH 6.8, and 0.1 % SDS. The gels 
were polymerized by the addition of freshly prepared 0.1 % ammonium persulfate and 
0.01 % TEMED. Protein samples were mixed with an equal volume of 2 X sample 
buffer (100 mM Tris, pH 6.8, 4 % SDS, 20 % glycerol, 10 % β-mercaptoethanol, and 
0.4 % bromophenol blue) and boiled for 5 min before loaded into the gel.  
Electrophoresis was carried out in 1 X SDS-PAGE running buffer (25 mM Tris, pH 
8.3, 192 mM glycine and 0.1 % SDS) at a constant voltage of 200 V. 
2.15 Western blot analysis   
After SDS-PAGE, proteins were transferred to nitrocellulose membranes. 
The membranes were blocked with 5 % nonfat dry milk in PBS with 0.1 % Tween-20 
(PBST) for 1 h at 22 ˚C. Blots were then immunolabeled with the desired antibodies 




stripping buffer (62.5 mM Tris-HCl, pH 6.7, 2 % SDS, and 0.7 % 
β-mercaptoethanol). Blots were then washed for 30 min with three changes of PBST 
at 22 ˚C. Efficacy of stripping was determined by re-exposure of the membranes to 
ECL. Thereafter, membranes were reblocked and immunolabeled as desired. 
Immunolabeling was detected by the enhanced chemiluminescence (ECL) kit 
according to the manufacturer’s instructions. 
2.16 Immunofluorescence and microscopy 
Cells were grown on coverslips in complete medium until 40-50 % 
confluence and then transfected with C3 exoenzyme. After 24 h post-transfection, 
cells were deprived of serum for 16 h and treated with GH for 30 min. After that, cells 
were fixed in 4 % paraformaldehyde in PBS for 20 min, washed by PBS and blocked 
in 2 % BBX (0.1 % Triton X-100, 0.1 % BSA, 250 mM NaCl, prepared in PBS). The 
cells were then incubated with the polyclonal antibody against Stat5 for 1 h at room 
temperature. After washed by BBX, cells were incubated with anti-rabbit IgG 
conjugated with Cy3. The nonspecifically bound antibody was removed by washing 
in BBX. Thereafter, DAPI nuclear staining was performed for 5 min. Labeled cells 
were visualized with Leica DM RXA2 fluorescent microscope. Images were 
converted to the tagged-information-file format and processed with the Adobe 




2.17 Gel electrophoretic mobility shift assay (GEMSA) 
Nuclear extracts were prepared as described above. The double-stranded 
Spi-GLE1 probe was labeled with biotin at the 3’ end according to the manufacturer’s 
instructions. Briefly, 5 pmol of each complementary oligonucleotide of the probe 
DNA was labeled by biotin-N4-CTP in the presence of terminal deoxynucleotidyl 
transferase (TdT) at 37 ˚C for 30 min. The reactions were stopped by EDTA and then 
TdT was extracted by chloroform: isoamyl alcohol. Then the two completed 
end-labeling reactions were annealed at room temperature for 1 h. The binding 
reactions for GEMSA were performed by preincubating 10 µg of nuclear extract of 
each sample with 1 µg of poly (dI· dC) in binding buffer (10 mM Tris, 50 mM KCl, 1 
mM dithiothreitol, pH 7.5, 0.5 mM EDTA) for 15 min on ice. For supershift analysis, 
the extract was incubated with the antibody against Stat5, RhoA or p300 for another 
10 min on ice. After that, 20 fmol Spi-GLE1 probe was added. The binding mixture 
was incubated at room temperature for 20 min. The samples were separated by 
electrophoresis on 6 % non-denaturing polyacrylamide gel in 0.5 X TBE buffer at 120 
V at 4 ˚C, followed by transfer to Hybond-N® membrane at 380 mA for 30 min. After 
that, the membrane was blocked for 15 min and incubated with Streptavidin-HRP 
conjugate for another 15 min. After washing, the biotin-labeled DNA was detected by 





2.18 RalA, Rap and Ras activity assays 
Serum starved cells were stimulated with hGH as indicated and then lysed 
on ice for 15 min in Ral buffer (50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 2.5 mM 
MgCl2, 10 % glycerol, 1 % Nonidet P-40, 1 mM PMSF, 1 mM Na3VO4 and 1 tablet 
of Complete™ protease inhibitor cocktail per 50 ml). After lysis, samples were 
centrifuged at 14,000 rpm at 4 ˚C for 10 min and the protein concentrations of the 
lysates were measured. 500 µg of cell lysates were immediately affinity precipitated 
at 4 ˚C for 1 h with 50 µg of GST-RalGDS-RBD or 15 µg of GST-RalBP1-RBD or 
GST-Raf1-RBD fusion proteins that had been freshly precoupled to glutathione 
agarose beads. The precipitates were washed three times with Ral buffer and the 
bound proteins were eluted in 20 µl laemmli sample buffer. Samples were separated 
by 12 % polyacrylamide SDS-PAGE, and detected by western blot analysis. 
2.19 RhoA activity assay 
Serum starved cells were stimulated with hGH as indicated and then lysed 
on ice for 15 min in 1 X MLB buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1 % 
NP-40, 10 mM MgCl2, 1 mM EDTA, 2 % glycerol, 500 mM NaF, 1 mM Na3VO4 and 
1 tablet of Complete™ protease inhibitor mini mixture per 10 ml). After that, samples 
were centrifuged at 14,000 rpm at 4 ˚C for 10 min and the protein concentrations of 
the supernatants were measured. 800 µg of cell lysates were immediately affinity 




been freshly precoupled to glutathione agarose beads. The precipitates were washed 
three times with MLB buffer and the bound RhoA-GTP was eluted in 20 µl laemmli 
sample buffer. Samples were separated by 12 % polyacrylamide SDS-PAGE, and 
detected by monoclonal RhoA antibody. 
2.20 p44/42 MAP kinase assay  
p44/42 MAPK kinase assays were performed according to the 
manufacturer’s instructions. Briefly, cells were lysed at 4 ˚C in lysis buffer provided 
and the cell extract containing 200 µg of protein per sample was incubated for 4 h or 
overnight with 15 µl immobilized phospho-specific p44/42 MAP kinase 
(Thr202/Tyr204) monoclonal antibody. Then the pellets were washed twice with 500 
µl of lysis buffer and twice with 500 µl of kinase assay buffer provided. The kinase 
reactions were performed in the presence of 2 µg of Elk-1 fusion protein and 200 µM 
ATP at 30 ˚C for 30 min.  Elk-1 phosphorylation was detected by use of a specific 
phospho-Elk1 (Ser383) antibody. 
2.21 JNK/SAPK assay  
SAPK/JNK assays were performed according to the manufacturer’s 
instructions. Briefly, cells were lysed at 4 ˚C in lysis buffer provided and the cell 
extract containing 250 µg total protein per sample was incubated overnight at 4 ˚C 
with 20 µl c-Jun (residue 1-89) fusion protein glutathione sepharose beads. Then the 




assay buffer provided. The kinase assay was performed in the presence of 100 µM 
ATP at 30 ˚C for 30 min.  c-Jun phosphorylation was detected by use of a specific 
phospho-c-Jun (Ser63) antibody. 
2.22 PKA kinase activity assay  
1 mg of cell lysates per sample were prepared and immunoprecipitated by 4 
µg PKA antibody or control antibody. The immunoprecipitates were washed twice by 
lysis buffer and twice by ADB buffer (20 mM MPOS, PH 7.2, 25 mM 
β-glycerophosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM DTT). Kinase 
reactions were performed in the presence of 2 µM cAMP, 100 µM Kemptide 
(LRRASLG), 400 nM PKC inhibitor peptide, 4 µM Compound R24571 and Mg+/ATP 
cocktail containing 10 µCi [γP32] ATP at 30 ˚C for 10 min. 25 µl of the reaction buffer 
was blotted on the P81 paper square for each sample. The assay squares were washed 
three times with 0.75 % phosphoric acid and once with acetone. The radioactivity was 
measured by scintillation counter. The cpm of the enzyme sample was subtracted by 
that of the control sample.    
2.23 ROCK activity assay  
500 µg of cells lysates per sample were prepared and immunoprecipitated as 
described previously by ROCK polyclonal antibody. The immunoprecipitates were 
washed by lysis buffer and resuspended in 50 µl Tris/ATP buffer (50 mM Tris-HCl, 




µM ATP). The kinase reactions were performed in the presence of 1 µg recombinant 
MYPT1 (654-880) at 30 ˚C for 30 min. MYPT1 phosphorylation was detected by use 
of a specific phospho-MYPT1 (Thr696) antibody. 
2.24 p300/HAT activity assay 
500 µg nuclear extracts were prepared as described above and then 
subjected to immunoprecipitation by 10 µg p300 monoclonal antibody or control 
monoclonal antibody. The immunoprecipitates were washed three times by PBS and 
once by assay buffer (50 mM Tris-base, pH 8.0, 10 % glycerol, 0.1 mM EDTA and 1 
mM dithiothreitol). The enzymatic reactions were performed at 30 ˚C for 30 min in 
the presence of 10 µg core histones and 20 µM acetyl-CoA containing 0.5 µCi [3H] 
acetylCoA. 5 µl of each sample was blotted on the P81 paper in triplicate. The paper 
squares were washed three times in TCA and once in acetone. The radioactivity was 
measured by scintillation counter. The cpm of the enzyme sample was subtracted by 
that of the negative control sample.    
2.25 Luciferase reporter assay   
Either 0.2 µg of the reporter plasmid pFR-Luc and 4 ng of the 
corresponding fusion trans-activator plasmid or 0.5 µg of Spi-GLE1-Luc reporter 
plasmid were transfected with 0.8 µg of DNA of interest into cells grown in 2 % 
serum containing DMEM medium upon 60-80 % cell confluence. 0.4 µg of 




efficiency. After 36 h, cells were stimulated with 50 nM GH for 6 h immediately or 
after chemical pretreatment for 30-60 min. Cells were washed by PBS twice and lysed 
in RLB buffer (25 mM glycylglycine, pH 7.8, 1 % Triton X-100, 15 mM MgSO4, 4 
mM EGTA, 1 mM dithiothreitol) for 20 min. The luciferase activity was measured in 
the presence of RAB buffer (25 mM glycylglycine, pH 7.8, 15 mM potassium 
phosphate, pH 7.8, 15 mM MgSO4, 4 mM EGTA, 1 mM dithiothreitol and 1 mM 
ATP) and 200 nM D-luciferin. β galactosidase activity was measured in the assay 
buffer (100 mM sodium phosphate, pH 7.3, 1 mM MgCl2, 50 mM β-mercaptoethanol, 
0.665 mg/ml ONPG). The luciferase activities were calculated as the fold of 
stimulation after normalized by protein content and the β galactosidase activity. 
2.26 Densitometric analysis of band intensities         
The intensities of the respective bands on the blots were quantitated using a 
Bio-Rad GS-700 imaging densitometer and analyzed with the Multi-Analyst program 
(version 1.0.1, Bio-Rad). In brief, bands on X-ray films were marked and their total 
integrated volumes were quantitated against the film background. Corrected 
integrated volumes (in arbitrary units) were plotted.  
2.27 Statistical analysis and presentation of data  
All experiments were performed at least three times. Numerical data were 
expressed as mean ± SD. Data were analyzed using the two-tailed t test or analysis of 












Src-CrkII-C3G Dependent Activation of Rap1 Switches Growth Hormone 




3.1 GH stimulation of NIH-3T3 cells increases the level of GTP bound Rap1 and 
Rap2. 
The GST fused Ral-GDS-RBD (Franke et al., 1997) was utilized as a 
specific probe to determine Rap1 and Rap2 activation in lysates of NIH-3T3 cells 
stimulated by GH. The GST fused Ral-GDS-RBD protein recognizes only the active 
GTP bound form of Rap1 and Rap2 but not the inactive GDP bound form of these 
molecules (Franke et al., 1997). I observed an increased level of GTP bound Rap1 
upon cellular stimulation with GH, first observed at 2 min after GH addition, 
sustained to 15 min, and followed by a decline from 30 to 60 min (Fig. 3.1A).  GH 
stimulation of NIH-3T3 cells also resulted in the formation of GTP-bound Rap2 
within 2 min. However, GH stimulated formation of GTP-bound Rap2 was not 
sustained, as observed for Rap1, and the level of GTP-bound Rap2 decreased 
immediately after 5 min (Fig. 3.1A). GH stimulation of NIH-3T3 cells did not alter 
Rap1 or Rap2 protein levels over the examined time period of stimulation (Fig. 3.1A). 
The GH stimulated formation of Rap1-GTP and Rap2-GTP was also dose dependent 
with the enhancement of Rap1-GTP and Rap2-GTP levels first observed at 0.5 nM 
GH. The maximal stimulation of Rap1-GTP was from 5 to 50 nM GH (Fig. 3.1B) 
while that of Rap2-GTP was at 5 nM GH (Fig. 3.1B). Thus Rap1 and Rap2 are two 



















Fig. 3.1 GH stimulates the formation of GTP bound Rap1 and Rap2 in NIH-3T3 
cells in both a time and dose dependent manner. NIH-3T3 cells were stimulated 
with the indicated doses of GH for the indicated time periods and the GST-linked 
probe Ral-GDS-RBD, which recognizes only the active GTP bound form of Rap1 and 
Rap2, was used to separate Rap-GTP from the inactive Rap-GDP. GTP bound Rap1 
and Rap2 were visualized by Western blot analysis. Total cellular Rap1 and Rap2 
were also determined in total cell lysate by Western blot analysis as protein loading 



















3.2 GH stimulated activation of Rap1 and Rap2 are cell density dependent 
During the course of experimentation, an effect of cell density in monolayer 
culture on the ability of GH to stimulate Rap1 and Rap2 activity was noticed. We 
therefore compared Rap activity under conditions of increasing cell density that 
approximated 40 %, 70 % and 100 % cell confluence, respectively. A decrease of 
both basal and GH stimulated Rap1 and Rap2 activity was observed with increasing 
cell density. GH stimulation of NIH-3T3 cells at 100 % confluence failed to stimulate 
the formation of GTP-bound Rap1 and only minimal activation of Rap2 by GH under 
these conditions was observed (Fig. 3.2). This effect of cell density on the ability of 
GH to stimulate the activation of Rap1 and Rap2 was not due to decreased Rap 
protein as the total level of Rap1 and Rap2 was equivalent at different cell densities 













Fig. 3.2 GH stimulated activation of Rap1 and Rap2 are regulated by cell 
density. NIH-3T3 cells were cultured until 40 %, 70 % or 100 % confluence before 
treatment with 50 nM GH for 2 minutes. The GST-linked probe Ral-GDS-RBD was 
used to separate Rap-GTP from Rap-GDP. GTP bound Rap1 and Rap2 were 
visualized by Western blot analysis. Total cellular Rap1 and Rap2 were also 
determined by Western blot analysis. The results presented are representative of a 












3.3 Full activation of Rap1 and Rap2 by GH requires both JAK2 and c-Src. 
GH activates both JAK2 and c-Src kinases independent of the other (Zhu et 
al., 2002). Two other small Ras-like GTPases, RalA and RalB, have been previously 
demonstrated to require the activity of both c-Src and JAK2 to be fully activated by 
GH (Zhu et al., 2002). I therefore next examined the requirement of JAK2 and c-Src 
for GH stimulated activation of Rap1 and Rap2. Upon forced expression of the JAK2 
kinase deficient mutant (K882E) (Rui et al., 2000), both the basal and GH stimulated 
formation of Rap1-GTP and Rap2-GTP were diminished, but GH stimulation of cells 
still resulted in increased Rap1 and Rap2 activity (Fig. 3.3). One previous study has 
demonstrated the efficacy of forced expression of JAK2-K882E to prevent GH 
stimulated activation of JAK2 and JAK2 dependent signal transduction (Zhu et al., 
2002). Forced expression of the c-Src kinase inactive mutant (K295R/Y527F) 
(Rahimi et al., 1998) also abrogated the ability of GH to stimulate the formation of 
GTP bound Rap1 and Rap2 (Fig. 3.3) but to a greater extent than that observed with 
JAK2-K882E. Co-transfection of cDNA for both JAK2-K882E and 
c-Src-K295R/Y527F completely prevented the ability of GH to stimulate the 
formation of GTP bound Rap1 and Rap2 (Fig. 3.3). Forced expression of either 
JAK2-K882E or c-Src-K295R/Y527F or both did not alter the total cellular level of 
Rap1 or Rap2 (Fig. 3.3). Forced expression of the kinase deficient JAK2 and c-Src 




the combined activities of both JAK2 and c-Src kinases are required for full activation 















Fig. 3.3 Full activation of Rap1 and Rap2 by GH requires both JAK2 and c-Src. 
NIH-3T3 cells were transiently transfected with empty vector or the expression 
construct containing either kinase dead JAK2 (K882E) or kinase dead c-Src 
(K295R/Y527F) or both and stimulated with 50 nM GH for 2 min. The GST-linked 
probe Ral-GDS-RBD which recognizes only the active GTP bound form of Rap1 and 
Rap2 was used to separate Rap-GTP from the inactive Rap-GDP. GTP bound Rap1 
and Rap2 were visualized by Western blot analysis. Total cellular Rap1 and Rap2 
were also determined in total cell lysates by Western blot analysis. The forced 
expression of JAK2-K882E and c-Src-K295R/Y527F was indicated. The results 
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3.4 C3G tyrosine phosphorylation is required for GH stimulated Rap1 and Rap2 
activation. 
C3G is a Rap specific GEF that accelerates the replacement of GDP by GTP 
so as to increase Rap activity (Gotoh et al., 1995). I therefore proceeded to examine 
the involvement of C3G in the GH stimulated formation of GTP-bound Rap1 and 
Rap2. Forced expression of C3G resulted in a dramatic enhancement of GH 
stimulated formation of GTP-bound Rap1 and Rap2 (Fig. 3.4A). It has been reported 
that tyrosine 504 of C3G is the critical tyrosine residue required for guanine 
nucleotide exchange activity for Rap1 (Ichiba et al., 1999).  To determine if GH 
stimulated C3G tyrosine phosphorylation was required for activation of Rap1 and 
Rap2, I therefore utilized a C3G mutant (C3G-Y504F) in which tyrosine 504 was 
substituted by phenylalanine (Ichiba et al., 1999). Forced expression of C3G-Y504F 
completely prevented the ability of GH to stimulate the formation of GTP bound 
Rap1 and Rap2 (Fig. 3.4A). Forced expression of either wild type C3G or 
C3G-Y504F did not alter the total cellular Rap1 or Rap2 and the level of forced 
expression was demonstrated by Western blot analysis (Fig. 3.4A). Tyrosine residue 
504 of C3G is therefore essential for GH stimulated activation of Rap1 and Rap2.  
I therefore examined whether GH stimulation of NIH-3T3 cells resulted in 
tyrosine phosphorylation of C3G. As observed in Fig. 3.4B, GH indeed stimulated the 




was first observed at 1 min, persisted to 15 min, and then declined at 30 to 60 min 
after stimulation with GH. Equivalent loading of immunoprecipitated C3G was 
demonstrated by reprobing of the membrane for C3G (Fig. 3.4B).  
To determine the kinases responsible for GH stimulated tyrosine 
phosphorylation of C3G, I utilized the kinase deficient mutants of both JAK2 
(JAK2-K882E) and c-Src (c-Src-K295R/Y527F). Similar to the pattern observed with 
GH stimulated formation of GTP-bound Rap1 and Rap2 (above), removal of the 
activities of both kinases was required for complete prevention of GH stimulated C3G 
tyrosine phosphorylation (Fig. 3.4C). Equivalent loading of immunoprecipitated C3G 
was demonstrated by reprobing of the membrane for C3G (Fig. 3.4C). Forced 
expression of the kinase deficient mutants of both JAK2 and c-Src was demonstrated 
by Western blot analysis (Fig. 3.4C). Taken together, I conclude that GH stimulated 
tyrosine phosphorylation of C3G which is catalyzed by both JAK2 and c-Src is 

















Fig. 3.4A Tyrosine 504 in C3G is required for GH stimulated Rap1-GTP and 
Rap2-GTP formation. NIH-3T3 cells were transiently transfected with the empty 
vector or the expression vector containing either wild type C3G or tyrosine site 
mutant C3G-Y504F. Cells were stimulated with 50 nM GH for 2 min. The 
GST-linked probe Ral-GDS-RBD recognizing only the GTP bound form of Rap was 
used to separate Rap-GTP from Rap-GDP. GTP bound Rap1 and Rap2 were 
visualized by western blot analysis. Total cellular Rap1 and Rap2 were also 
determined in total cell lysates by Western blot analysis as protein loading control. 
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Fig. 3.4B GH stimulates tyrosine phophorylation of C3G. NIH-3T3 cells were 
treated with 50nM GH for the indicated time period. Cell extracts were prepared and 
processed for determination of tyrosine phosphorylated C3G. Total C3G present in the 
C3G immunoprecipitates is indicated. The results presented are representative of a 























Fig. 3.4C GH stimulated C3G tyrosine phosphorylation is both JAK2 and c-Src 
dependent. NIH-3T3 cells were transiently transfected with the empty vector or the 
expression construct containing either the kinase dead JAK2-K882E or kinase dead 
c-Src-K295R/Y527F or both and then stimulated with GH. After that, the cell lysates 
were extracted and the tyrosine phosphorylation of C3G was determined. Total C3G 
present in the C3G immunoprecipitates is indicated. The forced expression of kinase 
dead JAK2 and c-Src is indicated. The results presented are representative of a 
minimum of three independent experiments. The results presented are representative 
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3.5 CrkII-C3G mediates GH stimulated Rap1 and Rap2 activity. 
It has been previously demonstrated that GH stimulates the formation of a 
multiprotein signaling complex centered around CrkII (Zhu et al., 1998a). CrkII and 
C3G are constitutively associated within this complex although GH stimulation of 
cells results in tyrosine phosphorylation of CrkII (Zhu et al., 1998a). CrkII is an 
adaptor protein and has been reported to recruit C3G to the vicinity of kinase 
molecules (Ichiba et al., 1999). Since I have demonstrated above that C3G is required 
for GH stimulated activation of Rap, I next proceeded to examine the involvement of 
CrkII in the GH stimulated formation of GTP-bound Rap1 and Rap2. Forced 
expression of CrkII enhanced the ability of GH to activate both Rap1 and Rap2 (Fig. 
3.5A). Forced expression of C3G, or CrkII together with C3G, resulted in a dramatic 
enhancement of GH stimulated formation of GTP-bound Rap1 and Rap2 (Fig. 3.5A). 
As shown above, forced expression of C3G-Y504F dramatically blocked GH 
stimulated formation of GTP-bound Rap1 and Rap2 (Fig. 3.4 A). Interestingly, forced 
expression of C3G-Y504F also inhibited CrkII enhanced Rap1 and Rap2 activity 
stimulated by GH, suggesting that the effect of CrkII on GH stimulated Rap1 and 
Rap2 activity was mediated by C3G (Fig. 3.5 B). Forced expression of CrkII and C3G 
was verified by Western blot analysis and expression of these proteins did not alter 
the total cellular level of either Rap1 or Rap2 (Fig. 3.5B). Thus, GH stimulated 
















Fig. 3.5A GH stimulated formation of GTP bound Rap1 and Rap2 is increased 
by CrkII and C3G. Wild type CrkII and C3G cDNAs were transiently transfected 
into NIH-3T3 cells before cell stimulation with 50 nM GH for 2 min. The GST-linked 
probe Ral-GDS-RBD was used to separate Rap-GTP from the inactive Rap-GDP. 
GTP bound Rap1 and Rap2 were visualized by Western blot analysis. Total cellular 
Rap1 and Rap2 were also determined in total cell lysates by Western blot analysis. 
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Fig. 3.5B CrkII enhanced Rap1 and Rap2 activity stimulated by GH requires 
C3G activity. CrkII and C3G-Y504F cDNAs were transiently transfected into 
NIH-3T3 cells before cell stimulation with 50 nM GH for 2 min. The GST-linked 
probe Ral-GDS-RBD was used to separate Rap-GTP from the inactive Rap-GDP. 
GTP bound Rap1 and Rap2 were visualized by Western blot analysis. Total cellular 
Rap1 and Rap2 were also determined in total cell lysates by Western blot analysis. 
The forced expression of CrkII and C3G-Y504F is indicated. The results presented 
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3.6 Rap1 prevents the sustained p44/42 MAP kinase activity stimulated by GH 
and mediates CrkII diminished Elk-1 transcriptional activity. 
Among the different Rap1 effectors, p44/42 MAP kinase has been 
extensively studied (Bos et al., 2001). Rap1 has been reported to either stimulate or 
inhibit p44/42 MAP kinase activity depending on the cellular context (Bos et al., 
2001). p44/42 MAP kinase is also activated by GH to exert pleiotropic cellular effects  
and its mechanism of activation has been extensively studied (Bos et al., 2001; Zhu et 
al., 2001). I therefore first examined the effect of forced expression of Rap1 on the 
ability of GH to stimulate p44/42 MAP kinase activity. GH stimulation of vector 
transfected NIH-3T3 cells resulted in a rapid and prolonged activation of p44/42 MAP 
kinase activity such that at 60 min after GH stimulation, p44/42 MAP kinase activity 
was still higher than that in the basal state (Fig. 3.6A). Forced expression of Rap1 did 
not affect the ability of GH to activate p44/42 MAP kinase but prevented the 
sustained activation of p44/42 MAP kinase (Fig. 3.6A). Thus, p44/42 MAP kinase 
activity was not detectable as early as 30 min after stimulation with GH in the 
presence of forcibly expressed Rap1. Concordantly, forced expression of dominant 
negative mutant Rap1S17N prolonged GH stimulated p44/42 MAP kinase activity in 
comparison to vector transfected control (Fig. 3.6A). Thus, markedly less diminution 
of p44/42 MAP kinase activity was observed at both 30 and 60 min after GH 




Activation of p44/42 MAP kinase by GH subsequently results in Elk-1 
mediated transcription and has been suggested to depend on MAP kinase activity 
which is sustained after more than 30 min of cell stimulation (Hodge et al., 1998; 
York et al., 1998). I therefore examined the effect of forced expression of both wild 
type Rap1 and Rap1S17N on the ability of GH to stimulate Elk-1 mediated 
transcription. Forced expression of wild type Rap1 completely prevented GH 
stimulated Elk-1 mediated transcription that was observed in vector transfected 
control (Fig. 3.6B). Rap1S17N consistently enhanced the ability of GH to stimulate 
Elk-1 mediated transcription (Fig. 3.6B). Rap1 therefore negatively regulates the 
ability of GH to maintain sustained activation of p44/42 MAP kinase activity and 
subsequent Elk-1 mediated transcription.  
CrkII, the upstream regulator responsible for GH stimulated activation of 
Rap1, has been demonstrated to prevent GH stimulated p44/42 MAP kinase activity 
upon forced expression (Goh et al., 2000). Therefore, I examined whether Rap1 
mediated the negative effect of CrkII on p44/42 MAP kinase activity. As shown in 
Fig. 3.6 C, forced expression of CrkII dramatically repressed GH stimulated Elk-1 
mediated transcription, while forced expression of Rap1S17N increased GH 
stimulated Elk-1 transactivation. Upon forced expression of both of them, the CrkII 
induced repression of Elk-1 mediated transcription was reverted by Rap1S17N. Thus, 
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Fig. 3.6A Rap1 prevents the sustained p44/42 MAP kinase activity stimulated by 
GH. NIH-3T3 cells were transiently transfected with the expression vectors for Rap1 
or Rap1S17N and stimulated with 50 nM GH for the indicated time periods. p44/42 
MAP kinase activity was determined as described in “material and methods” section. 
GH stimulated p44/42 MAP kinase activity in the presence of transiently transfected 
Rap1 or Rap1S17N are measured. The level of the transfected Rap1 and Rap1S17N 
were shown. Densitometric evaluation of the effects of Rap1 and Rap1S17N on GH 
stimulated p44/42 MAP kinase activation are also presented. 
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Fig. 3.6B Rap1 inhibits GH stimulated Elk-1 mediated transcription. NIH-3T3 
cells were transiently transfected with the expression vectors for Rap1 or Rap1S17N 
together with pFR-Luc and pFA2-Elk-1. The GH stimulated Elk-1 mediated 
transcription was determined by measuring luciferase activity as described in 
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Fig. 3.6C Rap1 mediates CrkII dependent diminution of Elk-1 transcriptional 
activity. NIH-3T3 cells were transiently transfected with the expression vectors for 
CrkII or Rap1S17N or both together with pFR-Luc and pFA2-Elk-1. The GH 
stimulated Elk-1 mediated transcription was determined by measuring luciferase 
activity as described in “materials and methods” section. Data presented are mean ± 
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3.7 Ras and Rap are activated by GH independent of the other. 
It has been previously demonstrated that activation of two small GTPases 
by GH, RalA and RalB, is partially Ras dependent (Zhu et al., 2002). I therefore 
examined whether the GH stimulated formation of Rap1 and Rap2 required prior 
activation of Ras. However, as shown in Fig. 3.7A, forced expression of either wild 
type or dominant negative mutant of Ras did not alter the ability of GH to stimulate 
the formation of GTP bound Rap1 or Rap2. I next examined whether Rap affected the 
ability of GH to activate Ras. Forced expression of wild type Rap1 did not alter the 
ability of GH to stimulate the formation of GTP-bound Ras (Fig. 3.7B). Concordantly, 
forced expression of Rap1S17N was without effect on GH stimulated Ras activity 
(Fig. 3.7B). Forced expression of Ras and Rap1 proteins was demonstrated by 



































Fig. 3.7A Rap is activated by GH independent of Ras. NIH-3T3 cells were 
transiently transfected with the expression vectors for wild type Ras or dominant 
negative RasS17N and stimulated with 50 nM GH for 2 min. The GST-linked probe 
Ral-GDS-RBD recognizing only the GTP bound form of Rap was used to separate 
Rap-GTP from Rap-GDP. GTP bound Rap1 and Rap2 was visualized by Western blot 
analysis. Total cellular Rap1 and Rap2 were also determined in total cell lysates by 
Western blot analysis as protein loading control. The forced expression of Ras is 
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Fig. 3.7B Ras is activated by GH independent of Rap1. NIH-3T3 cells were 
transiently transfected with the expression vectors for wild type Rap1 or dominant 
negative Rap1S17N and stimulated with GH. The GST linked probe Raf1-RBD 
recognizing only the GTP bound form of Ras was used to separate Ras-GTP from 
Ras-GDP. GTP bound Ras was visualized by Western blot analysis. Total cellular Ras 
was also determined in total cell lysates by Western blot analysis as protein loading 
control. The forced expression of Rap1 is indicated. The results presented are 
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3.8 RalA is required for GH stimulated p44/42 MAP kinase activity and 
subsequent Elk-1 mediated transcription.  
p44/42 MAP kinase has previously been demonstrated to be activated by 
GH in a Ras dependent manner (Vanderkuur et al., 1997). Since activation of RalA 
and RalB by GH is also Ras dependent (Zhu et al., 2002), the effect of RalA on GH 
stimulated p44/42 MAP kinase activity was examined. Forced expression of wild type 
RalA slightly increased the basal activity of p44/42 MAP kinase and resulted in a 
prolonged activation of p44/42 MAP kinase in response to GH (Fig. 3.8A).  
Consistently, forced expression of RalAS28N, the dominant negative mutant of RalA, 
decreased both the basal and GH stimulated activity of p44/42 MAP kinase (Fig. 
3.8A). Forced expression of RalA and RalAS28N were demonstrated by the presence 
of the FLAG-tagged RalA with a slightly slower mobility in SDS-PAGE than 
endogenous RalA (Fig. 3.8 A). Thus, RalA is required for full activation of p44/42 
MAP kinase stimulated by GH in NIH-3T3 cells. 
The effect of RalA on GH stimulated Elk-1 mediated transcription was 
further examined. As shown in Fig. 3.8 B, forced expression of RalA increased the 
basal level of Elk-1 mediated transcription and dramatically increased the ability of 
GH to stimulate transcription via Elk-1. Forced expression of RalAS28N reduced the 




Elk-1 mediated transcription. Thus RalA is required for full p44/42 MAP kinase 





















Fig. 3.8A RalA is required for GH stimulated p44/42 MAP kinase activity. 
NIH-3T3 cells were transiently transfected with the expression vectors for wild type 
RalA or dominant negative RalA (RalAS28N) and stimulated with GH for the 
indicated time periods. p44/42 MAP kinase activity was determined as described in 
materials and methods. GH stimulated p44/42 MAP kinase activity in the presence of 
transiently transfected wild type RalA or RalAS28N are presented respectively. The 
level of endogenous RalA and the transfected RalA or RalAS28N in NIH-3T3 cells 
was detected by Western blotting for RalA (transfected RalA is epitope tagged and 
hence exhibits less electrophoretic mobility). Experiments were repeated at least three 
times.
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Fig. 3.8B RalA is required for GH stimulated Elk-1 mediated transcription. 
NIH-3T3 cells were transiently transfected with the expression vectors for wild type 
RalA or dominant negative RalA (RalAS28N) together with pFR-Luc and 
pFA2-Elk-1 for determination of GH stimulated Elk-1 mediated transcriptional 
activity. Data presented are mean ± SD of triplicate determinations. Experiments were 
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3.9 Rap1 inhibits GH stimulated Elk-1 mediated transcription through 
inactivation of RalA 
RalGDS, the Rap1 effector and also a Ral specific GEF, provides a potential 
mechanism for the regulation of Ral activity by Rap1 (Albright et al., 1993; 
Spaargaren and Bischoff, 1994; Matsubara et al., 1999). Since RalA activity was 
required for full p44/42 MAP kinase activation by GH and subsequent Elk-1 mediated 
transcription, it is interesting to examine whether Rap1 inhibition of GH stimulated 
Elk-1 mediated transcription was via modulation of GH stimulated RalA activity. 
Forced expression of wild type Rap1 dramatically inhibited the ability of GH to 
stimulate the activation of RalA (Fig. 3.9A). Concordantly forced expression of the 
dominant negative Rap1S17N enhanced the ability of GH to stimulate the formation 
of GTP-bound RalA (Fig. 3.9A). Forced expression of Rap1 and Rap1S17N was 
demonstrated by Western blot analysis (Fig. 3.9A) and did not affect total cellular 
levels of RalA (Fig. 3.9A).  
I next examined the interaction between Rap1 and RalA for the ability of 
GH to stimulate Elk-1 mediated transcription as an indicator of p44/42 MAP kinase 
activity. GH stimulated Elk-1 mediated transcription was inhibited by forced 
expression of Rap1 and dramatically enhanced by forced expression of RalA (Fig. 
3.9B). Forced expression of Rap1 concommitant with RalA abrogated the ability of 




enhanced the fold stimulation by GH of Elk-1 mediated transcription. Dominant 
negative RalAS28N completely prevented GH stimulated Elk-1 mediated 
transcription in cells transfected either with empty vector or with Rap1S17N (Fig. 
3.9B). Thus, Rap1 influences the ability of GH to activate p44/42 MAP kinase and 
subsequent Elk-1 mediated transcription by modulation of GH stimulated formation 





















Fig. 3.9A Rap1 inhibits GH stimulated activation of RalA. NIH-3T3 cells were 
transiently transfected with the expression vectors for wild type Rap1 or dominant 
negative Rap1S17N and stimulated with 50 nM GH for 2 min. The GST-linked probe 
RLIP76-RBD recognizing only the GTP bound form of RalA was used to separate 
RalA-GTP from RalA-GDP. GTP bound RalA was visualized by Western blot 
analysis. Total cellular RalA was also determined as protein loading control. The 
forced expression of Rap1 and Rap1S17N is indicated. The results presented are 
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Fig. 3.9B Rap1 inhibits GH stimulated Elk-1 mediated transcription by 
inhibition of RalA activity. NIH-3T3 cells were transient transfected with the 
expression vectors for either Rap1 or a dominant negative form of Rap1 (Rap1S17N) 
in the presence or absence of the expression vectors for RalA or a dominant negative 
form of RalA (RalAS28N) together with pFR-Luc and pFA2-Elk-1. GH stimulated 
Elk-1 mediated transcription was determined by measuring luciferase activity as 
described in “materials and methods”. Data presented are mean ± SD of triplicate 
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3.10 C3G and Rap1 are utilized by CrkII to enhance GH stimulated JNK/SAPK 
activity and subsequent c-Jun mediated transcription. 
It has been previously reported that CrkII served as a molecular switch for 
the selective activation of JNK/SAPK by GH and concomitant inactivation of GH 
stimulated p44/42 MAP kinase (Goh et al., 2000). I therefore examined whether C3G 
and Rap1 were required for CrkII enhancement of GH stimulated JNK/SAPK activity. 
As demonstrated in Fig. 3.10A, forced expression of either CrkII or C3G enhanced 
GH stimulated JNK/SAPK activity. Forced co-expression of both CrkII and C3G 
further enhanced both basal and GH stimulated JNK/SAPK activity (Fig. 3.10A). 
Expression of the inactive C3G-Y504F mutant did not affect GH stimulated 
JNK/SAPK activity in NIH-3T3 cells. It could, however, prevent the enhanced GH 
stimulated JNK/SAPK activity observed upon forced expression of CrkII (Fig. 
3.10A). Forced expression of CrkII, C3G and C3G-Y504F was demonstrated by 
Western blot analysis (Fig. 3.10A). Similarly, as demonstrated in Fig. 3.10A, forced 
expression of either CrkII or Rap1 enhanced GH stimulated JNK/SAPK activity. 
Forced co-expression of both CrkII and Rap1 dramatically enhanced both basal and 
GH stimulated JNK/SAPK activity (Fig. 3.10A). Expression of the dominant negative 
Rap1S17N did not affect GH stimulated JNK/SAPK activity per se. It could, 




upon forced expression of CrkII (Fig. 3.10A). Forced expression of CrkII, Rap1 and 
Rap1S17N was demonstrated by Western blot analysis (Fig. 3.10A). 
I next examined the effect of forced expression of CrkII and C3G on the 
ability of GH to stimulate c-Jun mediated transcription. GH stimulation of NIH-3T3 
cells resulted in minimal stimulation of c-Jun mediated transcription (Fig. 3.10B). 
Forced expression of either CrkII or C3G enhanced the ability of GH to stimulate 
c-Jun mediated transcription (Fig. 3.10B). Concordant with JNK/SAPK activity, 
forced co-expression of both CrkII and C3G enhanced both basal and GH stimulated 
c-Jun mediated transcription. Again, similar to the effect observed with JNK/SAPK 
activity, the C3G-Y504F mutant did not affect GH stimulated c-Jun mediated 
transcription per se but did prevent the enhanced GH stimulated c-Jun mediated 
transcription observed upon forced expression of CrkII (Fig. 3.10B). Forced 
expression of either CrkII or Rap1 enhanced the ability of GH to stimulate c-Jun 
mediated transcription. Forced co-expression of both CrkII and Rap1 resulted in a 
dramatic enhancement of GH stimulated c-Jun mediated transcription (Fig. 3.10B). 
Similar to the effect observed with JNK/SAPK activity, the dominant negative 
Rap1S17N did not affect GH stimulated c-Jun mediated transcription per se but did 
prevent the enhanced GH stimulated c-Jun mediated transcription observed upon 
















Fig. 3.10A CrkII dependent GH stimulated JNK/SAPK activation is via C3G and 
Rap1. NIH-3T3 cells were transiently transfected with CrkII in the presence or 
absence of C3G, C3G-Y504F, Rap1, or Rap1S17N, and stimulated with 50 nM GH 
for the indicated time periods. JNK/SAPK kinase activity was determined as 
described in “material and methods”. The phosphorylation level of c-Jun fusion 
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Fig. 3.10B CrkII dependent GH stimulated c-Jun mediated transcription is via 
C3G and Rap1. C3G and Rap1 mediate CrkII enhanced GH stimulated c-Jun 
mediated transcription. NIH-3T3 cells were transiently transfected with CrkII or in the 
presence of the expression vectors for C3G, C3G-Y504F, Rap1, or Rap1S17N 
together with pFR-Luc and pFA2-c-Jun. GH stimulated c-Jun mediated transcription 
was determined by measuring luciferase activity as described in “materials and 
methods”. Data presented are mean ± SD of triplicate determinations. The results 












RhoA/ROCK Activation by Growth Hormone Abrogates p300/HDAC6 




4.1 GH stimulation of NIH-3T3 cells increases the activity of RhoA   
The GST fused Rhotekin-RBD was utilized as a specific probe to determine 
the level of RhoA activation in lysates of NIH-3T3 cells stimulated by GH. The 
Rhotekin-RBD probe recognizes only the active GTP bound form but not the inactive 
GDP bound form of RhoA (Reid et al., 1996). I observed a marked increase in the 
level of GTP bound RhoA upon cellular stimulation with GH, persisting from 2 min 
until 30 min after initial GH stimulation, followed by a decline to the basal level 60 
min after GH stimulation (Fig. 4.1).  The GH stimulated formation of RhoA-GTP 
was also dose dependent with an increase in GTP bound RhoA observed at 5 to 50 
nM GH but not at GH concentrations lower than 0.5 nM (Fig. 4.1). GH stimulation of 
NIH-3T3 cells did not alter the total level of RhoA protein over the examined time 
periods nor under differential dose conditions (Fig. 4.1). Thus, RhoA is a small 













Fig. 4.1 GH stimulates the formation of GTP bound RhoA in both a time and 
dose dependent manner. NIH-3T3 cells were stimulated with the indicated doses of 
GH for the indicated time periods and the GST-linked probe Rhotekin-RBD, which 
recognizes only the active GTP bound form of RhoA, was used to separate 
RhoA-GTP from the inactive RhoA-GDP. GTP bound RhoA was visualized by 
Western blot analysis. Total cellular RhoA was also determined in total cell lysate by 














4.2 GH stimulated activation of RhoA requires the kinase activity of JAK2  
GH activates both JAK2 and c-Src kinases independent of the other (Zhu et 
al., 2002). It has been demonstrated that two other small Ras-like GTPases, Ral and 
Rap, require the activity of both c-Src and JAK2 to be fully activated by GH (Zhu et 
al., 2002, this study). I therefore examined the requirement of JAK2 and c-Src for GH 
stimulated activation of RhoA. As observed in Fig. 4.2, upon forced expression of the 
JAK2 kinase deficient mutant (K882E) (Zhu et al., 2002), the basal level of 
RhoA-GTP was diminished and GH stimulated formation of RhoA-GTP was 
completely prevented. In contrast, forced expression of a c-Src kinase inactive mutant 
(K295R/Y527F) (Rui et al., 2000), under conditions which prevent GH stimulated 
activation of c-Src (Zhu et al., 2002), did not alter the ability of GH to stimulate 
formation of GTP bound RhoA. Co-transfection of both JAK2-K882E mutant and 
c-Src-K295R/Y527F mutant prevented the ability of GH to stimulate the activation of 
RhoA identical to that observed with forced expression of JAK2-K882E mutant alone. 
Forced expression of the kinase deficient mutants of JAK2 and c-Src was verified by 
Western blot analysis (Fig. 4.2) and their expression did not alter the total protein 
level of RhoA (Fig. 4.2). Therefore, I conclude that the kinase activity of JAK2, but 
























Fig. 4.2 GH stimulated activation of RhoA requires the kinase activity of JAK2. 
NIH-3T3 cells were transiently transfected with empty vector or the expression 
construct containing either kinase dead JAK2 (K882E) or kinase dead c-Src 
(K295R/Y527F) or both and stimulated with 50 nM GH for 2 min. The GST-linked 
probe Rhotekin-RBD which recognizes only the active GTP bound form of RhoA was 
used to separate RhoA-GTP from the inactive RhoA-GDP. GTP bound RhoA was 
visualized by Western blot analysis. Total cellular RhoA was also determined in total 
cell lysates by Western blot analysis. The forced expression of JAK2-K882E and 
c-Src-K295R/Y527F is indicated. The results presented are representative of a 
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4.3 p190RhoGAP inhibits GH stimulated RhoA activity  
p190RhoGAP, the most extensively studied GAP for Rho GTPases, 
regulates the activation state of RhoA through acceleration of GTP hydrolysis (Ridley 
et al., 1993). I therefore examined the effect of p190RhoGAP on GH stimulated 
RhoA activity. As observed in Fig. 4.3, GH stimulated RhoA activity was 
dramatically repressed by forced expression of p190RhoGAP. Forced expression of 
p190RhoGAP did not alter the total protein level of RhoA (Fig. 4.3). Forced 
expression of p190RhoGAP was verified by western blot analysis (Fig. 4.3). 
p190RhoGAP is therefore a potent inhibitor for GH stimulated formation of GTP 













Fig. 4.3 p190RhoGAP inhibits GH stimulated RhoA activity. p190RhoGAP 
cDNAs was transiently transfected into NIH-3T3 cells before cellular stimulation with 
50 nM GH for 2 min. The GST-linked probe Rhotekin-RBD which recognizes only 
the active GTP bound form of RhoA was used to separate RhoA-GTP from the 
inactive RhoA-GDP. RhoA-GTP was visualized by Western blot analysis. Total 
cellular RhoA and the forced expression level of p190RhoGAP were determined by 
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4.4 JAK2 induced dissociation of RhoA from the complex containing 
p190RhoGAP is required for GH stimulated RhoA activation  
Since both JAK2 and p190RhoGAP regulated GH stimulated formation of 
GTP bound RhoA, I examined the relationship between these molecules on the ability 
of GH to stimulate the activation of RhoA. As observed in Fig. 4.4A, forced 
expression of JAK2 increased both basal and GH stimulated RhoA activity as would 
be expected from the JAK2 dependent activation of RhoA by GH described above. 
Forced expression of p190RhoGAP prevented GH stimulated formation of 
RhoA-GTP and forced expression of p190RhoGAP concomitant with forced 
expression of JAK2 completely prevented the JAK2 enhanced activation of RhoA by 
GH (Fig. 4.4A). The replacement of Arg 1283 of p190RhoGAP by Ala has previously 
been reported to disrupt GAP activity (Tatsis et al., 1998). I therefore utilized this 
p190R1283A mutant to competitively antagonize the activity of endogenous 
p190RhoGAP. In Fig. 4.4A, forced expression of the p190R1283A mutant robustly 
enhanced both basal and GH stimulated formation of GTP bound RhoA. Forced 
expression of kinase deficient mutant JAK2-K882E prevented GH stimulated 
activation of RhoA (Fig. 4.4A). The lack of GH stimulated formation of GTP bound 
RhoA as a result of forced expression of JAK2-K882E was reversed by concomitant 
transfection with p190R1283A. The effect of p190RhoGAP on GH stimulated 




expression of p190RhoGAP, p190R1283A, JAK2 and JAK2-K882E were verified by 
Western blot analysis and the forced expression of these molecules did not alter the 
total cellular level of RhoA (Fig. 4.4A). Thus, GH stimulated formation of RhoA-GTP 
requires JAK2 kinase activity and subsequent inactivation of p190RhoGAP. 
One mechanism for the regulation of p190RhoGAP activity is by tyrosine 
phosphorylation (Arthur et al., 2000; Tatsis et al., 1998). I therefore first examined 
whether GH could affect the level of tyrosine phosphorylation of p190RhoGAP. 
p190RhoGAP was immunoprecipitated from extracts derived from cells stimulated 
with GH and the immunoprecipitates subject to Western blot analysis for 
phosphotyrosine. As shown in Fig. 4.4B, GH had no effect on the tyrosine 
phosphorylation status of p190RhoGAP despite equivalent amounts of p190RhoGAP 
being precipitated. In the basal unstimulated cellular state RhoA and p190RhoGAP 
are present within the same protein complex demonstrated by their 
co-immunoprecipitation (Fig. 4.4C). Despite the inability of GH to alter the tyrosine 
phosphorylation status of p190RhoGAP, GH stimulation of cells resulted in a 
decrease of co-immunoprecipitation between p190RhoGAP and RhoA (Fig 4.4C). 
The above effect of GH was prevented by forced expression of the kinase inactive 
mutant JAK2-K882E (Fig. 4.4C). Equivalent loading of p190RhoGAP is shown in 
Fig. 4.4C. Forced expression of JAK2-K882E was verified by Western blot analysis 
as observed in Fig. 4.4C. Thus, JAK2 kinase activity is required for GH stimulated 




release of RhoA from inhibition by p190RhoGAP and the increased level of active 
RhoA. 
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Fig. 4.4A p190RhoGAP inhibits JAK2 dependent RhoA activation stimulated by 
GH. cDNAs for wild type JAK2 and p190RhoGAP or dominant negative mutant 
JAK2-K882E and GAP defective mutant p190R1283A were transiently transfected 
into NIH-3T3 cells as indicated before cellular stimulation with 50 nM GH for 2 min. 
The GST-linked probe Rhotekin-RBD which recognizes only the GTP bound form of 
RhoA was used to separate RhoA-GTP from the inactive RhoA-GDP. GTP bound 
RhoA and the total cellular RhoA were visualized by Western blot analysis. The 
forced expression of JAK2 and p190 as well as their corresponding dominant negative 
mutants is also indicated. Densitometric evaluation of the effects of JAK2 and p190 
on GH stimulated RhoA activation is presented. The results presented are 







Fig. 4.4B p190RhoGAP is constitutively tyrosine phosphorylated independent of 
GH treatment. NIH-3T3 cells were stimulated with 50 nM GH for the indicated time 
periods. After that, the cell lysates were extracted and the tyrosine phosphorylation of 
p190RhoGAP was determined. Total p190RhoGAP present in the immunoprecipitates 
is indicated. The results presented are representative of a minimum of three 


















Fig. 4.4C JAK2 is required for GH stimulated dissociation of RhoA from the 
complex containing p190RhoGAP. NIH-3T3 cells were transiently transfected with 
the empty vector or the expression vector containing kinase dead mutant 
JAK2-K882E. Cells were stimulated with 50 nM GH for 2 min. After that, the cell 
lysates were extracted and RhoA bound with immunoprecipitated p190 was 
determined. Total p190 present in the immunoprecipitates and the forced expression 
level of JAK2-K882E are indicated. The results presented are representative of a 
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4.5 RhoA does not affect GH stimulated activation of JAK2-p44/42 MAP kinase 
pathway 
  RhoA has been reported to activate the JAK2/Stat3 pathway through the 
regulation of JAK2 tyrosine phosphorylation status and activity (Aznar et al., 2001). 
Clostridium botulinum C3 exoenzyme selectively inhibits RhoA activity by the 
ADP-ribosylation of residue Asn41 in the RhoA effector domain and has been utilized 
widely to investigate RhoA function (Aktories and Hall, 1989; Genth et al., 2003). As 
observed in Fig. 4.5, the GH stimulated activation of RhoA was dramatically 
repressed by forced expression of C3 exoenzyme. Forced expression of C3 
exoenzyme did not alter the total protein level of RhoA (Fig. 4.5). Fig. 4B also 
showed that ADP-ribosylated RhoA migrated slower in comparison to the unmodified 
species in SDS-PAGE, and this phenomenon has been reported previously (Genth et 
al., 2003). Forced expression of C3 exoenzyme was verified by Western blot analysis 
(Fig. 4.5). Thus C3 exoenzyme is a potent inhibitor of GH stimulated RhoA activity.  
I therefore utilized C3 exoenzyme to examine the effect of RhoA on the 
ability of GH to stimulate JAK2 and p44/42 MAP kinase activities. As observed in 
Fig. 4.5, forced expression of C3 exoenzyme did not alter the level of tyrosine 
phosphorylation of JAK2 stimulated by GH. Equivalent loading of JAK2 and the 
forced expression of C3 exoenzyme were demonstrated by Western blot analysis (Fig. 




p44/42 MAP kinase is utilized by GH to exert pleiotropic cellular effects 
and its mechanism of activation by GH has been extensively studied (Zhu et al., 2001; 
Zhu et al., 2002). RhoA has also previously been demonstrated to be involved in the 
stimulation of p44/42 MAP kinase activity in stretch induced signaling (Genth et al., 
2003). I therefore examined the effect of forced expression of C3 exoenzyme on GH 
stimulated p44/42 MAP kinase activity. GH stimulation of vector transfected 
NIH-3T3 cells resulted in a rapid and prolonged activation of p44/42 MAP kinase 
activity such that at 60 min after GH stimulation, p44/42 MAP kinase activity was 
still higher than in the basal state (Fig. 4.5). Forced expression of C3 exoenzyme did 
not affect the ability of GH to activate p44/42 MAP kinase nor alter the duration of 
the GH stimulated increase in p44/42 MAP kinase activity (Fig. 4.5). Thus, RhoA 
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Fig. 4.5 RhoA does not affect GH stimulated activation of JAK2-p44/42 MAP 
kinase pathway. C3 exoenzyme inhibits GH stimulated RhoA activity: C3 
exoenzyme cDNA was transiently transfected into NIH-3T3 cells before cellular 
stimulation with 50 nM GH for 2 min. The GST-linked probe Rhotekin-RBD which 
recognizes only the active GTP bound form of RhoA was used to separate RhoA-GTP 
from the inactive RhoA-GDP. GTP bound RhoA and total cellular RhoA were 
visualized by Western blot analysis. The forced expression level of C3 exoenzyme is 
indicated. The results presented are representative of a minimum of three independent 
experiments. RhoA does not participate in GH stimulation of JAK2: NIH-3T3 cells 
were transiently transfected with the expression vectors for C3 exoenzyme and 
stimulated with 50 nM GH. 1 mg of cell lysates per sample were immunoprecipitated 
with agarose beads precoupled with JAK2 antibody and processed for Western 
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proteins. The membrane was stripped and reprobed to demonstrate the equal loading 
of JAK2 proteins and the level of the transfected C3 exoenzyme was shown. The 
results presented are representative of a minimum of three independent experiments. 
RhoA does not participate in GH stimulation of p44/42 MAP kinase activity: 
NIH-3T3 cells were transiently transfected with the expression vectors for C3 
exoenzyme and stimulated with 50 nM GH for the indicated time periods. p44/42 
MAP kinase activity was determined as described in “material and methods” section. 
GH stimulated p44/42 MAP kinase activity in the presence of transiently transfected 
C3 exoenzyme is presented. The level of the transfected C3 exoenzyme was also 
shown. The results presented are representative of a minimum of three independent 
experiments. 
4.6 GH stimulates ROCK activity in a RhoA dependent manner 
ROCK is a major RhoA effector molecule mediating the majority of the 
reported cellular functions of RhoA (Aznar et al., 2003; Aspenstrom, 1999). I 
therefore examined whether the GH stimulated formation of GTP-bound RhoA 
resulted in the activation of ROCK. I observed a time dependent activation of ROCK 
kinase activity upon GH stimulation, first observed at 5 min, sustained until 30 min 
and then returned to the basal level after 60 min (Fig. 4.6). Forced expression of C3 
exoenzyme completely prevented the GH stimulation of ROCK activity (Fig. 4.6). 
Equivalent loading of ROCK protein and the forced expression of C3 exoenzyme 
were demonstrated by western blot analysis (Fig 4.6). Thus, GH stimulates ROCK 


























Fig. 4.6 GH stimulates ROCK activity in a RhoA dependent manner. NIH-3T3 
cells were transiently transfected with the expression vectors for C3 exoenzyme and 
stimulated with 50 nM GH for the indicated time periods. ROCK kinase activity was 
determined as described in “material and methods” section. GH stimulated ROCK 
kinase activity in the presence of transiently transfected C3 exoenzyme and the equal 
loading of ROCK proteins are presented. The level of the transfected C3 exoenzyme 
was also demonstrated. The results presented are representative of a minimum of 
three independent experiments. 
4.7 RhoA-ROCK are required for GH stimulated Stat5 mediated transcription 
The JAK-Stat pathway is one of the predominant pathways utilized by GH 
to mediate transcriptional activation (Zhu et al., 2001). GH-stimulated JAK2 
activation has been demonstrated to result in the tyrosine phosphorylation and 
transactivation of both Stat5 isoforms (Hansen et al., 1996). I therefore examined 
whether RhoA and/or ROCK are required for GH stimulated Stat5 mediated 
transcription by use of a reporter assay specific for both isoforms of Stat5 (Wood et 
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al., 1995).  GH stimulation of NIH-3T3 cells resulted in an approximate five-fold 
increase in Stat5 mediated transcription in comparison to the basal state (Fig. 4.7A). 
Forced expression of the C3 exoenzyme resulted in a decrease in the basal level of 
Stat5 mediated transcription and abrogated the ability of GH to stimulate Stat5 
mediated transcription. Forced expression of a ROCK kinase deficient mutant 
(ROCK-KD) also similarly abrogated the ability of GH to stimulate Stat5 mediated 
transcription (Fig. 4.7A). Activation of RhoA and ROCK by GH are therefore 
required for GH to stimulate Stat5 mediated transcription. 
Tyrosine phosphorylation of Stat5 is necessary for nuclear translocation and 
binding of Stat5 to its specific response element and subsequent activation of 
transcription (Hansen et al., 1996). Forced expression of C3 exoenzyme did not alter 
the ability of GH to acutely stimulate tyrosine phosphorylation of Stat5 (Fig. 4.7B) 
over 5 min to 60 min. Forced expression of C3 exoenzyme was demonstrated by 
Western blot analysis and did not alter the total cellular level of Stat5 (Fig. 4.7B). 
Similarly, forced expression of C3 exoenzyme did not alter the nuclear translocation 
of Stat5 in response to GH as determined by fluorescent microscopic analysis (Fig. 
4.7C). Further, as observed in Fig. 4.7D, forced expression of C3 exoenzyme did not 
affect binding of Stat5 to its DNA response element (SPI-GLE1) stimulated by GH. 
Binding of Stat5 to SPI-GLE1 was verified by supershift analysis with a specific Stat5 
antibody (Fig. 4.7D). The expression of C3 exoenzyme was demonstrated by Western 




of Stat5, were contained in the GH stimulated complex binding to SPI-GLE1 (Fig. 
4.7D). It has previously been demonstrated that c-Cbl mediated degradation of Stat5 
abrogates GH stimulated Stat5 mediated transcription independent of tyrosine 
phosphorylation, nuclear translocation or DNA binding of Stat5 (Goh et al., 2002). 
Such degradation resulted in reduced levels of tyrosine phosphorylated Stat5 within 
2-6 h after GH stimulation (Goh et al., 2002). Forced expression of C3 exoenzyme 
did not alter the amount of tyrosine phosphorylated nor total Stat5 within 6 h of GH 
stimulation (Fig. 4.7F). Thus, RhoA regulates GH stimulated Stat5 mediated 
transcription through a mechanism other than initial activation and DNA binding of 


















Fig. 4.7A RhoA-ROCK are required for GH stimulated Stat5 mediated 
transcription. NIH-3T3 cells were transiently transfected with the expression vectors 
for C3 exoenzyme or kinase defective mutant ROCK-KD together with 




+ + - - - -
- - + + - -





















stimulated Stat5 mediated transcription was determined by measuring luciferase 
activity as described in “Materials and Methods”. The results were normalized by 
protein contents and β-gal activity. Data presented are mean ± SD of triplicate  


















Fig. 4.7B RhoA is not required for GH stimulated tyrosine phosphorylation of 
Stat5. NIH-3T3 cells were transiently transfected with the expression vectors for C3 
exoenzyme and then stimulated with 50 nM GH for the indicated time periods. 
Western blot analysis of 50 µg cell lysates per sample using the monoclonal antibody 
recognizing tyrosine phosphorylated Stat5A/B was performed. The membrane was 
stripped and reprobed with anti-Stat5 to demonstrate equal loading of Stat5 proteins. 
The level of forced expression of C3 exoenzyme was shown. The results presented are 








0      5     15     30    60      0      5     15   30   60 
C3 exoenzyme
vector
C3 exoenzyme + +- - - - -
- -+
++ +




























Fig. 4.7C RhoA is not required for GH stimulated nuclear translocation of Stat5. 
NIH-3T3 cells were transiently transfected with the expression vectors for C3 
exoenzyme and stimulated with 50 nM GH. The samples for confocal laser scanning 
microscopy were prepared and visualized as described in “Material and Method”. The 
effect of C3 exoenzyme on GH stimulated nuclear translocation of Stat5 was shown. 
Stat5 molecules were lableled with Cy3 visualized as red. C3 exoenzyme was fused 
with a GFP tag that was visualized as green. Nuclei were stained by DAPI visualized 
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Fig. 4.7D RhoA is not required for GH stimulated DNA binding of Stat5. 
NIH-3T3 cells were transiently transfected with the expression vectors for C3 
exoenzyme and stimulated with 50 nM GH. The nuclear extracts for GEMSA were 
prepared and were subject for reactions as described in “Material and Method”. The 
effect of C3 exoenzyme on GH stimulated DNA binding of Stat5 is presented. The 
level of forcefully expressed C3 exoenzyme is also demonstrated. The results 
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Fig. 4.7F RhoA is not required for GH stimulated degradation of Stat5. NIH-3T3 
cells were transiently transfected with the expression vector for C3 exoenzyme and 
then stimulated with 50 nM GH. Samples were collected 2 or 6 h after GH treatment 
and Western blot analysis of 50 µg cell lysates per sample was performed using the 
monoclonal antibody recognizing tyrosine phosphorylated Stat5A/B. The membrane 
was stripped and reprobed with anti-Stat5 to demonstrate equal loading of Stat5 
proteins. The forced expression of C3 exoenzyme was demonstrated. The results 
presented are representative of a minimum of three independent experiments. 
4.8 PKA inhibits GH stimulated Stat5 mediated transcription through 
inactivation of RhoA 
GH has been reported to stimulate CREB phosphorylation and CREB 
mediated transcription during adipocytic differentiation (Yarwood et al., 1998; Nam 
and Lobie, 2000). In addition, PKA/CREB has been previously observed to modulate 
Stat5 mediated transcription in erythroid cells (Boer et al., 2002). Furthermore, PKA 
has been demonstrated to reduce the activity of RhoA by phosphorylation of RhoA on 
serine residue 188 (Ellerbroek et al., 2003). I therefore examined whether RhoA 
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would be the pivot for potential crosstalk between the PKA and JAK2-Stat5 
pathways. I first examined whether GH could stimulate PKA and subsequent CREB 
mediated transcription in NIH-3T3 cells utilized in this study. I observed that GH 
stimulation of NIH-3T3 cells did not affect PKA activity, phosphorylation of CREB 
nor CREB mediated transcription (Fig. 4.8A). In contrast, forskolin was able to 
stimulate PKA activity, CREB phosphorylation and CREB mediated transcription 
(Fig. 4.8A). Thus, the NIH-3T3 cells utilized in this study possess a functional 
PKA/CREB pathway that is not responsive to GH stimulation.   
I next examined the effect of increased cAMP on the ability of GH to 
stimulate the formation of GTP-bound RhoA. As shown in Fig. 4.8B, 8-Br-cAMP or 
forskolin (FSK) abrogated the formation of GTP-bound RhoA stimulated by GH. 
Conversely, a myristoylated PKA specific inhibitor (PKAi) enhanced the GH 
stimulated formation of GTP bound RhoA (Fig. 4.8B). I proceeded to examine the 
effect of modulation of PKA activity on the ability of RhoA to enhance GH 
stimulated Stat5 mediated transcription. As observed in Fig. 4.8C, forskolin 
abrogated, whereas PKAi markedly enhanced, the magnitude of GH stimulated Stat5 
mediated transcription. Concordantly, forced expression of the mutant RhoAS188A, 
not subject to inhibition by PKA, dramatically increased GH stimulated Stat5 
mediated transcription (Fig. 4.8C).  Forskolin failed to prevent the enhancement of 
GH stimulated Stat5 transcriptional activity observed with forced expression of 




stimulated Stat5 activity (Fig. 4.8C). Consistently, the enhancement of GH stimulated 
Stat5 mediated transcription observed in the presence of the PKA inhibitor was 
completely prevented by forced expression of the C3 exoenzyme inhibiting RhoA 
(Fig. 4.8C). I therefore conclude that RhoA is the pivot for crosstalk between PKA 


















































































Fig. 4.8A GH does not affect PKA activity, the level of phosphorylation on serine 
residue 133 of CREB or CREB mediated transcription. NIH-3T3 cells were 
stimulated with 50 nM of GH for the indicated time periods and 20 µM forskolin 
(FSK) for 30 min. The PKA activity was measured as described in “Material and 
Method”. The cpm of each sample was converted to fold stimulation compared with 
that of nonstimulated sample. 50 µg of each sample was used for Western blot 
analysis with the polyclonal antibody recognizing serine 133 phosphorylated CREB. 
The membrane was stripped and reprobed with anti-CREB to demonstrate equal 
loading of CREB proteins. The results presented are representative of a minimum of 
three independent experiments. NIH-3T3 cells were transiently transfected with the 
expression vectors for pFR-Luc and pFA2-CREB together with β-gal vector. Cells 
were treated with 50 nM GH or 20 µM forskolin (FSK) for 6 h and CREB mediated 
transcription was determined by measuring luciferase activity as described in 























































Fig. 4.8B PKA inhibits GH stimulated RhoA activity. NIH-3T3 cells were 
pretreated with 500 µM 8-Br-cAMP, 20 µM FSK, or 10 µM PKA inhibitor for 30 min 
before stimulated with 50 nM hGH for 2 min. The GST-linked probe Rhotekin-RBD 
which recognizes only the active GTP bound form of RhoA was used to separate 
RhoA-GTP from the inactive RhoA-GDP. GTP bound RhoA and the total cellular 
RhoA were visualized by Western blot analysis. The results presented are 
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Fig. 4.8C PKA inhibits GH stimulated Stat5 mediated transcription via 
phosphorylation of serine residue 188 of RhoA. NIH-3T3 cells were transient 
transfected with the expression vectors for either RhoAS188A mutant or C3 
exoenzyme together with Spi 2.1-GLE1-Luc and β-gal vector. Cells were pretreated 
with either 20 µM FSK or 10 µM myristoylated PKA inhibitor as indicated for 30 min 
prior to stimulation with 50 nM GH for 6 h. GH stimulated Stat5 mediated 
transcription was determined by measuring luciferase activity as described in 
“Materials and Methods”. The results were normalized by protein contents and β-gal 
activity.  Data presented are mean ± SD of triplicate determinations. Experiments 
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4.9 p300 inhibits GH stimulated RhoA mediated Stat5 transcriptional activity by 
recruiting HDAC6 
p300 is a transcriptional cofactor with histone acetylase activity which may 
either activate or repress transcription (Sterner and Berger, 2000; Baluchamy et al., 
2003; Girdwood et al., 2003). Indeed, p300 has previously been demonstrated to 
enhance prolactin stimulated Stat5 mediated transcription (Pfitzner et al., 1998).  
Previous studies have suggested that RhoA regulates transcription via repression of 
p300/CBP (Su et al., 2002; Rattan et al., 2003). I therefore examined the potential 
role of p300 in the effect of RhoA on GH dependent Stat5 mediated transcription. 
Forced expression of p300 reduced the basal level of Stat5 mediated transcription and 
completely abrogated GH stimulated Stat5 mediated transcription (Fig. 4.9A). I next 
examined whether the histone acetylase activity of p300 was required for repression 
of GH stimulated Stat5 mediated transcription. HAT activity was not affected by 
cellular stimulation with GH nor was it altered by forced expression of the C3 
exoenzyme (Fig. 4.9A). I also utilized the p300mutAT2 with 6 amino acids mutated in 
the HAT domain with resultant defective HAT activity (Mitsiou and Stunnenberg, 
2003). Concordantly, the inhibitory effect of p300 was independent of HAT activity, 
as forced expression of p300mutAT2 also dramatically abrogated GH stimulated Stat5 
mediated transcription (Fig. 4.9A). I next examined whether the CRD1 domain of 




CRD1 domain is responsible for the repressor activity of p300 through SUMO 
modification dependent recruitment of histone deacetylase 6 (HDAC6) (Girdwood et 
al., 2003). Forced expression of the p300CRD1 domain mutant (p300∆CRD1) did not 
significantly repress GH stimulated Stat5 mediated transcription (Fig. 4.9A).  Further 
evidence that the repressor ability of p300 on GH stimulated Stat5 mediated 
transcription was due to its association with histone deacetylase activity was provided 
by the observation that the deacetylase inhibitor, Trichostatin A (TSA), reversed the 
abrogation of GH stimulated Stat5 mediated transcription as a consequence of forced 
expression of p300 (Fig. 4.9A). Forced expression of HDAC6, the histone deacetylase 
associating with the CRD1 domain of p300, also dramatically abrogated GH 
stimulated Stat5 mediated transcription (Fig. 4.9B). The inhibitory effect of the forced 
expression of HDAC6 on GH stimulated Stat5 mediated transcription was also 
reversed in the presence of TSA (Fig. 4.9B). Forced expression of the p300∆CRD1 
mutant prevented inhibition of GH stimulated Stat5 mediated transcription as a 
consequence of forced expression of HDAC6 (Fig. 4.9B), indicative that HDAC6 
association with p300 is required for repression of GH stimulated Stat5 mediated 
transcription.  
I next examined the involvement of p300 in the RhoA dependent 
enhancement of GH stimulated Stat5 mediated transcription. As shown in Fig. 4.9C, 
forced expression of p300 eliminated the enhancement of GH stimulated Stat5 




Conversely and concordant with the above observation, forced expression of 
p300∆CRD1 relieved GH stimulated Stat5 mediated transcription from the 
suppression consequent to forced expression of the C3 exoenzyme (Fig. 4.9C). p300 
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Fig. 4.9A p300 inhibits GH stimulated Stat5 mediated transcription requiring 
CRD1 domain and HDAC activity. NIH-3T3 cells were transient transfected with 
the expression vectors for wild type p300, p300mutAT2 which is a HAT activity 
defective mutant or p300ΔCRD1 mutant together with Spi 2.1-GLE1-Luc and β-gal 
vector. Cells were pretreated with 200 nM TSA or DMSO as indicated for 30 min 
prior to stimulation with 50 nM GH for 6 h. GH stimulated Stat5 mediated 
transcription was determined by measuring luciferase activity as described in 
“Materials and Methods”. The results were normalized by protein contents and β-gal 
activity. Data presented are mean ± SD of triplicate determinations. Experiments were 
repeated three times. GH does not affect HAT activity of p300: NIH-3T3 cells were 
treated with 50 nM hGH for time periods as indicated. The HAT activity of p300 was 
measured as described in “Materials and Methods”. The cpm of each sample was 



























































Fig. 4.9B HDAC6 inhibits GH stimulated Stat5 mediated transcription requiring 
CRD1 domain of p300. NIH-3T3 cells were transient transfected with the expression 
vectors for HDAC6 either alone or combined with p300 or p300ΔCRD1 together 
with Spi 2.1-GLE1-Luc and β-gal vector. Cells were pretreated with DMSO or 200 
nM TSA for 30 min as indicated prior to stimulation with 50 nM GH for 6 hrs. GH 
stimulated Stat5 mediated transcription was determined by measuring luciferase 
activity as described in “Materials and Methods”. The results were normalized by 
protein contents and β-gal activity. Data presented are mean ± SD of triplicate 
determinations. Experiments were repeated three times. 
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Fig. 4.9C p300 inhibits GH stimulated RhoA mediated Stat5 transcriptional 
activity. NIH-3T3 cells were transient transfected with the expression vectors for 
either p300 or p300ΔCRD1 in the presence or absence of the expression vectors for 
RhoAS188A or C3 exoenzyme together with Spi 2.1-GLE1-Luc and β-gal vector. 
Cells were then stimulated with 50 nM GH for 6 hrs. GH stimulated Stat5 mediated 
transcription was determined by measuring luciferase activity as described in 
“Materials and Methods”. The results were normalized by protein contents and β-gal 
activity. Data presented are mean ± SD of triplicate determinations. Experiments were 
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Part I: Src-CrkII-C3G dependent activation of Rap1 switches growth hormone 
stimulated p44/42 MAP kinase and JNK/SAPK activities 
In the present study I have demonstrated that cellular stimulation with GH 
results in a rapid activation of the Ras-like small GTPases, Rap1 and Rap2. To date, 
Ras and Ral, the other two close relatives of Rap, together with Rac have been 
reported to participate in GH signal transduction (Winston and Hunter, 1995; Zhu et 
al., 2002; Diakonova et al., 2002) suggestive of a significant role for small Ras-like 
GTPases in the cellular effects of GH. Rap1 has also been demonstrated to be 
activated by other members of the cytokine receptor superfamily to which the GH 
receptor belongs, including EPO and IL-3 (Arai et al., 2001).  
It is interesting to note that cell density exerted a significant inhibitory 
effect on both basal and GH stimulated Rap activity. This is consistent with a 
previous report demonstrating that basal Rap1 activity is cell density dependent 
(Posern et al., 1998). Rap1 has also been demonstrated to be activated upon cell 
adhesion to ECM and is implicated in integrin-mediated cell adhesion in various cells 
in response to diverse extracellular stimuli (Bos et al., 2001). Integrins, the 
transmembrane glycoproteins that usually bind cells to ECM, may also bind cells to 
cells in a calcium dependent manner (Hynes, 1987). The involved integrins are 
heterodimers composed of both the α subunit and the β-2 subunit. Although integrins 




cadherin that is linked with the actin cytoskeleton through β-catenin (Takeichi, 1988). 
Recently, a novel β-catenin interacting protein with a putative Rap1GEF activity has 
been identified (Kawajiri et al., 2000), suggesting a role for Rap1 in the regulation of 
cell-cell contact. Furthermore, the yeast Rap1 homologue, Bud1, can directly activate 
Cdc24, an exchange factor for Cdc42 which is involved in the recruitment of actin 
cytoskeleton to the bud site (Michelitch and Chant, 1996). Rap2 has been 
demonstrated to bind specifically with actin filaments to interact with cytoskeletal 
components (Torti et al., 1999). I have also observed a GH dependent association 
between Rap1 and actin by co-immunoprecipitation (Ling and Lobie, data not 
shown). Proliferation of NIH-3T3 cells is known to be highly sensitive to contact 
inhibition (Wieser et al., 1990). In this regard it is interesting that autocrine 
production of GH has been observed in human mammary carcinoma cells to cause 
disassembly of adherens junctions and loss of intercellular contact (Mukhina et al., 
paper submitted). How this phenomenon relates to the inability of GH to activate 
Rap1 in confluent cells remains to be determined. 
I have demonstrated here that full activation of Rap1 and Rap2 by GH 
requires the combined activity of both JAK2 and c-Src, although c-Src is the 
predominant kinase utilized by GH for this purpose. I have therefore described 
another JAK2 independent mechanism by which GH affects cellular function. In 
addition, the findings have determined that JAK2 and c-Src activate Rap through 




concordant with the recent observation that GH stimulated activation of RalA and 
RalB also required both c-Src and JAK2 (Zhu et al., 2002). It has been previously 
demonstrated that GH activates JAK2 and c-Src independent of, and parallel to, each 
other (Zhu et al., 2002). The two kinases obviously converge for joint 
phosphorylation of C3G required for Rap activation by GH and the relative 
contribution of each kinase may simply depend on the relative expression of JAK2 or 
c-Src in a particular cell type. Both JAK and c-Src have previously been demonstrated 
to be utilized for activation of Rap1 (Lekmine et al., 2002; Schmitt and Stork, 2002). 
One example of JAK dependent activation of Rap1 is the requirement of JAK1 and 
Tyk2 for Rap1 activation in type I IFN signaling (Lekmine et al., 2002). Src 
dependent Rap1 activation is essential for integrin mediated cell adhesion and 
formation of focal adhesion structures (Li et al., 2002). The adaptor protein CrkII has 
been identified to mediate Src dependent Rap1 activation (Xing et al., 2000). It has 
been previously demonstrated that CrkII is constitutively associated with C3G in 
CHO-GHR cells (Zhu et al., 1998a) and GH stimulated Rap activation is CrkII-C3G 
dependent (this study). CrkII possesses a pivotal role in GH signal transduction and is 
central to the formation of a large multiprotein signaling complex upon GH 
stimulation of cells (Zhu et al., 1998a; Goh et al., 2000). Thus, CrkII may recruit C3G 
to the vicinity of JAK2 to facilitate C3G tyrosine phosphorylation by JAK2. FAK 
may act as a bridge between CrkII and JAK2 since GH can stimulate the association 




activated by GH also forms part of the multi-protein complex centered around CrkII 
(Zhu et al., 1998a). Interestingly, an increased association stimulated by GH is also 
observed between FAK and c-Src (Zhu et al., 1998a) and therefore CrkII may 
facilitate the formation of this double kinase complex together with C3G. In any case, 
cellular stimulation with GH results in the tyrosine phosphorylation of C3G. It has 
been reported that the phosphorylation of tyrosine residue 504 (Y504) in C3G is 
critical for C3G dependent Rap1 activation, presumably as phosphorylation of Y504 
in C3G represses the negative regulation of C3G activity by its N-terminal domain 
(Ichiba et al., 1999). Consistent with this observation, the C3G-Y504F mutant, in 
which Y504 is replaced by the nonphosphorylable residue phenylalanine, prevented 
GH stimulated formation of GTP-bound Rap. Both JAK2 and c-Src must therefore 
phosphorylate this same residue to achieve activation of Rap1 by GH. CrkII-C3G 
dependent activation of Rap1 therefore constitutes another JAK2 independent 
pathway utilized by GH. 
I have demonstrated here that the forced expression of wild type Rap1 
prevented the prolonged activation of p44/42 MAP kinase activity observed after 
cellular stimulation with GH. Concordantly, forced expression of the dominant 
negative mutant of Rap1 prolonged the activation of p44/42 MAP kinase by GH. 
Several studies have previously demonstrated that Rap1, or mutants thereof, can 
inhibit the p44/42 MAP kinase pathway (Bos et al., 2001). For example, a 




p44/42 MAP kinase activity and Ras-p44/42 MAP kinase stimulated IL-2 expression 
(Boussiotis et al., 1997; Cook et al., 1993; Palsson et al., 2000). IL-1 stimulated 
activation of Rap1 was also observed to repress Ras-mediated activation of p44/42 
MAP kinase signaling (Arai et al., 2001). These observations support a model of Rap 
function stating that Rap1 is a functional antagonist of Ras activity; originating from 
the demonstration of Rap1 reversion of the K-ras transformed phenotype in NIH-3T3 
cells (Kitayama et al., 1989). There are therefore two possible mechanisms for Rap1 
to inhibit Ras signaling. First, Ras and Rap1 may possess a regulator and effector 
relationship in the same pathway.  However, it has been demonstrated that Rap1 is 
not upstream of Ras (Cook et al., 1993) which is also observed in this study and here 
we report that GH stimulated Rap activation is not Ras dependent. Therefore, a more 
plausible mechanism is that Ras and Rap1 are involved in distinct pathways while 
competing for the same effector(s). Due to the striking structural similarity in the 
effector domain of Rap1 and Ras (Pizon et al., 1988), it has been proposed that Rap1 
interferes with Ras signaling pathway by sequestering the Ras substrate Raf-1 kinase. 
However, although Rap1 binds to Raf-1 in vitro and in vivo (Herrmann et al., 1996; 
Boussiotis et al., 1997; Okada et al., 1998), there is still no demonstration to date that 
Rap1 inhibits Raf-1 kinase activity (Bos et al., 2001). Furthermore, Raf kinase 
independent regulation of p44/42 MAP kinase by Rap1 has been identified recently 
(Posern et al., 1998). GH stimulated p44/42 MAP kinase activation has been 




I observed no association between Rap1 and Raf-1 in NIH-3T3 cells either in the 
quiescent or GH stimulated state (data not shown). I have, however, demonstrated 
here that RalA, another Ras-like small GTPase, is required for full activation of 
p44/42 MAP kinase stimulated by GH and Rap1 inhibits p44/42 MAP kinase activity 
through inactivation of RalA. It is interesting to note that the overexpression of 
dominant negative mutant Rap1S17N or wild type RalA results in an extended 
activation of p44/42 MAP kinase but does not increase the maximal level of GH 
stimulated p44/42 MAP kinase activity. A similar phenomenon has been described for 
nerve growth factor (NGF) stimulated activation of p44/42 MAP kinase in PC12 cells 
(York et al., 1998). In that example, Ras was required for the initial activation of 
p44/42 MAP kinase stimulated by NGF, and the small GTPase Rap1 maintained the 
activation of p44/42 MAP kinase (York et al., 1998). Interestingly, the 
Rap1-sustained activation of p44/42 MAP kinase by NGF was required for full 
activation of Elk-1 mediated transcription (York et al., 1998). Conversely, I observed 
that overexpression of Rap1S17N and RalA resulted in dramatic increase of GH 
stimulated Elk-1 mediated transcription, indicative that Rap1 and RalA are pivotal 
components in the mediation of GH stimulated p44/42 MAP kinase pathway. 
Analogously, the decreased GH stimulated p44/42 MAP kinase activity observed 
upon overexpression of Rap1 or dominant negative mutant RalAS28N may simply be 
due to the inability of the cells to maintain p44/42 MAP kinase in an activated form 




negative RalAS28N resulted in the absence of GH stimulated Elk-1 mediated 
transcription. Therefore, RalA regulation of p44/42 MAP kinase activity to produce 
sustained high level activation would be required for the full transcriptional program 
initiated upon activation of p44/42 MAP kinase by GH.    
The inhibition of the GH stimulated formation of GTP-bound RalA by Rap1 
is mediated by RalGDS, a putative effector shared by Ras and Rap1. As a member of 
the RalGEF family, RalGDS contains RBDs that bind to activated Ras or Rap1 in 
vitro and in vivo (Spaargaren and Bischoff, 1994).  One group has demonstrated that 
Ras dependent activation of Ral is inhibited by Rap1 due to the retention of RalGDS 
to the compartment where Rap1 is located, instead of being recruited by Ras to the 
site of Ral (Matsubara et al., 1999). Subcellular localization of Rap1 is mainly at 
cytosol and the perinuclear compartment, different to that of Ras and Ral localized at 
the plasma membrane. RalGDS is found in the cytosol and can be recruited to plasma 
membrane by Ras in order to activate Ral (Matsubara et al., 1999). It has been 
reported that co-localization of Ras and Ral on the plasma membrane is necessary for 
Ral activation in COS cells (Kishida et al., 1997). Furthermore the localization of 
RalGDS to the plasma membrane is sufficient for Ral activation (Matsubara et al., 
1999). Both Ras and Rap1 have the binding domain specific for RalGDS, however, 
Rap1 has higher affinity to RalGDS than Ras and promotes the translocation of 
RalGDS to the compartment where Ral is not found, providing a mechanism that 




It has been demonstrated that GH stimulated activation of RalA and RalB 
occurs in a biphasic manner (Zhu et al., 2002). It is therefore interesting to note that 
GH stimulated activation of RalA occurs earlier than that of Rap1 and the trough of 
GH stimulated RalA activity is coincident with the sustained phase of GH stimulated 
Rap1 activation. Furthermore, when GH stimulated formation of GTP-bound Rap1 
decreased at 30 min, GH stimulated RalA activity peaked simultaneously for the 
second time. Rap1 is therefore presumably involved in a cellular mechanism to limit 
the ability of GH to maintain elevated p44/42 MAP kinase activity but without 
interference in the initial activation of p44/42 MAP kinase by GH. It is also 
noteworthy that GH can activate RalA even at a concentration as low as 0.005 nM 
whereas full activation of Rap1 by GH is observed at concentrations of 5-50 nM. 
Secretion of GH is sexually dimorphic in most species to date and is responsible for 
male specific growth patterns (Eden, 1979). The sexually dimorphic pattern of 
secretion is characterized in males by consecutive peaks and troughs in GH serum 
concentration (Eden, 1979; Tannenbaum and Martin, 1976). In rats, the peak values of 
GH can be greater than 200 ng/ml (about 8 nM) and trough values are less than 1 
ng/ml (about 0.05 nM) (Tannenbaum and Martin, 1976). Our results suggest that 
Rap1, unlike RalA, would be activated by GH only when the pulsatile GH secretion 
reaches the peak which would subsequently attenuate RalA activity and subsequent 
p44/42 MAP kinase activity. How the differential activation of RalA and Rap1 relates 




p44/42 MAP kinase activity is also pertinent to aberrant signaling in human cancer 
and constitutive activation of this kinase has been observed in some tumors 
(Sebolt-Leopold, 2000). Attenuation of GH stimulated p44/42 MAP kinase activity by 
Rap1 would therefore limit the oncogenic potential of GH. The limiting effect of 
Rap1 on GH stimulated p44/42 MAP kinase activity is consistent with previous 
reports concerning the ability of Rap1 to reverse oncogenic transformation (Kitayama 
et al., 1989). In agreement with our findings, other groups have also demonstrated 
that both LPA and EGF can induce a substantial Rap1 activation and Rap1V12 
(constitutive Rap1-GTP) attenuates the activation of p44/42 MAP kinases by those 
mitogens (Cook et al., 1993; Posern et al., 1998; Zwartkruis et al., 1998). 
Furthermore, CrkII, identified in this report as an upstream activator of Rap1, has also 
been demonstrated previously to inhibit p44/42 MAP kinase activation by GH (Goh et 
al., 2000) and our study further demonstrates that Rap1 is responsible for this CrkII 
mediated prevention of p44/42 MAP kinase activity in GH signaling. Therefore we 
have identified a pathway mediated through CrkII-C3G-Rap1 which modulates GH 
stimulated p44/42 MAP kinase activity by suppression of RalA. This negative 
regulatory pathway may be pivotal to ensure precise regulation of GH stimulated 
p44/42 MAP kinase signaling.  
I have previously demonstrated that CrkII is utilized by GH for activation of 
JNK/SAPK (Zhu et al., 1998a). Here I have further demonstrated that C3G dependent 




activation. C3G has previously been reported to be upstream of JNK/SAPK and a 
CrkII-C3G complex is believed to activate JNK/SAPK through a pathway involving 
the MLK family proteins (Tanaka et al., 1997; Tanaka and Hanafusa, 1998). 
However, neither the dominant negative Rap1S17N nor functionally deficient 
C3G-Y504F can prevent GH stimulated JNK/SAPK activation in NIH-3T3 cells 
suggesting that there must also exist CrkII-C3G independent pathways for the 
activation of JNK/SAPK by GH (see Fig. 5.1). One possible molecule is via the 
adaptor protein Nck and we have previously demonstrated that Nck is phosphorylated 
by cellular stimulation with GH (Zhu et al., 1998a). Nck connects to the JNK/SAPK 
pathway by association with SH3 domain associated protein serine/threonine kinases 
such as PAK or NIK (Bokoch et al., 1996; Su et al., 1997). One recent report has also 
demonstrated that gastrin stimulated JNK/SAPK activation is Src dependent but CrkII 
independent (Dehez et al., 2002). It has been proposed that multi-domain scaffold 
proteins, such as JIP, axin, and arrestin regulate JNK/SAPK activation in response to 
different stimuli (Debez et al., 2002).  A SHP-2 dependent JNK/SAPK activation by 
insulin has also been identified (Fukunaga et al., 2000). This pathway is mediated by 
H-Ras and not by CrkII, because Rac, known as the major downstream effector for 
CrkII dependent JNK/SAPK activation, is not required for insulin stimulated 
JNK/SAPK activation (Fukunaga et al., 2000). Thus, GH may utilize the CrkII 
independent pathways described above for the activation of JNK/SAPK, in addition to 




CrkII is minimal such as NIH-3T3 cells utilized for this study. CrkII may also utilize 
other effector molecules to activate JNK/SAPK in response to GH, such as Rac and 
R-Ras which are required for v-Crk dependent JNK/SAPK activation (Mochizuki et 
al., 2000). However, as the CrkII enhancement of GH stimulated JNK/SAPK activity 
is largely inhibited by C3G-Y504F or Rap1S17N (this study), it is likely that 
C3G-Rap1 is the major pathway downstream of CrkII required for activation of 
JNK/SAPK by GH. The activation of JNK/SAPK by GH provides another pathway 
by which GH may affect cellular function. JNK/SAPK is involved in many cellular 
processes, including transcriptional regulation, proliferation and apoptosis (Herdegen 
et al., 1997) and it is likely that GH utilizes JNK/SAPK for some of these purposes. 
Although there is considerable evidence demonstrating that activation of JNK/SAPK 
and c-Jun can trigger apoptosis, reports have also accumulated that JNK/SAPK 
signaling to c-Jun can inhibit apoptosis and promote proliferation dependent on cell 
type and stimulus (Leppa and Bohmann, 1999). In fibroblasts, the replacement of 
Ser63 and Ser73 of c-Jun by nonphosphorylable alanines results in defective 
proliferation and loss of protection from apoptosis induced by UV irradiation 
(Wisdom et al., 1999). The phosphorylation of c-Jun on Ser63 and Ser73 by 
JNK/SAPK increases its transcriptional activity (Pulverer et al., 1991; Smeal et al., 
1991). Thus, GH may utilize JNK/SAPK to execute its documented proliferative and 
anti-apoptotic effects in a CrkII dependent or independent manner, determined by the 




In summary, I have demonstrated here that GH stimulates the formation of 
GTP-bound Rap1 and Rap2 in NIH-3T3 cells. GH stimulated activation of Rap is 
predominantly mediated by c-Src dependent tyrosine phosphorylation of C3G. GH 
utilizes the inhibitory effect of Rap1 to limit activation of p44/42 MAP kinase 
pathway via inhibition of RalA. In addition, I have demonstrated that the 
CrkII-C3G-Rap1 pathway is utilized by GH as a molecular switch from p44/42 MAP 
kinase signaling to JNK/SAPK signaling. A diagram summarizing GH utilization of 
the Ras-like small GTPases to regulate MAP kinase pathways is provided in Fig. 5.1. 
The identification of another JAK2 independent signaling pathway by GH will 
dramatically increase our understanding of the mechanisms utilized by GH to achieve 








Fig. 5.1 Schematic diagram of GH stimulated pathways leading to either Elk-1 or 
c-Jun mediated transcription. The demonstrated pathways are indicated by the solid 






















Part II: RhoA/ROCK Activation by Growth Hormone Abrogates p300/HDAC6 
Repression of Stat5 Mediated Transcription.  
Multiple members of the family of small Ras-like GTPases have been 
demonstrated to participate in the cellular effects of GH (Smeal et al., 1991; 
Diakonova et al., 2002; Zhu et al., 2002). Ras itself and RalA are required for GH 
stimulated activation of p44/42 MAP kinase and subsequent Elk-1 mediated 
transcription (Zhu et al., 2002). Rap1 constrains the activity of GH stimulated p44/42 
MAP kinase through inactivation of RalA (this study). GH also stimulates Rac 
activation to regulate actin cytoskeleton rearrangement and cell motility (Diakonova 
et al., 2002). Herein, I have identified another small GTPase, RhoA, as a regulator of 
GH stimulated Stat5 mediated transcription in NIH-3T3 cells.  
RhoA is inactivated by its specific inhibitor GAPs and the most extensively 
studied one is p190RhoGAP (Mackay and Hall, 1998). I have demonstrated here that 
GH stimulation results in dissociation of RhoA from the complex containing 
p190RhoGAP in a JAK2 dependent manner with subsequent activation of RhoA. 
Since Rho proteins bind weakly to their GAPs, the observation of RhoA present in the 
complex containing p190RhoGAP is not an evidence for direct association between 
them; instead it suggests that some intermediate molecules participate in the complex 
formation so allow RhoA to be accessible to p190RhoGAP. Disrupting this complex 




molecules are potential mechanisms of JAK2 dependent activation of RhoA. Since 
p190RhoGAP activity can be regulated by tyrosine phosphorylation (Arthur et al., 
2000; Tatsis et al., 1998), it is valid to assume p190RhoGAP would be the target of 
JAK2. However, I have observed that GH does not stimulate the tyrosine 
phosphorylation of p190RhoGAP. Redistribution of p190RhoGAP from the cytosol to 
a detergent insoluble fraction has previously been demonstrated to be involved in the 
activation of RhoA and tyrosyl-phosphorylation of p190RhoGAP is not required for 
this event (Chen et al., 2003). GH stimulated JAK2 activity may be required for the 
phosphorylation of other molecules which in turn disrupt the association of RhoA 
with the p190RhoGAP complex and thus activate RhoA. For example, cytokine 
stimulated tyrosine phosphorylation of SOCS-3 results in prolonged activation of Ras 
due to binding of p120RasGAP with tyrosine phosphorylated SOCS-3 and subsequent 
release of Ras (Cacalano et al., 2001). Whether an analogous mechanism exists for 
GH stimulated JAK2 dependent activation of RhoA remains to be determined. 
I have demonstrated here that activation of RhoA is required for GH 
stimulated Stat5 mediated transcription. I observed that the effect of RhoA was not 
due to altered tyrosine phosphorylation, nuclear translocation, DNA binding nor 
degradation of Stat5. However, it has been recently reported that an oncogenic mutant 
of RhoA promoted tyrosine phosphorylation and DNA binding activity of Stat5A by a 
JAK2 dependent mechanism (Benitah et al., 2003). However, I observed no effect of 




tyrosine phosphorylation of Stat5. The oncogenic form of RhoA is therefore 
exhibiting a different spectrum of activity compared to the wild type molecule under 
physiological stimulation. Differential functioning of oncogenic mutants of other 
signaling molecules compared to the wild type form has previously been reported 
(Fischbach and Settleman, 2003; Jin and Exton, 2000; Lucas et al., 2002). For 
example, oncogenic Ras constitutively activates PLD by a PKC independent 
mechanism which is different to the PKC dependent mechanism used by wild type 
Ras (Lucas et al., 2002). Instead, I have observed that GH activated RhoA increases 
GH stimulated Stat5 mediated transcription by abrogation of p300/HDAC6 repression 
of Stat5 mediated transcription.  
In principle, transcription requires the DNA be accessible to transcription 
factors and RNA polymerase. However, chromatin structure impedes such access 
(Armstrong and Emerson, 1998). Therefore, although ligand stimulated 
phosphorylation and subsequent DNA binding of transcription factors is required for 
transcriptional activation, it is not sufficient to initiate transcription. Chromatin 
remodeling and function of transcriptional cofactors and components of the basal 
transcription machinery are all required to ensure proper transcription initiation 
(Armstrong and Emerson, 1998). p300 and CREB binding protein (CBP), a family of 
transcription cofactors with intrinsic histone acetyltransferase (HAT) activity, play a 
key role in the regulation of promoter activity by many transcription factors, including 




Here I demonstrate that p300 inhibits GH stimulated Stat5 mediated transcription. 
Although p300 has been regarded as transcription coactivator, it has also been 
demonstrated to possess repressor ability (Chan and La Thangue, 2001; Baluchamy et 
al., 2003; Girdwood et al., 2003). It has been reported that p300 inhibits p53 mediated 
transcription of the Bax promoter (Girdwood et al., 2003). p300 also mediates the 
downregulation of c-Myc and this effect does not require the HAT activity of p300 
(Baluchamy et al., 2003). Interestingly, I also observed that the inhibitory effect of 
p300 on GH stimulated Stat5 mediated transcription is independent of HAT activity 
as the HAT activity deficient p300mutAT2 mutant also inhibited GH stimulated Stat5 
mediated transcription. Furthermore, GH did not stimulate HAT activity. p300 also 
acts as a scaffold for the assembly of multiple cofactor complexes. This function can 
either activate or inactivate transcription, determined by the property of the protein(s) 
recruited by p300 (Chan and La Thangue, 2001). It is noteworthy that a HDAC 
activity is required for p300 to diminish Stat5 transcriptional activity, suggesting that 
p300 may assemble with a HDAC. Indeed, a CRD1 (cell cycle regulatory domain 1) 
region on p300 has recently been demonstrated to be crucial for recruitment of 
HDAC6 and this event is the mechanism of the transcription repressive effect of p300 
on p53 (Girdwood et al., 2003). Concordantly, I have demonstrated herein that the 
inhibition of GH stimulated Stat5 mediated transcription by p300 is attributed to 
CRD1 mediated recruitment of HDAC6. HDAC6 is one member of the histone 




HDACs convert chromatin to a condensed state by catalyzing deacetylation of 
histones and thus serve as a key mechanism for transcriptional repression (de Ruijter 
et al., 2003). HDAC6 has been demonstrated to inhibit the transcription of NF-κB and 
Runx (Zhang and Kone, 2002). It has been recently suggested that the recruitment of 
HDAC6 by p300 is achieved by sumoylation of CRD1 domain on p300 (Girdwood et 
al., 2003). Both HDAC6 and p300 are substrates for ubiquitin-related SUMO 
modifier (Girdwood et al., 2003; Maisse et al., 2003). SUMO attaches the lysine 
residues of the target protein in a way analogous to that of ubiquitylation, however, 
unlike ubiquitylation, sumoylation does not accelerate protein degradation, but 
mediate protein-protein interaction, subcellular compartmentation and protein stability 
(Kirsh et al., 2002). Thus SUMO serves as the bridge between HDAC6 and CRD1 of 
p300. HDAC1 and HDAC4 can also be modified by SUMO (David et al., 2002), 
however, only HDAC6 can interact with sumoylated CRD1 of p300 (Girdwood et al., 
2003), indicating that HDAC6 functions exclusively in p300 mediated transcriptional 
repression.   
I further demonstrate that p300 mediates the effect of RhoA on GH 
stimulated Stat5 mediated transcription. The antagonistic relationship between RhoA 
and p300 has recently been established by accumulating evidence. It has been 
reported that RhoA inhibited, while its negative regulator, RhoGDI, stimulated 
CBP/p300 mediated ER dependent transactivation (Su et al., 2002). Concordantly, 




2003). The mechanism of RhoA inhibition of p300 is still unclear. However, as a 
serine/threonine kinase, the RhoA effector ROCK may affect the activity of p300 via 
phosphorylation. p300 is phosphorylated in both quiescent and proliferating cells 
presumably through CDKs (Janknecht and Hunter, 1996), while CBP can be 
phosphorylated by PKA, CaM-dependent kinase N and p44/42 MAP kinase (Chan 
and La Thangue, 2001). Little is known of how phosphorylation affects p300/CBP 
functions, although phosphorylation of p300 appears to increase its HAT activity 
(Ait-Si-Ali et al., 1998). It is also possible that an intermediate molecule is the 
substrate of phosphorylation which in turn affects p300 activity. Indeed it has recently 
been demonstrated that phosphorylation of Elk-1 enhances its interaction with p300 
with resultant activation of p300 (Li et al., 2003). It is possible that GH stimulated 
activation of ROCK results in phosphorylation of p300 or a p300 interacting protein 
so as to disrupt the recruitment of HDAC6 by CRD1, and thus release Stat5 mediated 
transcription from p300/HDAC6 mediated repression. The precise mechanism by 
which RhoA/ROCK regulate p300, and whether phosphorylation participates in this 
event, requires further elucidation.  
Herein, I have observed that cAMP/PKA inhibits GH stimulated Stat5 
mediated transcription but GH itself does not affect PKA-CREB pathway. Interaction 
between PKA and the cellular effects of GH has previously been reported. For 
example, it has been demonstrated that cAMP/PKA pathway mediates the effects of 




GH (Sirotkin and Makarevich, 2002). cAMP also potentiates the ability of GH to 
prime preadipocytes for differentiation and simultaneously stimulates the 
phosphorylation and activation of CREB (Yarwood et al., 1998). However, the GH 
stimulated activation of CREB was reported to be independent of PKA (Yarwood et 
al., 1998) and it has not been addressed whether the effect of cAMP on GH primed 
differentiation is mediated through activation of CREB. Thus, cAMP/PKA 
modulation of GH signaling does not necessarily require GH dependent regulation of 
the PKA-CREB pathway. Instead, I have identified that the effect of cAMP/PKA on 
GH stimulated Stat5 mediated transcription requires serine residue 188 in RhoA, 
mediating repression of RhoA activity. It has previously been demonstrated that 
cAMP/PKA antagonize RhoA/ROCK activity, through phosphorylation of serine 
residue 188 which possibly increases the squelching of RhoA by its negative regulator 
RhoGDI (Ellerbroek et al., 2003; Qiao et al., 2003; Leemhuis et al., 2002). One 
recent study has further demonstrated an antagonistic effect of PKA on RhoA/ROCK 
mediated gene expression (Heusinger-Ribeiro et al., 2001). It has been reported that 
PGE2 and SCF enhance EPO mediated Stat5 transactivation by the 
PKA-CREB-CBP/p300 pathway (Boer et al., 2002; Boer et al., 2003). This apparent 
discordance between the above stimulating effect of PKA on Stat5 transcriptional 
activity and our findings that PKA inhibits Stat5 may be due to the different signaling 
pathways utilized by PKA upon different ligand stimulation in a different cellular 




stimulated Stat5 mediated transcription. Thus, PKA may divergently regulate Stat5 
transactivation by differential mechanisms and the selection is determined by the 
specific cellular conditions.  
In summary, I demonstrate here that small GTPase RhoA and its effector 
serine/ threonine kinase ROCK are activated by GH through JAK2 dependent 
dissociation of RhoA from its negative regulator p190RhoGAP. GH utilizes RhoA 
and ROCK to abrogate the repression of Stat5 mediated transcription by HDAC6 
recruited by p300, thereby dramatically enhancing GH stimulated Stat5 mediated 
transcriptional activity. I also demonstrate that PKA inactivates RhoA through serine 
residue 188 which consequently suppresses GH stimulated Stat5 mediated 
transcription. A diagram summarizing this RhoA dependent pathway to regulate GH 
stimulated Stat5 mediated transcription is provided in Fig. 5.2. I have therefore 
provided a novel mechanism by which GH stimulated activation of one Ras-related 
small GTPase regulates Stat5 mediated transcription. The involvement of HDAC 
activity in GH stimulated gene transcription also raises the possibility of direct GH 








































Fig. 5.2 Schematic diagram of pathways mediated by p300-HDAC6 and RhoA to 




































General Discussion and Future Prospectives 
This project and other studies have suggested an essential role of Ras 
superfamily of small GTPases in GH signaling. Though Ras has been reported to be 
required for full activity of p44/42 MAP kinase stimulated by GH, the understanding 
of the role of small GTPases in GH signaling has just started.  
This study has suggested that other effectors in addition to Rap1 should be 
downstream of CrkII-C3G to regulate GH stimulated JNK/SAPK activity, since 
removal of endogenous Rap1 activity does not affect GH stimulated activation of 
JNK/SAPK. Rac, another small GTPase activated upon GH stimulation, is one 
candidate as it also regulates the activity of JNK/SAPK (Lim et al., 1996; Diakonova 
et al., 2002). Another possible molecule is R-Ras, which has been demonstrated to 
mediate v-Crk and C3G dependent activation of JNK/SAPK (Mochizuki et al., 2000).  
This study provides a model that CrkII switches the p44/42 MAP kinase and 
JNK/SAPK activities in GH signaling. Since constitutively activated p44/42 MAP 
kinase is associated with oncogenesis while JNK/SAPK-c-Jun pathway can trigger 
apoptosis, it is interesting to investigate whether CrkII-C3G-Rap1 pathway serves as a 
cellular self-protection mechanism to prevent tumor formation. Alternatively, recent 
research also suggests JNK/SAPK pathway inhibits apoptosis and promotes 
proliferation; therefore under certain cellular context, this switch may be utilized by 




pathways than p44/42 MAP kinase pathway. Furthermore, DNA microarray analysis 
and comparison of the mRNA species regulated by p44/42 MAP kinase or 
JNK/SAPK upon GH stimulation will provide clues for the biological functions of the 
CrkII-C3G-Rap1 mediated switch in GH signaling,  
The first identified effect of Rho subfamily of small GTPases is to regulate 
actin cytoskeleton organization in fibroblasts. Activated RhoA induces the assembly 
of focal adhesion and stress fiber (Ridley and Hall, 1992). GH has been demonstrated 
to stimulate actin cytoskeleton reorganization in certain cell lines (Goh et al., 1997). 
Furthermore, it has been reported that GH stimulated motility of fibroblasts is 
involved in the acceleration of wound healing (Lal et al., 2000; Ohlsson et al., 1998). 
Whether RhoA as well as Rac (Diakonova et al., 2002) is responsible for GH induced 
actin cytoskeleton dynamics and cell motility is an interesting issue.  
In this study, RhoA is identified as one important mediator for GH 
stimulated Stat5 transcriptional activity. GH regulates many mRNA species at the 
transcription level to affect the functions of various tissues, such as bone. Recent 
studies have demonstrated that GH is important for bone remodeling which is 
regulated by a balance between bone formation and resorption (Ohlsson et al., 1998). 
Coordinated proliferation and differentiation of growth plate chondrocytes is required 
for bone growth. Both GH and RhoA are important regulators of chondrocyte 




also required for bone resorption mediated by osteoclasts (Chellaiah et al., 2000). It is 
possible that the effect of GH on bone is mediated by RhoA through its regulation of 
transcriptional events. Further study on whether GH and RhoA crosstalk in the 
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We demonstrate here that growth hormone (GH) stim-
ulates the activation of RhoA and its substrate Rho ki-
nase (ROCK) in NIH-3T3 cells. GH-stimulated formation
of GTP-bound RhoA requires JAK2-dependent dissocia-
tion of RhoA from its negative regulator p190 RhoGAP.
Inactivation of RhoA does not affect GH-stimulated
JAK2 tyrosine phosphorylation nor p44/42 MAPK activ-
ity. However, RhoA and ROCK activities are required
for GH-stimulated, Stat5-mediated transcription. RhoA-
dependent enhancement of GH-stimulated, Stat5-medi-
ated transcription is due to repression of histone
deacetylase 6 activity recruited by transcription cofac-
tor p300 that negatively regulates GH-stimulated, Stat5-
mediated transcription. We also demonstrate that RhoA
is the pivot for cAMP-dependent protein kinase inhibi-
tion of GH-stimulated, Stat5-mediated transcription as a
consequence of cAMP-dependent protein kinase inacti-
vation of RhoA through serine residue 188 of RhoA. We
have therefore provided a novel mechanism by which a
Ras-like small GTPase, RhoA, can regulate Stat5-medi-
ated transcription.
RhoA belongs to the Rho subfamily of the Ras-related, small
GTPase superfamily that consists of five groups as follow: Ras,
Rho, Rab, Arf, and Ran (1). Twenty mammalian Rho family
members have been identified. Among them, RhoA, Rac, and
Cdc42 have been extensively studied (1). RhoA has been dem-
onstrated to be involved in diverse cellular processes including
cytoskeleton organization, hormone secretion, gene transcrip-
tion, cell cycle progression, and cell transformation (2). The
activity of RhoA is regulated by three classes of proteins: gua-
nine nucleotide exchange factors (GEFs),1 GTPase-activating
proteins (GAPs), and GDP dissociation inhibitors (GDIs) (1).
Numerous RhoA GEFs have been reported, including Lfc, Lsc,
Lbc, Net1, Dbl, Vav, and a newly identified GEF family con-
sisting of PDZ-RhoGEF, p115 RhoGEF, and LARG (3, 4). p190
RhoGAP is the best known GAP for RhoA, containing an N-
terminal GTP binding domain and a C-terminal domain pos-
sessing the GAP activity (5). p190 RhoGAP is pivotal for RhoA
inactivation in several signaling pathways (6–8). RhoGDIs
negatively regulate RhoGTPases activity by their extraction
from plasma membrane and subsequent formation of inactive
cytosolic complexes with them (9).
RhoA activity can be modulated by tyrosine kinases or serine
kinases. Tyrosine kinase Src negatively regulates RhoA by
activation of p190 RhoGAP (7). Another kinase modulating
RhoA activity is the serine kinase PKA that has been reported
to inactivate RhoA through phosphorylation of RhoA on serine
188 (10). Upon activation, RhoA interacts with and stimulates
effector proteins, including Rho kinase (ROCK), mDia, protein
kinase N, and phosphatidylinositol 4-phosphate 5-kinase (11).
As the most important effector, ROCK is implicated in the
various cellular functions downstream of RhoA, such as actin
cytoskeleton organization, transformation, and regulation of
transcription (11, 12).
The first demonstrated transcriptional event regulated by
RhoA was lysophosphatidic acid- and serum-induced serum
response factor-mediated transcription of the c-fos promoter in
NIH-3T3 cells (13). To date, several other RhoA-regulated tran-
scription factors have been identified, including NF-B, Stat3,
Stat5, ATF2, Max, and CHOP (14). Stats are important regu-
lators in cytokine signaling and are responsible for transcrip-
tional activation of target genes that control proliferation, dif-
ferentiation, and survival (15). RhoA triggers simultaneous
phosphorylation at both tyrosine and serine residues of Stat3
and subsequent activation of Stat3 essential for oncogenic
RhoA-mediated transformation (14). RhoA also promotes tyro-
sine phosphorylation and serine dephosphorylation of Stat5A
with a concomitant increase in Stat5A activity to mediate mor-
phological transition induced by oncogenic RhoA (16). Although
the mechanism for RhoA to regulate gene expression remains
unclear, recent studies suggest that it is possibly achieved
through the modulation of transcriptional cofactor p300/CBP
by RhoA. It has been reported (17) that RhoA inhibits inducible
nitric-oxide synthase expression via negative regulation of the
NF-B-CBP/p300 pathway. The antagonistic relationship be-
tween RhoA and the transcriptional cofactor CBP/p300 sug-
gested above is consistent with the previous findings (18) that
RhoA inhibited whereas RhoGDI stimulated CBP/p300-medi-
ated estrogen receptor-dependent transactivation.
Growth hormone (GH) regulates proliferation, differentia-
tion, apoptosis, and chemotaxis in various cell types (19). The
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predominant mechanism by which GH exerts its cellular func-
tion is through regulation of gene transcription (19). Stat5,
existing as the two isoforms 5A and 5B encoded by different
genes, is a major mediator of GH-dependent transcription (19).
GH-stimulated activation of Stat5 requires phosphorylation of
a single tyrosine residue in Stat5 by JAK2 (20). In addition to
tyrosine phosphorylation, the transcriptional activity of Stat5
can be regulated by serine phosphorylation, either positively or
negatively dependent on promoter context (21). Upon activa-
tion by GH, Stat5 binds to interferon--activated sequence-like
elements (GLE) in the promoter of several genes, such as the
serine protease inhibitor Spi 2.1, insulin I, cytochrome P450
3A, and -casein genes (22). Recently, chromatin remodeling
has also been proposed to regulate GH-stimulated Spi 2.1 gene
expression (23). Ras-like small GTPases have also been iden-
tified to be required for certain transcriptional events stimu-
lated by GH (24–26). Ras and RalA are required for GH-
stimulated p44/42 MAP kinase activity and subsequent Elk-1-
mediated transcription (25, 26). Rap1 constrains the activity of
GH-stimulated p44/42 MAP kinase and subsequent Elk-1-me-
diated transcription through inactivation of RalA (24). GH
stimulation of Rap1 also serves as a switch to activate CrkII-
enhanced c-Jun-mediated transcription (24). Rac, a Rho sub-
family small GTPase, has also been demonstrated to regulate
GH-stimulated actin cytoskeleton rearrangement and cell mo-
tility (28).
Transcriptional activation is generally correlated with his-
tone acetylation by histone acetyltransferase (HAT) complexes,
and repression is correlated with deacetylation by HDAC com-
plexes (29). The transcription cofactor p300 and its closely
related protein CBP, which are ubiquitous and critical regula-
tors of transcription, possess intrinsic HAT activity and can
activate transcription through histone acetylation-dependent
chromatin remodeling or acetylation of transcription activa-
tors, general transcription factors, and chromatin-associated
proteins (30). Alternatively, they serve as adaptors to bridge
transcription factors with the basic transcription machinery to
facilitate transcriptional initiation (30). However, p300 can
also repress transcription. It has been reported that p300
down-regulates c-Myc with subsequent cell cycle arrest at G1/S
transition (31). A recent report (32) has also identified a repres-
sion domain in p300 termed CRD1, which mediates repression
of p53-dependent transcription by recruitment of HDAC6 to
the transcription complex.
Here we demonstrate that cellular stimulation with GH re-
sults in the activation of RhoA and its substrate ROCK in
NIH-3T3 cells. The activation of RhoA by GH is achieved by
JAK2-dependent dissociation of RhoA from p190 RhoGAP. We
further demonstrate that GH utilizes the RhoA-ROCK path-
way to stimulate Stat5-mediated transcription through RhoA-
dependent prevention of recruitment of HDAC6 by p300. We
also identify PKA as a negative regulator of GH-stimulated,
Stat5-mediated transcription, and this cellular effect of PKA
requires the PKA phosphorylatable serine residue 188 of RhoA.
EXPERIMENTAL PROCEDURES
Materials—Recombinant human growth hormone (hGH) was a gen-
erous gift of Novo Nordisk (Singapore). The monoclonal antibodies
against p190 RhoGAP and ROCK were obtained from Transduction
Laboratories (Lexington, KY). The polyclonal antibodies against JAK2,
ROCK, or Stat5A/B, the monoclonal antibody against RhoA, and pro-
tein A/G plus agarose were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). GFP monoclonal antibody was purchased from Clon-
tech (Palo Alto, CA). The monoclonal antibodies against Src, p300,
phospho-Stat5A/B (Tyr-694/Tyr-699), Myc tag (clone 9E10), or phospho-
tyrosine (4G10) and the polyclonal antibody against phospho-MYPT
(Thr-696) were purchased from Upstate Biotechnology, Inc. (Lake
Placid, NY). Anti-mouse IgG conjugated to fluorescein isothiocyanate
and anti-rabbit IgG conjugated to Cy3 were from Sigma. Anti-mouse or
rabbit IgG conjugated to horseradish peroxidase and the ECL kit were
purchased from Amersham Biosciences. The p44/42 MAP kinase assay
kit was purchased from New England Biolabs (Beverly, MA). The biotin
DNA labeling kit was from Pierce. The transfection reagent EffecteneTM
was from Qiagen (Hilden, Germany). The complete protease inhibitor
mixture tablets were purchased from Roche Diagnostics. The
QuikChange® site-directed mutagenesis kit was purchased from Strat-
agene (La Jolla, CA). The -galactosidase enzyme activity assay system
was from Promega (Madison, WI). The [3H]acetyl-CoA was from
PerkinElmer Life Sciences. Myristoylated PKA inhibitor was from Cal-
biochem, trichostatin A was from Sigma, and forskolin and 8-Br-cAMP
were from Merck. DAPI was from Molecular Probes (Eugene, OR). P81
phosphocellulose paper squares were purchased from Upstate Biotech-
nology, Inc. (Lake Placid, NY). All other chemicals were obtained from
Sigma.
pGEX-3X-C21 construct containing the RBD of rhotekin, the pCAG-
Myc-ROCK construct, and the GFP-C3 exoenzyme expression vector
were the generous gifts of Dr. Shuh Narumiya (Kyoto, Japan). The wild
type RhoA cDNA was purchased from Upstate Biotechnology, Inc. The
kinase-defective mutant DNA constructs for c-Src and JAK2 were gen-
erously provided by Dr. Joan S. Brugge (Boston, MA) and Dr. Olli
Silvennoinen (Tampere, Finland), respectively. The wild type p190
RhoGAP expression vector and the GAP-defective mutant R1283A were
obtained from Dr. Ian Macara. The p300 wild type vector and HAT-
defective mutant p300MutAT2 were from Dr. Hendrik Stunnenberg
(Nijmegen, Netherlands). The p300CRD1-(1004–1045) mutant DNA
was a generous gift from Dr. Neil Perkins (Dundee, UK). The HDAC6
expression vector with a Myc tag was the kind gift from Dr. Tony
Kouzarides (Cambridge, UK). The Spi-GLE1-Luc plasmid was from Dr.
Haldosen (Karolinska, Sweden). The plasmid pFA2-CREB consisting of
the DNA binding domain of Gal4 (residue 1–147) fused with the trans-
activation domain of CREB (residue 1–280) and the pFR-Luc plasmid
containing luciferase reporter gene were purchased from Stratagene
(La Jolla, CA). All plasmids were prepared with the plasmid maxiprep
kit from Qiagen (Hilden, Germany).
Cell Culture and Treatment—NIH-3T3 cells were grown at 37 °C in
5% CO2 in Dulbecco’s modified Eagle’s medium containing 10% heat-
inactivated fetal bovine serum, 100 units/ml penicillin, 100 g/ml strep-
tomycin, and 2 mM L-glutamine. Unless otherwise indicated, the con-
centration of hGH was 50 nM. This concentration of GH was within the
physiological range for circulating rodent GH (33).
RhoA Activation Assay—Serum-starved cells were stimulated with
hGH as indicated and then lysed on ice for 15 min in 1 MLB buffer (25
mM HEPES, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 10 mM MgCl2, 1
mM EDTA, 2% glycerol, 500 mM NaF, 1 mM Na3VO4, and 1 tablet of
CompleteTM protease inhibitor mini mixture per 10 ml). After that the
samples were centrifuged at 14,000  g at 4 °C for 10 min, and the
protein concentrations of the supernatants were measured. 800 g of
cell lysates were immediately affinity-precipitated at 4 °C for 1 h with
30 g of GST-rhotekin-RBD fusion proteins freshly precoupled to glu-
tathione-agarose beads. The precipitates were washed three times with
MLB buffer, and the bound RhoA-GTP was eluted in 20 l of Laemmli
sample buffer. Samples were separated by 12% SDS-PAGE and de-
tected by monoclonal RhoA antibody.
Immunoprecipitation—After treatment as indicated, cells were lysed
at 4 °C for 20 min in 1% Nonidet P-40 lysis buffer (50 mM Tris-HCl, pH
7.4, 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 1 tablet Complete
TM
protease inhibitor mixture/10 ml). Cell lysates were centrifuged at
14,000  g for 15 min, and the supernatants were precleared by protein
A/G plus agarose. The agarose beads were removed by centrifugation,
and then the protein concentrations of the resulting supernatants were
determined. For each immunoprecipitation, 500 or 1000 g of protein
was incubated with 2 or 4 g of the corresponding antibody for 4 h or
overnight at 4 °C. Immunocomplexes were incubated with 40 l of
protein A/G plus agarose for 1 h or overnight. Immunoprecipitates were
washed three times with PBS or lysis buffer. The bound proteins were
eluted in Laemmli sample buffer and then resolved by SDS-PAGE.
Western Blot Analysis—After SDS-PAGE, proteins were transferred to
nitrocellulose membranes. The membranes were blocked with 5% nonfat
dry milk in PBS with 0.1% Tween 20 (PBST) for 1 h at 22 °C. Blots were
then immunolabeled with the desired antibodies for 1 h at 22 °C. For
reblotting, membranes were stripped at 50 °C for 30 min in stripping
buffer (62.5 mM Tris-HCl, pH 6.7, 2% SDS, and 0.7% -mercaptoethanol).
Blots were then washed for 30 min with three changes of PBST at 22 °C.
Efficacy of stripping was determined by re-exposure of the membranes to
ECL. Thereafter, membranes were reblocked and immunolabeled as de-
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sired. Immunolabeling was detected by the enhanced chemiluminescence
kit according to the manufacturer’s instructions.
Confocal Laser Scanning Microscopy—Cells were grown on coverslips
in complete medium until 40–50% confluence and then transfected with
C3 exoenzyme. At 24 h of post-transfection, cells were deprived of serum
for 16 h and treated with GH for 30 min. After that the cells were fixed in
4% paraformaldehyde in PBS for 20 min, washed by PBS, and blocked in
2% BBX (0.1% Triton X-100, 0.1% bovine serum albumin, 250 mM NaCl,
prepared in PBS). The cells were then incubated with the polyclonal
antibody against Stat5 for 1 h at room temperature. After being washed
by BBX, cells were incubated with anti-rabbit IgG conjugated with Cy3.
The nonspecifically bound antibody was removed by washing in BBX.
Thereafter, DAPI nuclear staining was performed for 5 min. Labeled cells
were visualized with a Leica DM RXA2 fluorescent microscope. Images
were converted to the tagged information file format and processed with
the Adobe Photoshop program.
Nuclear Extraction—Cells were rinsed once with ice-cold PBS and
incubated with 500 l of buffer A (10 mM Tris-HCl, pH 7.4, 10 mM KCl,
2 mM MgCl2, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluo-
ride, 1 tablet of CompleteTM protease inhibitor mini mixture per 10 ml)
at 4 °C for 30 or 60 min. The nuclei were collected by centrifugation at
4,000 rpm at 4 °C for 10 min and then lysed in 40 l of buffer B (20 mM
HEPES, pH 8.0, 400 mM NaCl, 1 mM EGTA, 10% glycerol, 1 mM
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 1 tablet of Com-
pleteTM protease inhibitor mini mixture per 10 ml) at 4 °C for 60 min.
The samples were then centrifuged and the supernatants collected. The
protein concentration were measured and diluted as described below.
Gel Electrophoretic Mobility Shift Assay—Nuclear extracts were pre-
pared as described above. The double-stranded Spi-GLE1 probe was
labeled by biotin onto the 3 end according to the manufacturer’s in-
structions. Briefly, 5 pmol of each complementary oligonucleotide of the
probe DNA was labeled by biotin-N4-CTP in the presence of terminal
deoxynucleotidyltransferase at 37 °C for 30 min. The reactions were
stopped by EDTA. Terminal deoxynucleotidyltransferase was extracted
by chloroform/isoamyl alcohol. Then the two completed end-labeling
reactions were annealed at room temperature for 1 h. The binding
reactions for gel electrophoretic mobility shift assay were performed by
preincubating 10 g of nuclear extract of each sample with 1 g of
poly(dIdC) in binding buffer (10 mM Tris, 50 mM KCl, 1 mM dithiothre-
itol, pH 7.5, 0.5 mM EDTA) for 15 min on ice. For supershift analysis,
the extracts were incubated with the antibodies against Stat5, RhoA, or
p300 for another 10 min on ice. 20 fmol of Spi-GLE1-LUC probe was
then added. The binding mixture was incubated at room temperature
for 20 min. The samples were separated by electrophoresis on 6%
nondenaturing polyacrylamide gel in 0.5 TBE buffer at 120 V at 4 °C,
followed by transfer to Hybond-N® membrane at 380 mA for 30 min.
After that, the membrane was blocked for 15 min and incubated with
streptavidin-horseradish peroxidase conjugate for another 15 min. Af-
ter washing, the biotin-labeled DNA was detected by the enhanced
chemiluminescence kit according to the manufacturer’s instructions.
p44/42 MAP Kinase Assay—p44/42 MAP kinase assays were per-
formed according to the manufacturer’s instructions. Briefly, cells were
lysed at 4 °C in the lysis buffer provided, and the cell extract containing
200 g of protein per sample was incubated for 4 h or overnight with 15
l of immobilized phospho-specific p44/42 MAP kinase (Tyr-202/Tyr-
204) monoclonal antibody. Then the pellets were washed twice with 500
l of lysis buffer and twice with the 500 l of kinase assay buffer
provided. The kinase reactions were performed in the presence of 2 g
of Elk-1 fusion protein and 200 M ATP at 30 °C for 30 min. Elk-1
phosphorylation was detected by use of a specific phospho-Elk1 (Ser-
383) antibody.
ROCK Activity Assay—500 g of cell lysates per sample were prepared
and immunoprecipitated as described previously by ROCK polyclonal
antibody. The immunoprecipitates were washed by lysis buffer and re-
suspended in 50 l of Tris/ATP buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM
EGTA, 0.1% -mercaptoethanol, 10 mM magnesium acetate, 100M ATP).
The kinase reactions were performed in the presence of 1 g of recombi-
nant MYPT1-(654–880) at 30 °C for 30 min. MYPT1 phosphorylation was
detected by use of a specific phospho-MYPT1 (Thr-696) antibody.
p300 HAT Activity Assay—500 g of nuclear extracts were prepared
as described above and then subjected to immunoprecipitation by 10 g
of p300 monoclonal antibody or control monoclonal antibody. The im-
munoprecipitates were washed three times by PBS and once by assay
buffer (50 mM Tris base, pH 8.0, 10% glycerol, 0.1 mM EDTA, and 1 mM
dithiothreitol). The enzymatic reactions were performed at 30 °C for 30
min in the presence of 10 g of core histones and 20 M acetyl-CoA
containing 0.5 Ci of [3H]acetyl-CoA. 5 l of each sample was blotted on
the P81 paper in triplicate. The paper squares were washed three times
in trichloroacetic acid and once in acetone. The radioactivity was meas-
ured by scintillation counter. The counts/min of the enzyme sample was
subtracted by that of the negative control sample.
Site-directed Mutagenesis—RhoA mutation (R188A) was generated
by PCR mutagenesis using Quikchange® site-directed mutagenesis
kit (Stratagene). The primer pairs are: 5-CGTGGGAAGAAAAAAG-
CTGGTTGCCTTGTCT-3 and 5-AGACAAGGCAACCAGCTTTTTT-
CTTCCCACG-3.
Luciferase Reporter Assay—Either 0.2 g of the reporter plasmid pFR-
Luc and 4 ng of the fusion trans-activator plasmid pFA2-CREB or 0.5 g
of Spi-GLE1-Luc reporter plasmid were transfected with 0.8 g of the
DNA of interest into cells grown in 2% serum containing Dulbecco’s
modified Eagle’s medium upon 60–80% cell confluence. 0.4 g of -galac-
tosidase reporter vector was co-transfected as the control for transfection
efficiency. After 36 h, cells were stimulated with 50 nM GH for 6 h
immediately or after chemical pretreatment for 30–60 min. Cells were
washed by PBS twice and lysed in RLB buffer (25 mM glycylglycine, pH
7.8, 1% Triton X-100, 15 mM MgSO4, 4 mM EGTA, 1 mM dithiothreitol) for
20 min. The luciferase activity was measured in the presence of RAB
buffer (25 mM glycylglycine, pH 7.8, 15 mM potassium phosphate, pH 7.8,
15 mM MgSO4, 4 mM EGTA, 1 mM dithiothreitol, and 1 mM ATP) and 200
nM D-luciferin. -Galactosidase activity was measured in the assay buffer
(100 mM sodium phosphate, pH 7.3, 1 mM MgCl2, 50 mM -mercaptoeth-
anol, 0.665 mg/ml o-nitrophenyl -D-galactopyranoside). The luciferase
activities were calculated as the fold of stimulation after normalized by
protein content and the -galactosidase activity.
Statistical Analysis and Presentation of Data—All experiments were
performed at least three times. In the case of Western blot analysis,
representative data from one experiment are presented. Numerical
data were expressed as mean  S.D. Data were analyzed using the
two-tailed t test or analysis of variance. Results were considered signif-
icant at the 5% level.
RESULTS
GH Stimulation of NIH-3T3 Cells Increases the Activity of
RhoA—We utilized the GST-fused rhotekin-RBD as a specific
probe to determine the level of RhoA activation in lysates of
NIH-3T3 cells stimulated by GH. The rhotekin-RBD probe
recognizes only the active GTP-bound form but not the inactive
GDP-bound form of RhoA (34). We observed a marked increase
in the level of GTP-bound RhoA upon cellular stimulation with
GH, persisting from 2 to 30 min after initial GH stimulation,
followed by a decline to the basal level 60 min after GH stim-
ulation (Fig. 1A). The GH-stimulated formation of RhoA-GTP
was also dose-dependent with an increase in GTP-bound RhoA
observed at 5–50 nM GH but not at GH concentrations lower
than 0.5 nM (Fig. 1C). GH stimulation of NIH-3T3 cells did not
alter the total level of RhoA protein over the examined time
periods nor under differential dose conditions (Fig. 1, B and D).
Thus, RhoA is a small Ras-like GTPase utilized by GH to exert
its effect on cellular function.
GH-stimulated Activation of RhoA Requires the Kinase Ac-
tivity of JAK2—GH activates both JAK2 and c-Src kinases
independent of the other (25). We have demonstrated previ-
ously that two other small Ras-like GTPases, Ral and Rap,
require the activity of both c-Src and JAK2 to be fully activated
by GH (25). We therefore examined the requirement of JAK2
and c-Src for GH-stimulated activation of RhoA. As observed in
Fig. 1E, upon forced expression of the JAK2 kinase-deficient
mutant (K882E) (35), the basal level of RhoA-GTP was dimin-
ished, and GH-stimulated formation of RhoA-GTP was com-
pletely prevented. In contrast, forced expression of a c-Src
kinase-inactive mutant (K295R/Y527F) (36), under conditions
that prevent GH-stimulated activation of c-Src (25), did not
alter the ability of GH to stimulate formation of GTP-bound
RhoA. Co-transfection of both JAK2-K882E mutant and c-Src-
K295R/Y527F mutant prevented the ability of GH to stimulate
the activation of RhoA identical to that observed with forced
expression of JAK2-K882E mutant alone. Forced expression of
the kinase-deficient mutants of JAK2 and c-Src was verified by
Western blot analysis (Fig. 1, G and H), and their expression
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did not alter the total protein level of RhoA (Fig. 1F). Therefore,
we conclude that the kinase activity of JAK2, but not c-Src, is
required for GH-stimulated formation of GTP-bound RhoA.
p190 RhoGAP Inhibits GH-stimulated RhoA Activity—p190
RhoGAP, the most extensively studied GAP for Rho GTPases,
regulates the activation state of RhoA through acceleration of
GTP hydrolysis (37). We therefore examined the effect of p190
RhoGAP on GH-stimulated RhoA activity. As observed in Fig.
2A, GH-stimulated RhoA activity was dramatically repressed
by forced expression of p190 RhoGAP. Forced expression of
p190 RhoGAP did not alter the total protein level of RhoA (Fig.
2B). Forced expression of p190 RhoGAP was verified by West-
ern blot analysis (Fig. 2C). p190 RhoGAP is therefore a potent
inhibitor for GH-stimulated formation of GTP-bound RhoA.
JAK2-induced Dissociation of RhoA from p190 RhoGAP Is
Required for GH-stimulated RhoA Activation—Because both
JAK2 and p190 RhoGAP regulated GH-stimulated formation of
GTP bound RhoA, we examined the relationship between these
molecules on the ability of GH to stimulate the activation of
RhoA. As observed in Fig. 3A, forced expression of JAK2 in-
creased both basal and GH-stimulated RhoA activity as would
be expected from the JAK2-dependent activation of RhoA by
GH described above. Forced expression of p190 RhoGAP pre-
vented GH-stimulated formation of RhoA-GTP, and the forced
expression of p190 RhoGAP concomitant with the forced ex-
pression of JAK2 completely prevented the JAK2-enhanced
activation of RhoA by GH (Fig. 3A). The replacement of Arg-
1283 of p190 RhoGAP by Ala has been reported previously
to disrupt GAP activity (6). We therefore utilized this
p190R1283A mutant to competitively antagonize the activity of
endogenous p190 RhoGAP. In Fig. 3E, forced expression of the
p190R1283A mutant robustly enhanced both basal and GH-
stimulated formation of GTP-bound RhoA. Forced expression of
the kinase-deficient mutant JAK2-K882E prevented GH-
stimulated activation of RhoA (Fig. 3E). The lack of GH-
stimulated formation of GTP-bound RhoA as a result of forced
expression of JAK2-K882E was reversed by concomitant trans-
fection with p190R1283A. The effect of p190 RhoGAP on GH-
stimulated formation of GTP-bound RhoA is therefore exerted
downstream of JAK2. Forced expression of p190 RhoGAP,
p190R1283A, JAK2, and JAK2-K882E was verified by Western
blot analysis (Fig. 3, C, D, G, and H), and the forced expression
of these molecules did not alter the total cellular level of RhoA
(Fig. 3, B and F). Thus, GH-stimulated formation of RhoA-GTP
requires JAK2 kinase activity and subsequent inactivation of
p190 RhoGAP.
One mechanism for the regulation of p190 RhoGAP activity
is tyrosine phosphorylation (6, 7). We therefore first examined
whether GH could affect the level of tyrosine phosphorylation
of p190 RhoGAP. p190 RhoGAP was immunoprecipitated from
extracts derived from cells stimulated with GH and the immu-
FIG. 1. GH stimulation of NIH-3T3 cells increases the forma-
tion of GTP-bound RhoA in a JAK2-dependent manner. A–D, GH
stimulates the formation of GTP-bound RhoA in both a time- and
dose-dependent manner. NIH-3T3 cells were stimulated with the indi-
cated doses of GH for the indicated times, and the GST-linked probe
rhotekin-RBD, which recognizes only the active GTP bound form of
RhoA, was used to separate RhoA-GTP from the inactive RhoA-GDP.
GTP-bound RhoA (A and C) was visualized by Western blot analysis.
Total cellular RhoA (B and D) was also determined in total cell lysate by
Western blot analysis. The results presented are representative of a
minimum of three independent experiments. E–H, GH-stimulated ac-
tivation of RhoA requires the kinase activity of JAK2. NIH-3T3 cells
were transiently transfected with empty vector or the expression con-
struct containing either kinase-dead JAK2 (K882E) or kinase-dead
c-Src (K295R/Y527F) or both and stimulated with 50 nM GH for 2 min.
The GST-linked probe rhotekin-RBD, which recognizes only the active
GTP-bound form of RhoA, was used to separate RhoA-GTP from the
inactive RhoA-GDP. GTP-bound RhoA (E) was visualized by Western
blot analysis. Total cellular RhoA (F) was also determined in total cell
lysates by Western blot analysis. The forced expression of JAK2-K882E
and c-Src-K295R/Y527F is indicated (G and H).
FIG. 2. p190 RhoGAP inhibits GH-stimulated RhoA activity. p190
RhoGAP cDNA was transiently transfected into NIH-3T3 cells before
cellular stimulation with 50 nM GH for 2 min. The GST-linked probe
rhotekin-RBD, which recognizes only the active GTP-bound form of RhoA,
was used to separate RhoA-GTP from the inactive RhoA-GDP. GTP-
bound RhoA (A) was visualized by Western blot analysis. Total cellular
RhoA (B) was also determined in total cell lysates by Western blot anal-
ysis. The forced expression level is indicated (C).
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noprecipitates subject to Western blot analysis for phospho-
tyrosine. As shown in Fig. 3J, GH had no effect on the tyrosine
phosphorylation status of p190 RhoGAP despite equivalent
amounts of p190 RhoGAP being precipitated (Fig. 3K). In the
basal unstimulated cellular state, RhoA and p190 RhoGAP are
associated with each other (Fig. 3L). Despite the inability of GH
to alter the tyrosine phosphorylation status of p190 RhoGAP,
GH stimulation of cells resulted in a dissociation between p190
RhoGAP and RhoA as observed in Fig. 3L. The GH-stimulated
dissociation of RhoA and p190 RhoGAP was prevented by
FIG. 3. JAK2-dependent dissocia-
tion of RhoA from p190 RhoGAP is
required for GH-stimulated RhoA ac-
tivation. A–H, p190 RhoGAP inhibits
JAK2-dependent RhoA activation stimu-
lated by GH. cDNAs for wild type JAK2
and p190 RhoGAP or dominant negative
mutant JAK2-K882E and GAP-defective
mutant p190R1283A were transiently
transfected into NIH-3T3 cells as indi-
cated before cellular stimulation with 50
nM GH for 2 min. The GST-linked probe
rhotekin-RBD, which recognizes only the
GTP-bound form of RhoA, was used to
separate RhoA-GTP from the inactive
RhoA-GDP. GTP-bound RhoA (A and E)
was visualized by Western blot analysis.
Total cellular RhoA (B and F) was also
determined in total cell lysates by West-
ern blot analysis. The forced expression of
JAK2 and p190 as well as their corre-
sponding dominant negative mutants is
indicated (C, D, G, and H). Densitometric
evaluation of the effects of JAK2 and p190
on GH-stimulated RhoA activation is pre-
sented in I. J and K, p190 is constitutively
tyrosine-phosphorylated independent of
GH treatment. NIH-3T3 cells were stim-
ulated with 50 nM GH for the indicated
times. After that, the cell lysates were
extracted, and the tyrosine phosphoryla-
tion of p190 was determined (J). Total
p190 present in the immunoprecipitates
is indicated (K). L–N, JAK2 is required for
the dissociation of RhoA from p190 stim-
ulated by GH. NIH-3T3 cells were tran-
siently transfected with the empty vector
or the expression vector containing kinase
dead mutant JAK2-K882E. Cells were
stimulated with 50 nM GH for 2 min. The
cell lysates were then extracted, and
RhoA bound with immunoprecipitated
p190 was determined (L). Total p190
present in the immunoprecipitates is in-
dicated (M). The forced expression level of
JAK2-K882E is indicated (N).
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forced expression of the kinase-inactive mutant JAK2-K882E
(Fig. 3L). Equivalent loading of p190 RhoGAP is shown in Fig.
3M. Forced expression of JAK2-K882E was verified by Western
blot analysis as observed in Fig. 3N. Thus, JAK2 kinase activ-
ity is required for GH-stimulated dissociation of p190 RhoGAP
and RhoA with the resultant release of RhoA from inhibition by
p190 RhoGAP and the formation of GTP-bound RhoA.
RhoA Does Not Affect GH-stimulated Activation of JAK2-
p44/42 MAP Kinase Pathway—RhoA has been reported to ac-
tivate the JAK2/Stat3 pathway through the regulation of JAK2
tyrosine phosphorylation status and activity (14). Clostridium
botulinum C3 exoenzyme selectively inhibits RhoA activity by
the ADP-ribosylation of residue Asn-41 in the RhoA effector
domain and has been utilized widely to investigate RhoA func-
tion (38, 39). As observed in Fig. 4A, the GH-stimulated acti-
vation of RhoA was dramatically repressed by forced expres-
sion of C3 exoenzyme. Forced expression of C3 exoenzyme did
not alter the total protein level of RhoA (Fig. 4B). Fig. 4B also
showed that ADP-ribosylated RhoA migrated slower in com-
parison to the unmodified species in SDS-PAGE, and this phe-
nomenon has been reported previously (39). Forced expression
of C3 exoenzyme was verified by Western blot analysis (Fig.
4C). Thus C3 exoenzyme is a potent inhibitor of GH-stimulated
RhoA activity.
We therefore utilized C3 exoenzyme to examine the effect of
RhoA on the ability of GH to stimulate JAK2 and p44/42 MAP
kinase activities. As observed in Fig. 4D, forced expression of
C3 exoenzyme did not alter the level of tyrosine phosphoryla-
tion of JAK2 stimulated by GH. The equivalent loading of
JAK2 and the forced expression of C3 exoenzyme were demon-
strated by Western blot analysis (Fig. 4, E and F). Therefore,
RhoA does not participate in GH stimulation of JAK2.
p44/42 MAP kinase is utilized by GH to exert pleiotropic
cellular effects (19), and its mechanism of activation by GH has
FIG. 4. RhoA does not affect GH-
stimulated activation of JAK2-p44/42
MAP kinase pathway. A–C, C3 exoen-
zyme inhibits GH-stimulated RhoA activ-
ity. C3 exoenzyme cDNA was transiently
transfected into NIH-3T3 cells before cel-
lular stimulation with 50 nM GH for 2
min. The GST-linked probe rhotekin-
RBD, which recognizes only the active
GTP-bound form of RhoA, was used to
separate RhoA-GTP from the inactive
RhoA-GDP. GTP-bound RhoA (A) was vi-
sualized by Western blot analysis. Total
cellular RhoA (B) was also determined in
total cell lysates by Western blot analysis.
The forced expression level of C3 exoen-
zyme is indicated (C). D–F, RhoA does not
participate in GH stimulation of JAK2.
NIH-3T3 cells were transiently trans-
fected with the expression vectors for C3
exoenzyme and stimulated with 50 nM
GH. 1 mg of cell lysates per sample was
immunoprecipitated with agarose beads
precoupled with JAK2 antibody and pro-
cessed for Western blotting analysis with
a monoclonal antibody recognizing tyro-
sine-phosphorylated proteins (D). The
membrane was stripped and reprobed to
demonstrate the equal loading of JAK2
proteins (E). The level of the transfected
C3 exoenzyme is shown in F. G and H,
RhoA does not participate in GH stimula-
tion of p44/42 MAP kinase activity. NIH-
3T3 cells were transiently transfected
with the expression vectors for C3 exo-
enzyme and stimulated with 50 nM GH
for the indicated times. p44/42 MAP
kinase activity was determined as de-
scribed under “Experimental Proce-
dures.” GH-stimulated p44/42 MAP
kinase activity in the presence of tran-
siently transfected C3 exoenzyme is pre-
sented in G. The level of the transfected
C3 exoenzyme is shown in H.
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been studied extensively (3, 26, 29). RhoA has also been dem-
onstrated previously (40) to be involved in the stimulation of
p44/42 MAP kinase activity in stretch-induced signaling. We
therefore examined the effect of forced expression of C3 exoen-
zyme on GH-stimulated p44/42 MAP kinase activity. GH stim-
ulation of vector-transfected NIH-3T3 cells resulted in a rapid
and prolonged activation of p44/42 MAP kinase activity such
that 60 min after GH stimulation, p44/42 MAP kinase activity
was still higher than in the basal state (Fig. 4G). Forced ex-
pression of C3 exoenzyme did not affect the ability of GH to
activate p44/42 MAP kinase nor alter the duration of the GH-
stimulated increase in p44/42 MAP kinase activity (Fig. 4G).
Thus, RhoA activity does not participate in GH stimulation of
p44/42 MAP kinase activity.
GH Stimulates ROCK Activity in a RhoA-dependent Man-
ner—ROCK is a major RhoA effector molecule mediating the
majority of the reported cellular functions of RhoA (11, 12). We
therefore examined whether the GH-stimulated formation of
GTP-bound RhoA resulted in the activation of ROCK. We ob-
served a time-dependent activation of ROCK kinase activity
upon GH stimulation, first observed at 5 min, sustained until
30 min, and then returned to the basal level after 60 min (Fig.
5A). Forced expression of C3 exoenzyme completely prevented
the GH stimulation of ROCK activity (Fig. 5A). Equivalent
loading of ROCK protein and the forced expression of C3 ex-
oenzyme were demonstrated by Western blot analysis (Fig. 5, B
and C). Thus, GH stimulates ROCK activity in a RhoA-depend-
ent manner. As we have demonstrated that GH-stimulated
formation of RhoA-GTP requires JAK2 kinase activity and
subsequent inactivation of p190 RhoGAP, we further examined
the dependence of GH-stimulated ROCK activity on JAK2 and
p190 RhoGAP. As observed in Fig. 5D, forced expression of
JAK2 robustly increased both basal and GH-stimulated ROCK
activity, whereas forced expression of p190 RhoGAP prevented
GH-stimulated ROCK activity. When p190 RhoGAP was forc-
ibly expressed concomitantly with JAK2, the JAK2-enhanced
activation of ROCK by GH was dramatically inhibited (Fig.
5D). Concordantly, forced expression of the p190R1283A mu-
tant enhanced both basal and GH-stimulated ROCK activity.
Forced expression of the kinase-deficient mutant JAK2-K882E
prevented GH-stimulated activation of ROCK, and the inhibi-
tory effect of JAK2-K882E on GH-stimulated ROCK activity
was reversed by concomitant transfection with p190R1283A
(Fig. 5D). Equivalent loading of ROCK protein and forced ex-
pression of p190 RhoGAP, p190R1283A, JAK2, and JAK2-
K882E were verified by Western blot analysis (Fig. 5, E–G).
Therefore, GH-stimulated ROCK activation is elicited by for-
mation of GTP-bound RhoA that requires JAK2 kinase activity
and subsequent inactivation of p190 RhoGAP.
RhoA-ROCK Is Required for GH-stimulated, Stat5-mediated
Transcription—The JAK-Stat pathway is one of the predomi-
nant pathways utilized by GH to mediate transcriptional acti-
vation (19). GH-stimulated JAK2 activation has been demon-
strated to result in the tyrosine phosphorylation and
transactivation of both Stat5 isoforms (20). We therefore exam-
ined whether RhoA and/or ROCK are required for GH-stimu-
lated, Stat5-mediated transcription by use of a reporter assay
specific for both isoforms of Stat5 (41). GH stimulation of NIH-
3T3 cells resulted in an approximate 5-fold increase in Stat5-
mediated transcription in comparison to the basal state (Fig.
FIG. 5. GH stimulates ROCK activ-
ity in a RhoA-dependent manner.
A–C, NIH-3T3 cells were transiently
transfected with the expression vectors
for C3 exoenzyme and stimulated with 50
nM GH for the indicated times. ROCK ki-
nase activity was determined as described
under “Experimental Procedures.” GH-
stimulated ROCK kinase activity in the
presence of transiently transfected C3 ex-
oenzyme is presented in A. The equal
loading of ROCK proteins is demon-
strated in B. The level of the transfected
C3 exoenzyme is shown in C. D–G, NIH-
3T3 cells were transiently transfected
with the expression vectors for wild type
JAK2 and p190 RhoGAP or dominant
negative mutant JAK2-K882E and GAP-
defective mutant p190R1283A and stim-
ulated with 50 nM GH for 15 min. ROCK
kinase activity was determined as de-
scribed under “Experimental Proce-
dures.” GH-stimulated ROCK kinase ac-
tivity is presented in D. The equal loading
of ROCK proteins is demonstrated in E.
The level of JAK2 and p190 RhoGAP as
well as their corresponding dominant
negative mutants is shown in F.
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6A). Forced expression of the C3 exoenzyme resulted in a de-
crease in the basal level of Stat5-mediated transcription and
abrogated the ability of GH to stimulate Stat5-mediated tran-
scription. Forced expression of a ROCK kinase-deficient mu-
tant (ROCK-KD) also similarly abrogated the ability of GH to
stimulate Stat5-mediated transcription (Fig. 6A). Activation of
RhoA and ROCK by GH is therefore required for GH to stim-
ulate Stat5-mediated transcription.
Tyrosine phosphorylation of Stat5 is necessary for nuclear
translocation and binding of Stat5 to its specific response ele-
ment and subsequent activation of transcription (20). Forced
expression of C3 exoenzyme did not alter the ability of GH to
FIG. 6. RhoA-ROCK are required for
GH-stimulated, Stat5-mediated tran-
scription. A, RhoA and ROCK activity are
required for GH-stimulated, Stat5-mediated
transcription. NIH-3T3 cells were tran-
siently transfected with the expression vec-
tors for C3 exoenzyme or kinase-defective
mutant ROCK-KD together with Spi2.1-
GLE1-Luc and -galactosidase vector. Cells
were treated with 50 nM GH, and GH-
stimulated, Stat5-mediated transcription
was determined by measuring luciferase ac-
tivity as described under “Experimental Pro-
cedures.” The results were normalized by
protein contents and -galactosidase activ-
ity. Data presented are mean  S.E. of trip-
licate determinations. Experiments were re-
peated three times. B–D, RhoA is not
required for GH-stimulated tyrosine phos-
phorylation of Stat5. NIH-3T3 cells were
transiently transfected with the expression
vectors for C3 exoenzyme and then stimu-
lated with 50 nM GH for the indicated times.
Western blot analysis of 50 g of cell lysates
per sample using the monoclonal antibody
recognizing tyrosine-phosphorylated
Stat5A/B was performed (B). The membrane
was stripped and reprobed with anti-Stat5
to demonstrate equal loading of Stat5 pro-
teins (C). The level of forced expression of C3
exoenzyme was shown (D). E, RhoA is not
required for GH-stimulated nuclear translo-
cation of Stat5. NIH-3T3 cells were tran-
siently transfected with the expression vec-
tors for C3 exoenzyme and stimulated with
50 nM GH. The samples for confocal laser
scanning microscopy were prepared and vi-
sualized as described under “Experimental
Procedures.” The effect of C3 exoenzyme on
GH-stimulated nuclear translocation of
Stat5 was shown. Stat5 molecules were la-
beled with Cy3 indicated as red. C3 exoen-
zyme was fused with a GFP tag that is
indicated as green. Nuclei were stained by
DAPI indicated as blue. F and G, RhoA is
not required for GH-stimulated DNA bind-
ing of Stat5. NIH-3T3 cells were tran-
siently transfected with the expression vec-
tors for C3 exoenzyme and stimulated with
50 nM GH. The nuclear extracts for gel
electrophoretic mobility shift assay were
prepared and were subject for reactions as
described under “Experimental Proce-
dures.” The effect of C3 exoenzyme on GH-
stimulated DNA binding of Stat5 is shown
(F). The level of forcefully expressed C3
exoenzyme is shown in G. H–J, RhoA is not
required for GH-stimulated degradation of
Stat5. NIH-3T3 cells were transiently
transfected with the expression vector for
C3 exoenzyme and then stimulated with 50
nM GH. Samples were collected 2 or 6 h
after GH treatment, and Western blot
analysis of 50 g of cell lysates per sample
was performed by using the monoclonal an-
tibody recognizing tyrosine-phosphory-
lated Stat5A/B (H). The membrane was
stripped and reprobed with anti-Stat5 to
demonstrate equal loading of Stat5 pro-
teins (I). The forced expression of C3 exoen-
zyme is shown in J. The results presented
are representative of a minimum of three
independent experiments.
GH Activates RhoA32744
acutely stimulate tyrosine phosphorylation of Stat5 (Fig. 6B)
over 5–60 min. Forced expression of C3 exoenzyme was dem-
onstrated by Western blot analysis and did not alter the total
cellular level of Stat5 (Fig. 6, C and D). Similarly, forced ex-
pression of C3 exoenzyme did not alter the nuclear transloca-
tion of Stat5 in response to GH as determined by confocal laser
scanning microscopic analysis (Fig. 6E). Furthermore, as ob-
served in Fig. 6F, forced expression of C3 exoenzyme did not
affect GH-stimulated binding of Stat5 to its DNA-response
element (SPI-GLE1). Binding of Stat5 to SPI-GLE1 was veri-
fied by supershift analysis with a specific Stat5 antibody (Fig.
6F). The expression of C3 exoenzyme was demonstrated by
Western blot analysis (Fig. 6G). Neither RhoA nor p300, a
reported transcriptional regulator of Stat5, was contained in
the GH-stimulated complex binding to SPI-GLE1 (Fig. 6F). It
has been demonstrated previously that c-Cbl-mediated degra-
dation of Stat5 abrogates GH-stimulated, Stat5-mediated tran-
scription independent of tyrosine phosphorylation, nuclear
translocation, or DNA binding of Stat5 (42). Such degradation
resulted in reduced levels of tyrosine-phosphorylated Stat5
within 2–6 h after GH stimulation (42). Forced expression of
C3 exoenzyme did not alter the amount of tyrosine phospho-
rylated nor total Stat5 within 6 h of GH stimulation (Fig. 6H).
Thus, RhoA regulates GH-stimulated, Stat5-mediated tran-
scription through a mechanism other than initial activation
and DNA binding of Stat5 or degradation of activated Stat5.
PKA Inhibits GH-stimulated, Stat5-mediated Transcription
through Inactivation of RhoA—GH has been reported to stim-
ulate CREB phosphorylation and CREB-mediated transcrip-
tion during adipocytic differentiation (43, 44). In addition,
PKA/CREB has been observed previously (45) to modulate
Stat5-mediated transcription in erythroid cells. Furthermore,
PKA has been demonstrated to reduce the activity of RhoA by
phosphorylation of RhoA on serine residue 188 (46). We there-
fore examined whether RhoA would be the pivot for potential
cross-talk between the PKA and JAK2-Stat5 pathways. We
observed that GH stimulation of NIH-3T3 cells did not affect
PKA activity, phosphorylation of CREB, nor CREB-mediated
transcription, however, forskolin was able to stimulate all
three above-mentioned events (data not shown), suggesting
that NIH-3T3 cells utilized in this study possess a functional
PKA/CREB pathway that is not responsive to GH stimulation.
However, as shown in Fig. 7A, 8-Br-cAMP or forskolin abro-
gated the formation of GTP-bound RhoA stimulated by GH.
Conversely, a myristoylated PKA-specific inhibitor enhanced
the GH-stimulated formation of GTP-bound RhoA (Fig. 7A). We
proceeded to examine the effect of modulation of PKA activity
on the ability of RhoA to enhance GH-stimulated, Stat5-medi-
ated transcription. As observed in Fig. 7C, forskolin abrogated,
and PKA-specific inhibitor markedly enhanced, the magnitude
of GH-stimulated, Stat5-mediated transcription. Concordantly,
forced expression of the mutant RhoAS188A, not subject to
inhibition by PKA, dramatically increased GH-stimulated,
Stat5-mediated transcription (Fig. 7C). Forskolin failed to pre-
vent the enhancement of GH-stimulated Stat5 transcriptional
activity observed with forced expression of RhoAS188A, indi-
cating that PKA required serine residue 188 of RhoA to inhibit
GH-stimulated Stat5 activity (Fig. 7C). Consistently, the en-
hancement of GH-stimulated, Stat5-mediated transcription ob-
served in the presence of the PKA inhibitor was completely
prevented by forced expression of the C3 exoenzyme inhibiting
RhoA (Fig. 7C). We therefore conclude that RhoA is the pivot
FIG. 6—continued
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for cross-talk between PKA and GH-stimulated, Stat5-medi-
ated transcription.
p300 Inhibits GH-stimulated RhoA-mediated Stat5 Transcrip-
tional Activity by Recruiting HDAC6—p300 is a transcriptional
cofactor with histone acetylase activity that may either activate
or repress transcription (31, 32, 47). Indeed, p300 has been dem-
onstrated previously to enhance prolactin-stimulated, Stat5-me-
diated transcription (49). Previous studies (17, 18) have sug-
gested that RhoA regulates transcription via repression of p300/
CBP. We therefore examined the potential role of p300 in the
effect of RhoA on GH-dependent Stat5-mediated transcription.
Forced expression of p300 reduced the basal level of Stat5-medi-
ated transcription and completely abrogated GH-stimulated,
Stat5-mediated transcription (Fig. 8A). We next examined
whether the histone acetylase activity of p300 was required for
repression of GH-stimulated, Stat5-mediated transcription. HAT
activity was not affected by cellular stimulation with GH nor was
it altered by forced expression of the C3 exoenzyme (Fig. 8B). We
also utilized the p300mutAT2 with 6 amino acids mutated in the
HAT domain with resultant defective HAT activity (50). Concor-
dantly, the inhibitory effect of p300 was independent of HAT
activity, as forced expression of p300mutAT2 also dramatically
abrogated GH-stimulated, Stat5-mediated transcription (Fig.
8A). We next examined whether the CRD1 domain of p300 was
required for repression of GH-stimulated, Stat5-mediated tran-
scription. The CRD1 domain is responsible for the repressor
activity of p300 through SUMO modification-dependent recruit-
ment of HDAC6 (32). Forced expression of the p300CRD1 domain
mutant (p300CRD1) did not significantly repress GH-stimu-
lated, Stat5-mediated transcription (Fig. 8A). Further evidence
that the repressor ability of p300 on GH-stimulated, Stat5-medi-
ated transcription was due to its association with histone
deacetylase activity was provided by the observation that the
deacetylase inhibitor, trichostatin A (TSA), reversed the abroga-
tion of GH-stimulated, Stat5-mediated transcription as a conse-
quence of forced expression of p300 (Fig. 8A). Forced expression
of HDAC6, the histone deacetylase associating with the CRD1
domain of p300, also dramatically abrogated GH-stimulated,
Stat5-mediated transcription (Fig. 8C). The inhibitory effect of
the forced expression of HDAC6 on GH-stimulated, Stat5-medi-
ated transcription was also reversed in the presence of TSA (Fig.
8C). Forced expression of the p300CRD1 mutant prevented
inhibition of GH-stimulated, Stat5-mediated transcription as a
consequence of forced expression of HDAC6 (Fig. 8C), indicating
that HDAC6 association with p300 is required for repression of
GH-stimulated, Stat5-mediated transcription.
We next examined the involvement of p300 in the RhoA-de-
pendent enhancement of GH-stimulated, Stat5-mediated tran-
scription. As shown in Fig. 8D, forced expression of p300 elim-
inated the enhancement of GH-stimulated, Stat5-mediated
transcription as a consequence of forced expression of
RhoAS188A. Conversely and concordant with the above obser-
vation, forced expression of p300CRD1 relieved GH-stimu-
lated, Stat5-mediated transcription from the suppression con-
sequent to forced expression of the C3 exoenzyme (Fig. 8D).
p300 is therefore downstream of the effect of RhoA on GH-
stimulated, Stat5-mediated transcription.
DISCUSSION
Multiple members of the family of small Ras-like GTPases
have been demonstrated to participate in the cellular effects of
GH (24, 25, 26, 28). Ras itself and RalA are required for GH-
stimulated activation of p44/42 MAP kinase and subsequent
Elk-1 mediated transcription (25, 26). Rap1 constrains the
activity of GH-stimulated p44/42 MAP kinase through inacti-
vation of RalA (24). GH also stimulates Rac activation to reg-
ulate actin cytoskeleton rearrangement and cell motility (28).
Here we have identified another small GTPase, RhoA, as a
regulator of GH-stimulated, Stat5-mediated transcription in
NIH-3T3 cells.
The activity of RhoA is tightly controlled by both positive
regulators GEFs and negative regulators GAPs and GDIs (2).
We have demonstrated here that GH stimulation results in
disassociation of p190 RhoGAP from RhoA in a JAK2-depend-
ent manner with subsequent activation of RhoA. Redistribu-
tion of p190 from the cytosol to a detergent-insoluble fraction
has been demonstrated previously (8) to be involved in the
activation of RhoA by epidermal growth factor and oncogenic
H-RasV12. Phosphorylation of p190 RhoGAP is not required for
redistribution of p190 RhoGAP nor activation of RhoA (8). We
also observe that although GH stimulation results in a disso-
ciation of p190 RhoGAP and RhoA, GH does not stimulate the
FIG. 7. PKA inhibits GH-stimulated, Stat5-mediated transcrip-
tion through inactivation of RhoA. A and B, PKA inhibits GH-
stimulated RhoA activity. NIH-3T3 cells were pretreated with 500 M
8-Br-cAMP, 20 M forskolin, or 10 M PKA inhibitor for 30 min before
stimulating with 50 nM hGH for 2 min. The GST-linked probe rhotekin-
RBD, which recognizes only the active GTP-bound form of RhoA, was
used to separate RhoA-GTP from the inactive RhoA-GDP. GTP-bound
RhoA (A) was visualized by Western blot analysis. Total cellular RhoA
(B) was also determined in total cell lysates by Western blot analysis. C,
PKA inhibits GH-stimulated, Stat5-mediated transcription via phos-
phorylation of serine residue 188 of RhoA. NIH-3T3 cells were tran-
siently transfected with the expression vectors for either RhoAS188A
mutant or C3 exoenzyme together with Spi2.1-GLE1-Luc and -galac-
tosidase vector. Cells were pretreated with either 20 M forskolin or 10
M myristoylated PKA inhibitor as indicated for 30 min prior to stim-
ulation with 50 nM GH for 6 h. GH-stimulated, Stat5-mediated tran-
scription was determined by measuring luciferase activity as described
under “Experimental Procedures.” The results were normalized by pro-
tein contents and -galactosidase activity. Data presented are mean 
S.E. of triplicate determinations. Experiments were repeated three
times.
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tyrosine phosphorylation of p190 RhoGAP. However, other
studies have reported that the GAP activity of p190 can be
regulated by Src-dependent tyrosine phosphorylation (6, 7). In
this regard it is interesting to note that GH stimulation of the
formation of GTP-bound RhoA is entirely JAK2-dependent.
This is despite the observation that GH also stimulates Src
activity in this cell line (25) and predominantly utilizes Src for
the activation of RalA and Rap1 (24, 25). GH-dependent JAK2
activity necessary for the RhoA-RhoGAP dissociation may be
required for the phosphorylation of other molecules potentially
involved in the activation of RhoA. For example, cytokine-
stimulated tyrosine phosphorylation of SOCS-3 results in pro-
longed activation of Ras due to binding of p120RasGAP with
tyrosine phosphorylated SOCS-3 (53). Whether an analogous
mechanism exists for GH-stimulated JAK2-dependent activa-
tion of RhoA remains to be determined.
We have demonstrated here that activation of RhoA is re-
quired for GH-stimulated, Stat5-mediated transcription. We
observed that the effect of RhoA was not due to altered tyrosine
phosphorylation, nuclear translocation, DNA binding, nor deg-
radation of Stat5. However, it has been reported recently (16)
that an oncogenic mutant of RhoA promoted tyrosine phospho-
rylation and DNA binding activity of Stat5A by a JAK2-de-
pendent mechanism. Concordant with the lack of effect of RhoA
on GH-stimulated tyrosine phosphorylation of Stat5, we also
observed no effect of GH-activated RhoA on JAK2 tyrosine
phosphorylation required for its activity and tyrosine phospho-
rylation of Stat5. The oncogenic form of RhoA is therefore
FIG. 8. p300 inhibits GH-stimulated RhoA-mediated Stat5 transcriptional activity by recruiting HDAC6. A, p300 inhibits GH-
stimulated, Stat5-mediated transcription requiring the CRD1 domain and HDAC activity. NIH-3T3 cells were transiently transfected with the
expression vectors for wild type p300, p300mutAT2, which is a HAT activity-defective mutant, or p300CRD1 mutant together with Spi2.1-GLE1-
Luc and -galactosidase vector. Cells were pretreated with 200 nM TSA or Me2SO as indicated for 30 min prior to stimulation with 50 nM GH for
6 h. GH-stimulated, Stat5-mediated transcription was determined by measuring luciferase activity as described under “Experimental Procedures.”
The results were normalized by protein contents and -galactosidase activity. Data presented are mean  S.E. of triplicate determinations.
Experiments were repeated three times. B, GH does not affect HAT activity of p300. NIH-3T3 cells were treated with 50 nM hGH for the times as
indicated. The HAT activity of p300 was measured as described under “Experimental Procedures.” The counts/min of each sample were converted
to fold stimulation compared with that of the nonstimulated sample. C, HDAC6 association with p300 is required for repression of GH-stimulated,
Stat5-mediated transcription. NIH-3T3 cells were transiently transfected with the expression vectors for HDAC6 either alone or combined with
p300 or p300CRD1 together with Spi2.1-GLE1-Luc and -galactosidase vector. Cells were pretreated with Me2SO or 200 nM TSA for 30 min as
indicated prior to stimulation with 50 nM GH for 6 h. GH-stimulated, Stat5-mediated transcription was determined by measuring luciferase
activity as described under “Experimental Procedures.” The results were normalized by protein contents and -galactosidase activity. Data
presented are mean  S.E. of triplicate determinations. Experiments were repeated three times. D, p300 inhibits GH-stimulated RhoA-mediated
Stat5 transcriptional activity. NIH-3T3 cells were transiently transfected with the expression vectors for either p300 or p300CRD1 in the
presence or absence of the expression vectors for RhoAS188A or C3 exoenzyme together with Spi2.1-GLE1-Luc and -galactosidase vector. Cells
were then stimulated with 50 nM GH for 6 h. GH-stimulated, Stat5-mediated transcription was determined by measuring luciferase activity as
described under “Experimental Procedures.” The results were normalized by protein contents and -galactosidase activity. Data presented are
mean  S.E. of triplicate determinations. Experiments were repeated three times.
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exhibiting a different spectrum of activity compared with the
wild type molecule under physiological stimulation. Differen-
tial functioning of oncogenic mutants of other signaling mole-
cules compared with the wild type form has been reported
previously (54–56). For example, oncogenic Ras constitutively
activates phospholipase D by a protein kinase C-independent
mechanism that is different from the protein kinase C-depend-
ent mechanism used by wild type Ras (56). Instead, we have
observed that GH-activated RhoA increases GH-stimulated,
Stat5-mediated transcription by abrogation of p300/HDAC6
repression of Stat5-mediated transcription.
In principle, transcription requires the DNA be accessible to
transcription factors and RNA polymerase. However, chroma-
tin structure impedes such access (29). Therefore, although
ligand-stimulated phosphorylation and subsequent DNA bind-
ing of transcription factors is required for transcriptional acti-
vation, it is not sufficient to initiate transcription. Chromatin
remodeling and function of transcriptional cofactors and com-
ponents of the basal transcription machinery are all required to
ensure proper transcription initiation (29). p300 and CBP, a
family of transcription cofactors with intrinsic histone acetyl-
transferase (HAT) activity, play a key role in the regulation of
promoter activity by many transcription factors including p53,
NF-B, AP1, and Stats (14, 57). Here we demonstrate that
p300 inhibits GH-stimulated Stat5 transcription. Although
p300 has been regarded as transcription co-activator, it has
also been demonstrated to possess repressor ability (30–32). It
has been reported that p300 inhibits p53-mediated transcrip-
tion of the Bax promoter (32). p300 also mediates the down-
regulation of c-Myc, and this effect does not require the HAT
activity of p300 (31). Most interesting, we also observed that
the inhibitory effect of p300 on GH-stimulated, Stat5-mediated
transcription is independent of HAT activity as the HAT activ-
ity-deficient p300mutAT2 mutant also inhibited GH-stimu-
lated, Stat5-mediated transcription. Furthermore, GH did not
stimulate HAT activity. p300 also acts as a scaffold for the
assembly of multiple cofactor complexes. This function can
either activate or inactivate transcription, as determined by
the property of the protein(s) recruited by p300 (30). It is
noteworthy that an HDAC activity is required for p300 to
diminish Stat5 transcriptional activity, suggesting that p300
may assemble with an HDAC. Indeed, a CRD1 (cell cycle reg-
ulatory domain 1) region on p300 has been demonstrated re-
cently to be crucial for recruitment of HDAC6, and this event is
the mechanism of the transcription-repressive effect of p300 on
p53 (32). Concordantly, we have demonstrated here that the
inhibition of GH-stimulated, Stat5-mediated transcription by
p300 is attributed to CRD1-mediated recruitment of HDAC6.
HDAC6 is one member of the HDAC family that includes 11
members (58). HDACs convert chromatin to a condensed state
by catalyzing deacetylation of histones and thus serve as a key
mechanism for transcriptional repression (58). HDAC6 has
been demonstrated to inhibit the transcription of NF-B and
Runx (59). It has been suggested recently that the recruitment
of HDAC6 by p300 is achieved by sumoylation of the CRD1
domain on p300 (32). Both HDAC6 and p300 are substrates for
the ubiquitin-related SUMO modifier (32, 60). SUMO attaches
to the lysine residues of the target protein in a way analogous
to that of ubiquitination; however, unlike ubiquitination,
sumoylation does not accelerate protein degradation but medi-
ates protein-protein interaction, subcellular compartmenta-
tion, and protein stability (61). Thus SUMO serves as the
bridge between HDAC6 and CRD1 of p300. HDAC1 and
HDAC4 can also be modified by SUMO (62); however, only
HDAC6 can interact with sumoylated CRD1 of p300 (32), indi-
cating that HDAC6 functions exclusively in p300-mediated
transcriptional repression.
We further demonstrate that p300 mediates the effect of
RhoA on GH-stimulated, Stat5-mediated transcription. The
antagonistic relationship between RhoA and p300 has been
FIG. 9. Schematic diagram of path-
ways mediated by p300-HDAC6 and
RhoA to regulate GH-stimulated
Stat5 transcriptional activity.
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established recently by accumulating evidence. It has been
reported that RhoA inhibited whereas its negative regulator,
RhoGDI, stimulated CBP/p300-mediated estrogen receptor-de-
pendent transactivation (18). Concordantly, RhoA down-regu-
lates inducible nitric-oxide synthase expression via inhibition
of CBP/p300 (17). The mechanism of RhoA inhibition of p300 is
still unclear. However, as a serine/threonine kinase, the RhoA
effector ROCK may affect the activity of p300 via phosphoryl-
ation. p300 is phosphorylated in both quiescent and proliferat-
ing cells presumably through cyclin-dependent kinases (64),
whereas CBP can be phosphorylated by PKA, CaM-dependent
kinase N, and p44/42 MAP kinase (30). Little is known of how
phosphorylation affects p300/CBP functions, although phos-
phorylation of p300 appears to increase its HAT activity (65). It
is also possible that an intermediate molecule is the substrate
of phosphorylation which in turn affects p300 activity. Indeed,
it has recently been demonstrated that phosphorylation of
Elk-1 enhances its interaction with p300 with resultant acti-
vation of p300 (66). It is possible that GH-stimulated activation
of ROCK results in phosphorylation of p300 or a p300-interact-
ing protein so as to disrupt the recruitment of HDAC6 by
CRD1, and thus release Stat5-mediated transcription from
p300/HDAC6-mediated repression. The precise mechanism by
which RhoA/ROCK regulates p300, and whether phosphoryla-
tion participates in this event, requires further elucidation.
Here we have observed that cAMP/PKA inhibits GH-stimu-
lated, Stat5-mediated transcription, but GH itself does not
affect the PKA-CREB pathway. Interaction between PKA and
the cellular effects of GH has been reported previously. For
example, it has been demonstrated that the cAMP/PKA path-
way mediates the effects of GH in ovarian granulosa cells by
up-regulation of the protein level of PKA itself by GH (67).
cAMP also potentiates the ability of GH to prime preadipocytes
for differentiation and simultaneously stimulate the phospho-
rylation and activation of CREB (43). However, the GH-stim-
ulated activation of CREB was reported to be independent of
PKA (43), and it has not been addressed whether the effect of
cAMP on GH-primed differentiation is mediated through acti-
vation of CREB. Thus, cAMP/PKA modulation of GH signaling
does not necessarily require GH-dependent regulation of the
PKA-CREB pathway. Instead, we have identified that the ef-
fect of cAMP/PKA on GH-stimulated, Stat5-mediated tran-
scription requires serine residue 188 in RhoA, thus mediating
repression of RhoA activity. It has been demonstrated previ-
ously (46, 48, 63) that cAMP/PKA antagonizes RhoA/ROCK
activity through phosphorylation of serine residue 188, which
possibly increases the squelching of RhoA by its negative reg-
ulator RhoGDI. One recent study (27) has further demon-
strated an antagonistic effect of PKA on RhoA/ROCK-mediated
gene expression. It has been reported that prostaglandin E2
and stem cell factor enhance erythropoiten-mediated Stat5
transactivation by the PKA-CREB-CBP/p300 pathway (45, 51).
This apparent discordance between the above stimulating ef-
fect of PKA on Stat5 transcriptional activity and our findings
that PKA inhibits Stat5 may be due to the different signaling
pathways utilized by PKA upon different ligand stimulation in
a different cellular context. In our system, PKA does not utilize
CREB (data not shown) to regulate GH-stimulated, Stat5-me-
diated transcription. Thus, PKA may divergently regulate
Stat5 transactivation by differential mechanisms, and the se-
lection is determined by the specific cellular conditions.
In summary, we demonstrate here that small GTPase RhoA
and its effector serine/threonine kinase ROCK are activated by
growth hormone through JAK2-dependent dissociation of RhoA
from its negative regulator p190 RhoGAP. GH utilizes RhoA
and ROCK to abrogate the repression of Stat5-mediated tran-
scription by HDAC6 recruited by p300, thereby dramatically
enhancing GH-stimulated, Stat5-mediated transcriptional ac-
tivity. We also demonstrate that PKA inactivates RhoA
through serine residue 188 that consequently suppresses GH-
stimulated, Stat5-mediated transcription. A diagram summa-
rizing this RhoA-dependent pathway to regulate GH-stimu-
lated, Stat5-mediated transcription is provided in Fig. 9. We
have therefore provided a novel mechanism by which GH-
stimulated activation of Ras-like small GTPases regulates
Stat5-mediated transcription stimulated by GH. The involve-
ment of HDAC activity in GH-stimulated gene transcription
also raises the possibility of direct GH participation in epige-
netic modification of gene expression (52).
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Hormone-stimulated p44/42 MAP Kinase and JNK/SAPK Activities*
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We demonstrate here that growth hormone (GH) stim-
ulates the activation of Rap1 and Rap2 in NIH-3T3 cells.
Full activation of Rap1 and Rap2 by GH necessitated the
combined activity of both JAK2 and c-Src kinases, al-
though c-Src was predominantly required. GH-stimu-
lated Rap1 and Rap2 activity was also demonstrated to
be CrkII-C3G-dependent. GH stimulated the tyrosine
phosphorylation of C3G, which again required the com-
bined activity of JAK2 and c-Src. C3G tyrosine residue
504 was required for GH-stimulated Rap activation. Ac-
tivated Rap1 inhibited GH-stimulated activation of RalA
and subsequent GH-stimulated p44/42 MAP kinase activ-
ity and Elk-1-mediated transcription. In addition, we
demonstrated that C3G-Rap1 mediated CrkII enhance-
ment of GH-stimulated JNK/SAPK activity. We have
therefore identified a linear JAK2-independent path-
way switching GH-stimulated p44/42 MAP kinase and
JNK/SAPK activities.
The Rap proteins (Rap1 and Rap2) belong to the Ras-like
small GTPase superfamily, which consists of at least 13 mem-
bers (1). In this family, Ras has been extensively studied and
was originally regarded as a transforming oncogene since Ras
genes have been found mutated in about 15% of all human
tumors (2). It possesses an important role in cell growth and
differentiation as it has been demonstrated to be required for
activation of p44/42 MAP1 kinase activity by a number of
growth factors including growth hormone (GH) (3–5). Rap1 is
closely related to Ras and was initially identified as a suppres-
sor of the K-ras transformed phenotype (6). Structurally, Rap1
shares striking similarity with Ras in the effector domain. It
has been suggested that Rap1 antagonizes Ras activity by
sequestration of its target, Raf-1, in the inactive form (7). In
addition, several studies have demonstrated that both Rap1
and Ras can bind the same effectors, such as Raf-1 and RalGDS
(8). Rap2 exhibits 60% identity to Rap1 and shares most of the
effector proteins with Ras and Rap1 (9). The function of Rap2 is
more limited compared with Rap1, although an antagonistic
effect of Rap2 on Ras-mediated transcription has been reported
(10).
One common mechanism utilized by small GTPases to reg-
ulate cellular function is to cycle between the inactive GDP-
bound state and the active GTP-bound state. Guanine nucleo-
tide exchange factors (GEFs) facilitate GDP dissociation and
allow the more abundant GTP to rebind, while GTPase-acti-
vating proteins (GAPs) accelerate GTP hydrolysis to complete
the cycle (1, 7). C3G is a Rap-specific GEF since it predomi-
nantly catalyzes the guanine nucleotide exchange reaction for
Rap1 and Rap2 (10, 11). C3G was originally identified as a
major protein bound to the SH3 domain of c-Crk (12). There are
three proline-rich sequences that bind to the SH3 domain of
c-Crk in the central region of C3G and one C-terminal CDC25
homology domain catalyzing the GEF reaction of Rap (13). The
function of the C3G N terminus remains unknown but recent
studies have reported the association of p130cas to this region
(14). C3G is activated by c-Crk-mediated membrane recruit-
ment. Two isoforms of c-Crk protein are generated by alterna-
tive mRNA splicing. The larger form is CrkII, containing one
SH2 domain and two SH3 domains, while the smaller form is
CrkI, which lacks the C-terminal SH3 domain and one negative
regulatory tyrosine residue compared with CrkII. CrkII is more
abundant than CrkI in normal cells; therefore, CrkII is the
major adaptor for C3G (15). A number of growth factors and
cytokines stimulate the recruitment of the Crk-C3G complex to
the membrane where tyrosine kinases are located such that
C3G tyrosine residue 504 is phosphorylated with a resultant
increase in its GEF activity (16, 17).
GH is the primary regulator of postnatal somatic growth and
metabolism (18, 19). It utilizes special groups of signaling mol-
ecules to regulate the transcription of specific genes required
for the above processes. These signaling molecules include: 1)
receptor-tyrosine kinases (EGF receptor) (20) and non-recep-
tor-tyrosine kinases (JAK2, Ref. 3; c-Src; c-Fyn, Ref. 21; and
FAK, Ref. 22), although in the case of the EGF receptor it may
be used simply as an adaptor protein; 2) members of the MAP
kinase family including p44/42 MAP kinase (23), p38 MAP
kinase (24), and JNK/SAPK (21) and their respective down-
stream effectors; 3) members of the insulin receptor substrate
(IRS) group including IRS-1, -2, and -3, which may act as
docking proteins for further activation of signaling molecules
including phosphatidylinositol 3-kinase (25); 4) small Ras-like
GTPases (26); and 5) STAT family members including STATs 1,
3, 5a, and 5b (27, 28), which constitute one group of signaling
molecules involved in transcriptional regulation by GH. Al-
though JAK2 is postulated to be required for GH signal trans-
duction, our group has recently identified a JAK2-independent
pathway regulating GH-stimulated p44/42 MAP kinase activ-
ity (29). GH stimulated the formation of GTP-bound RalA and
subsequent phospholipase D activation, required for the acti-
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vation of p44/42 MAP kinase by GH in a c-Src-dependent
manner.
Here we have demonstrated that cellular stimulation with
GH results in the activation of both Rap1 and Rap2 in NIH-3T3
cells. The activation of Rap by GH was achieved by the com-
bined JAK2- and c-Src-dependent tyrosine phosphorylation of
C3G. GH-stimulated Rap1 activation was utilized to negatively
modulate GH-stimulated p44/42 MAP kinase activity and sub-
sequent Elk-1-mediated transcription through inhibition of
RalA activity. Concomitantly, GH stimulated C3G-dependent
activation of Rap1-enhanced JNK/SAPK activity and subse-
quent c-Jun-mediated transcription in response to GH. Rap1 is
therefore a GH effector molecule activated in a JAK2-independ-
ent manner.
EXPERIMENTAL PROCEDURES
Materials—Recombinant human growth hormone (hGH) was a gen-
erous gift of Novo Nordisk (Singapore). CrkII monoclonal antibody, Ras
monoclonal antibody, RalA monoclonal antibody, and PY20 monoclonal
antibody were obtained from Transduction Laboratories (Lexington,
KY). JAK2 polyclonal antibody, C3G polyclonal antibody, c-Src poly-
clonal antiserum, Rap1 polyclonal antibody, Rap2 polyclonal antibody,
and protein A/G plus agarose were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Secondary anti-IgG antibodies and the en-
hanced chemiluminescence (ECL) kit were purchased from Amersham
Biosciences. The p44/42 MAP kinase assay kit and SAPK/JNK assay kit
were purchased from New England Biolabs (Beverly, MA). The trans-
fection reagent Effectene was purchased from Qiagen (Hilden,
Germany). The complete protease inhibitor mixture tablets were pur-
chased from Roche Diagnostics (Mannheim, Germany). All other re-
agents were obtained from Sigma Chemical.
pET15b-GST-RalGDS-RBD construct encoding the 97 amino acids
spanning RBD of RalGDS, pGEX4T3-GST-RalBD construct for GST-
RLIP-RBD containing amino acids 397–518 of human RLIP76 and
pGEX2T-RBD construct for GST-Raf1-RBD containing amino acids 51–
131 of Raf-1 (8, 30, 31) were the generous gifts of Dr. Johannes L. Bos
(Utrecht, Netherlands). The wild-type and dominant-negative Rap1A
plasmids were kindly provided by Dr. Alfred Wittinghofer (Dortmund,
Germany). The dominant-negative c-Src plasmid was obtained from Dr.
Joan S. Brugge (Boston, MA). The dominant-negative JAK2 plasmid
was a kind gift of Dr. Olli Silvennoinen (Tampere, Finland). The wild-
type CrkII expression vector and the wild-type and mutant form of C3G
were generously provided by Dr. Michiyuki Matsuda (Tokyo, Japan).
The dominant-negative Ras plasmid was purchased from Upstate Bio-
technology. The fusion trans-activator plasmid (pFA-Elk-1) consisting
of the DNA binding domain of Gal4 (residues 1–147) and the transac-
tivation domain of Elk-1 were purchased from Stratagene (La Jolla,
CA). All plasmids were prepared with the plasmid maxiprep kit from
Qiagen.
Cell Culture and Treatment—NIH-3T3 cells were grown at 37 °C in
5% CO2 in Dulbecco’s modified Eagle’s medium containing 10% heat-
inactivated fetal bovine serum, 100 units/ml penicillin, 100 g/ml strep-
tomycin, and 2 mM L-glutamine. Prior to treatment, cells were deprived
for 20–24 h in medium containing 0.5% fetal bovine serum. Unless
otherwise indicated, the concentration of hGH was 50 nM. This concen-
tration of GH is within the physiological range for circulating rodent
GH (32).
Rap, Ral, and Ras Activation Assays—Serum-deprived cells were
stimulated with hGH as indicated and then lysed on ice for 15 min in
Ral buffer (50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 2.5 mM MgCl2, 10%
glycerol, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM
Na3VO4, and 1 tablet complete protease inhibitor mixture per 50 ml).
After lysis samples were centrifuged at 14,000  g at 4 °C for 10 min,
and the protein concentrations of the lysates were measured. 500 g of
cell lysates were immediately affinity-precipitated at 4 °C for 1 h with
50 g of GST-RalGDS-RBD or 15 g of GST-RalBP1-RBD or GST-Raf1-
RBD fusion proteins that had been freshly precoupled to glutathione-
agarose beads. The precipitates were washed three times with Ral
buffer, and the bound proteins were eluted in 20 l of Laemmli sample
buffer. Samples were separated by 12% polyacrylamide SDS-PAGE and
detected by Western blot analysis.
Immunoprecipitation—After treatment as indicated, cells were lysed
at 4 °C for 20 min in 1% Nonidet P-40 lysis buffer (50 mM Tris-HCl, pH
7.4, 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 1 tablet complete prote-
ase inhibitor mixture per 50 ml). Cell lysates were centrifuged at
14,000 g for 15 min, and the supernatants were precleared by protein
A/G plus agarose chromatography. The agarose beads were removed by
centrifugation, and then the protein concentrations of the resulting
supernatants were determined. For each immunoprecipitation, 500–
1000 g of protein was incubated with 4–8 g of corresponding anti-
body for 4 h or overnight at 4 °C. Immunocomplexes were collected by
incubating with 40 l of protein A/G plus agarose for 1 h or overnight.
Immunoprecipitates were washed three times with IP buffer (10 mM
Tris-HCl, pH 7.4, 1% Triton X-100, 1% Nonidet P-40, 150 mM NaCl, 1
mM EDTA, pH 8.0, 1 mM EGTA, pH 8.0, 1 mM phenylmethylsulfonyl
fluoride, 1 mM Na3VO4, 1 tablet complete protease inhibitor mixture per
50 ml). The bound proteins were eluted in Laemmli sample buffer and
then resolved by 8–10% SDS-PAGE.
Western Blot Analysis—After SDS-PAGE, proteins were transferred
to nitrocellulose membranes. The membranes were blocked with 5%
nonfat dry milk in phosphate-buffered saline with 0.1% Tween-20
(PBST) for 1 h at 22 °C. Blots were then immunolabeled with the
desired antibodies for 1 h at 22 °C. For reblotting, membranes were
stripped at 50 °C for 30 min in the solution containing 62.5 mM Tris-
HCl, pH 6.7, 2% SDS, and 0.7% mercaptoethanol. Blots were then
washed for 30 min with several changes of PBST at 22 °C. Efficacy of
stripping was determined by re-exposure of the membranes to ECL.
Thereafter, membranes were reblocked and immunolabeled as de-
scribed above.
p44/42 MAP Kinase Assay—p44/42 MAPK kinase assays were per-
formed according to the manufacturer’s instructions. Briefly, cells were
lysed at 4 °C in lysis buffer provided, and the cell extract containing 200
g of protein per sample was incubated for 4 h or overnight with 15 l
of immobilized phosphospecific p44/42 MAP kinase (Tyr-202/Tyr-204)
monoclonal antibody. The pellets were washed twice with 500 l of lysis
buffer and twice with 500 l of kinase assay buffer provided. The kinase
reactions were performed in the presence of 2 g of Elk-1 fusion protein
and 200 M ATP at 30 °C for 30 min. Elk-1 phosphorylation was de-
tected by use of a specific phospho-Elk1 (Ser-383) antibody.
SAPK/JNK Assay—SAPK/JNK assays were performed according to
the manufacturer’s instructions. Briefly, cells were lysed at 4 °C in lysis
buffer provided and the cell extract containing 250 g of total protein
per sample was incubated overnight at 4 °C with 20 l of c-Jun fusion
protein beads. The pellets were washed twice with 500 l of lysis buffer
and twice with 500 l of kinase assay buffer provided. The kinase assay
was performed in the presence of 100 M ATP at 30 °C for 30 min. c-Jun
phosphorylation was detected by use of a specific phospho-c-Jun (Ser-
63) antibody.
Elk-1 Reporter Assay—Cells were cultured to 60–80% confluence in
6-well plates and transfected with 0.4 g of the reporter plasmid pFR-
Luc, 8 ng of the fusion trans-activator plasmid pFA-Elk1, and 1 g of
the expression plasmid as indicated or empty vector in each well. 25 l
of Effectene was used for each microgram of DNA according to the
manufacturer’s instructions. DNA-lipid complex was diluted in medium
containing 2% fetal bovine serum for 16–20 h. 50 nM hGH was added for
an additional 24 h. The cells were washed in cold phosphate-buffered
saline twice and then lysed with 150 l of 1 lysis buffer (25 mM
Tris-phosphate, pH 7.8, 2 mM EDTA, 2 mM EDTA, 2 mM dithiothreitol,
10% glycerol, 1% Triton X-100) for 20 min, and supernatant was col-
lected by centrifugation at 14,000 g for 15 min. The luciferase activity
was detected and normalized by protein content.
c-Jun Reporter Assay—Cells were cultured to 60–80% confluence in
6-well plates and transfected with 0.2 g of the reporter plasmid pFR-
Luc, 4 ng of the fusion trans-activator plasmid pFA-cJun, and 1 g of
the expression plasmid as indicated or empty vector in each well. 25 l
of Effectene was used for each microgram of DNA according to the
manufacturer’s instructions. DNA-lipid complex was diluted in medium
containing 5% fetal bovine serum for 12 h. 50 nM hGH was added for an
additional 18 h. The cells were washed in cold phosphate-buffered
saline twice and then lysed with 150 l of 1 lysis buffer (25 mM
Tris-phosphate, pH 7.8, 2 mM EDTA, 2 mM EDTA, 2 mM dithiothreitol,
10% glycerol, 1% Triton X-100) for 20 min, and supernatant was col-
lected by centrifugation at 14,000 g for 15 min. The luciferase activity
was detected and normalized by protein content.
Statistical Analysis and Presentation of Data—All experiments were
performed at least three times. Numerical data were expressed as




GH Stimulation of NIH-3T3 Cells Increases the Level of
GTP-bound Rap1 and Rap2—We utilized the GST fused Ral-
GDS-RBD (33) as a specific probe to determine Rap1 and Rap2
activation in lysates of NIH-3T3 cells stimulated by GH. The
GST-fused Ral-GDS-RBD protein recognizes only the active
GTP-bound form of Rap1 and Rap2 but not the inactive GDP-
bound form of these molecules (33). We observed an increased
level of GTP-bound Rap1 upon cellular stimulation with GH,
first at 2 min after GH addition, sustained to 15 min, and
followed by a decline from 30 to 60 min (Fig. 1A). GH stimula-
tion of NIH-3T3 cells also resulted in the formation of GTP-
bound Rap2 within 2 min. However, GH-stimulated formation
of GTP-bound Rap2 was not sustained, as observed for Rap1,
and the level of GTP-bound Rap2 decreased immediately after
5 min (Fig. 1C). GH stimulation of NIH-3T3 cells did not alter
Rap1 or Rap2 protein levels over the examined time period of
stimulation (Fig. 1, B and D). The GH-stimulated formation of
Rap1-GTP and Rap2-GTP was also dose-dependent with the
enhancement of Rap1-GTP and Rap2-GTP levels first observed
at 0.5 nM GH. The maximal stimulation of Rap1-GTP was from
5 to 50 nM GH (Fig. 1E) while that of Rap2-GTP was at 5 nM GH
(Fig. 1G). Thus Rap1 and Rap2 are two signaling molecules
utilized by GH to exert its effect on cellular function.
GH-stimulated Activation of Rap1 and Rap2 Are Cell Density-
dependent—During the course of experimentation, an effect of
cell density in monolayer culture on the ability of GH to stim-
ulate Rap1 and Rap2 activity was noticed. We therefore com-
pared Rap activity under conditions of increasing cell density
that approximated 40, 70, and 100% cell confluence, respec-
tively. A decrease of both basal and GH-stimulated Rap1 and
Rap2 activity was observed with increasing cell density. Thus,
GH stimulation of NIH-3T3 cells at 100% confluence failed to
stimulate the formation of GTP-bound Rap1 and only minimal
activation of Rap2 by GH under these conditions was observed
(Fig. 2, A and C). This effect of cell density on the ability of GH
to stimulate the formation of Rap1-GTP and Rap2-GTP was not
due to decreased Rap protein as the total cellular level of both
Rap1 and Rap2 was equivalent at different cell densities (Fig.
2, B and D). GH activation of Rap1 and Rap2 was therefore cell
density-dependent.
Full Activation of Rap1 and Rap2 by GH Requires both JAK2
and c-Src—GH activates both JAK2 and c-Src kinases inde-
pendent of the other (29). We have previously demonstrated
that two other small Ras-like GTPases, RalA and RalB, require
the activity of both c-Src and JAK2 to be fully activated by GH
(29). We therefore next examined the requirement of JAK2 and
c-Src for GH-stimulated activation of Rap1 and Rap2. Upon
forced expression of the JAK2 kinase-deficient mutant (K882E)
(34), both the basal and GH-stimulated formation of Rap1-GTP
and Rap2-GTP were diminished, but GH stimulation of cells
still resulted in increased Rap1 and Rap2 activity (Fig. 3, A and
C). We have previously demonstrated the efficacy of forced
expression of JAK2-K882E to prevent GH-stimulated activa-
tion of JAK2- and JAK2-dependent signal transduction (29).
Forced expression of the c-Src kinase inactive mutant (K295R/
Y527F) (35) also abrogated the ability of GH to stimulate the
formation of GTP bound Rap1 and Rap2 (Fig. 3, A and C) to a
greater extent than that observed with JAK2-K882E. Co-trans-
fection of cDNA for both JAK2-K882E and c-Src-K295R/Y527F
completely prevented the ability of GH to stimulate the forma-
FIG. 1. GH stimulates the formation of GTP-bound Rap1 and
Rap2 in NIH-3T3 cells in both a time- and dose-dependent man-
ner. NIH-3T3 cells were stimulated with the indicated doses of GH for
the indicated time periods and the GST-linked probe Ral-GDS-RBD,
which recognizes only the active GTP-bound form of Rap1 and Rap2,
was used to separate Rap-GTP from the inactive Rap-GDP. GTP-bound
Rap1 (A, E) and Rap2 (C, G) were visualized by Western blot analysis.
Total cellular Rap1 (B, F) and Rap2 (D, H) were also determined in total
cell lysate by Western blot analysis as a protein loading control. The
results presented are representative of a minimum of three independ-
ent experiments.
FIG. 2. GH-stimulated activation of Rap1 and Rap2 is regu-
lated by cell density. NIH-3T3 cells were cultured until 40, 70, or
100% confluence before treatment with 50 nM GH for 2 min. The
GST-linked probe Ral-GDS-RBD, which recognizes only the GTP-bound
form of Rap was used to separate Rap-GTP from Rap-GDP. GTP-bound
Rap1 (A) and Rap2 (C) were visualized by Western blot analysis. Total
cellular Rap1 (B) and Rap2 (D) were also determined in total cell lysates
by Western blot analysis as protein loading control. The results pre-
sented are representative of a minimum of three independent
experiments.
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tion of GTP-bound Rap1 and Rap2 (Fig. 3, A and C). Forced
expression of either JAK2-K882E or c-Src-K295R/Y527F or
both did not alter the total cellular level of Rap1 or Rap2 (Fig.
3, B and D). Forced expression of the kinase-deficient JAK2
and c-Src mutants were verified by Western blot analysis (Fig.
3, E and F). Therefore, we conclude that although the combined
activities of both JAK2 and c-Src kinases are required for full
activation of Rap1 and Rap2 by GH, c-Src is predominantly
utilized by GH to activate these molecules.
Overexpression of CrkII and C3G Enhances GH-stimulated
Rap1 and Rap2 Activity—We have previously demonstrated
that GH stimulates the formation of a multiprotein signaling
complex centered around CrkII (21). CrkII and C3G are con-
stitutively associated within this complex although hGH stim-
ulation of cells results in tyrosine phosphorylation of CrkII
(21). CrkII is an adaptor protein and has been reported to
recruit C3G to the vicinity of kinase molecules (17). C3G is a
Rap-specific GEF that accelerates the replacement of GDP by
GTP so as to increase Rap activity (11). We therefore proceeded
to examine the involvement of CrkII and C3G in the GH stim-
ulated formation of GTP-bound Rap1 and Rap2. Forced expres-
sion of CrkII enhanced the ability of GH to activate both Rap1
and Rap2 (Fig. 4, A and C). Forced expression of C3G, or CrkII
together with C3G, resulted in a dramatic enhancement of
GH-stimulated formation of GTP-bound Rap1 and Rap2 (Fig. 4,
A and C). Forced expression of CrkII and C3G was verified by
Western blot analysis (Fig. 4, E and F) and expression of these
proteins did not alter the total cellular level of either Rap1 or
Rap2 (Fig. 4, B and D). Thus, GH activation of Rap1 and Rap2
is CrkII-C3G-dependent.
C3G Tyrosine Phosphorylation Is Required for GH-stimu-
lated Rap1 and Rap2 Activation—Tyrosine phosphorylation of
C3G has been reported to be required for the GEF activity
necessary for Rap1 activation (17). We therefore first examined
whether GH stimulation of NIH-3T3 cells resulted in tyrosine
phosphorylation of C3G. As observed in Fig. 5A, GH indeed
stimulated the tyrosine phosphorylation of C3G. GH-stimu-
lated tyrosine phosphorylation of C3G was first observed at 1
min, persisted to 15 min, and then declined at 30–60 min after
stimulation with GH. Equivalent loading of immunoprecipi-
tated C3G was demonstrated by reprobing of the membrane for
C3G (Fig. 5B).
To determine the kinases responsible for hGH-stimulated
tyrosine phosphorylation of C3G we utilized the kinase-defi-
cient mutants of both JAK2 (JAK2-K882E) and c-Src (c-Src-
K295R/Y527F). Similar to the pattern observed with GH-stim-
ulated formation of GTP-bound Rap1 and Rap2 (above),
removal of the activities of both kinases was required for com-
plete prevention of GH-stimulated C3G tyrosine phosphoryla-
tion (Fig. 5C). Equivalent loading of immunoprecipitated C3G
was demonstrated by reprobing of the membrane for C3G (Fig.
5D). Forced expression of the kinase-deficient mutants of both
JAK2 and c-Src was demonstrated by Western blot analysis
(Fig. 5, E and F). Thus GH-stimulated tyrosine phosphoryla-
tion of C3G required the combined activities of both JAK2 and
c-Src.
We next examined whether tyrosine phosphorylation of C3G
was required for GH stimulated Rap1 and Rap2 activation. It
has been reported that tyrosine 504 of C3G is the critical
tyrosine residue required for guanine nucleotide exchange ac-
FIG. 3. Full activation of Rap1 and Rap2 by GH requires both
JAK2 and c-Src. NIH-3T3 cells were transiently transfected with
empty vector or the expression construct containing either kinase dead
JAK2 (K882E) or kinase dead c-Src (K295R/Y527F) or both and stim-
ulated with 50 nM GH for 2 min. The GST-linked probe Ral-GDS-RBD,
which recognizes only the active GTP-bound form of Rap1 and Rap2
was used to separate Rap-GTP from the inactive Rap-GDP. GTP-bound
Rap1 (A) and Rap2 (C) were visualized by Western blot analysis. Total
cellular Rap1 (B) and Rap2 (D) were also determined in total cell lysates
by Western blot analysis as protein loading control. The forced expres-
sion of JAK2-K882E and c-Src-K295R/Y527F is indicated (E, F). The
results presented are representative of a minimum of three independ-
ent experiments.
FIG. 4. GH-stimulated formation of GTP-bound Rap1 and Rap2
is increased by CrkII and C3G. Wild-type CrkII and C3G cDNAs
were transiently transfected into NIH-3T3 cells before cell stimulation
with 50 nM GH for 2 min. The GST-linked probe Ral-GDS-RBD, which
recognizes only the active GTP-bound form of Rap1 and Rap2 was used
to separate Rap-GTP from the inactive Rap-GDP. GTP-bound Rap1 (A)
and Rap2 (C) were visualized by Western blot analysis. Total cellular
Rap1 (B) and Rap2 (D) were also determined in total cell lysates by
Western blot analysis as protein loading control. The forced expression
of CrkII and C3G is indicated (E, F). The results presented are repre-
sentative of a minimum of three independent experiments.
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tivity for Rap1 (17). To determine if GH-stimulated C3G tyro-
sine phosphorylation was required for activation of Rap1 and
Rap2 we therefore utilized a C3G mutant (C3G-Y504F) in
which tyrosine 504 was substituted by phenylalanine (17). As
above, forced expression of wild-type C3G enhanced the ability
of GH to activate Rap1 and Rap2 whereas forced expression of
C3G-Y504F completely prevented the ability of GH to stimu-
late the formation of GTP-bound Rap1 and Rap2 (Fig. 5, G and
I). Forced expression of either wild-type C3G or C3G-Y504F did
not alter the total cellular Rap1 or Rap2 (Fig. 5, H and J) and
was demonstrated by Western blot analysis (Fig. 5K). GH-
stimulated phosphorylation of C3G tyrosine residue 504 is
therefore required for GH-stimulated formation of GTP-bound
Rap1 and Rap2.
Rap1 Inhibits GH-stimulated p44/42 MAP Kinase Activity
and Elk-1-mediated Transcription—Among the different Rap1
effectors, p44/42 MAP kinase has been extensively studied (1).
Rap1 has been reported to either stimulate or inhibit p44/42
MAP kinase activity depending on the cellular context (1).
p44/42 MAP kinase is also activated by GH (23) to exert pleio-
tropic cellular effects (19) and its mechanism of activation has
been extensively studied (3, 26, 29). We therefore first exam-
ined the effect of forced expression of Rap1 on the ability of GH
to stimulate p44/42 MAP kinase activity. GH stimulation of
vector-transfected NIH-3T3 cells resulted in a rapid and pro-
longed activation of p44/42 MAP kinase activity such that at 60
min after GH stimulation, p44/42 MAP kinase activity was still
higher than in the basal state (Fig. 6A). Forced expression of
Rap1 did not affect the ability of GH to activate p44/42 MAP
kinase but prevented the sustained activation of p44/42 MAP
kinase (Fig. 6A). Thus, p44/42 MAP kinase activity was not
detectable as early as 30 min after stimulation with GH in the
presence of forcibly expressed Rap1. Concordantly, forced ex-
pression of dominant-negative Rap1S17N prolonged GH-stim-
ulated p44/42 MAP kinase activity in comparison to vector-
transfected control (Fig. 6D). Thus, markedly less diminution
of p44/42 MAP kinase activity was observed at both 30 and 60
min after GH stimulation when Rap1 activation by GH was
inhibited.
Activation of p44/42 MAP kinase by GH subsequently results
in Elk-1-mediated transcription (36) and has been suggested to
depend on MAP kinase activity, which is sustained after more
than 30 min of cell stimulation (37). We therefore examined the
effect of forced expression of both wild-type Rap1 and
Rap1S17N on the ability of GH to stimulate Elk-1-mediated
transcription. Forced expression of wild-type Rap1 completely
prevented GH-stimulated Elk-1-mediated transcription that
was observed in the vector-transfected control (Fig. 6G).
Rap1S17N consistently enhanced the ability of GH to stimulate
Elk-1-mediated transcription (Fig. 6G). Rap1 therefore nega-
tively regulates the ability of GH to maintain sustained acti-
vation of p44/42 MAP kinase activity and subsequent Elk-1-
mediated transcription.
Ras and Rap Are Activated by GH Independent of the Other—
We have previously demonstrated that activation of two small
GTPases by GH, RalA and RalB, is partially Ras-dependent
(29). We therefore examined whether the GH-stimulated for-
mation of Rap1 and Rap2 required prior activation of Ras.
stimulated with 50 nM GH for 2 min. The GST-linked probe Ral-GDS-
RBD recognizing only the GTP-bound form of Rap was used to separate
Rap-GTP from Rap-GDP. GTP-bound Rap1 (G) and Rap2 (I) were
visualized by Western blot analysis. Total cellular Rap1 (H) and Rap2
(J) were also determined in total cell lysates by Western blot analysis as
protein loading control. The forced expression level of C3G and C3G-
Y504F is indicated (K). The results presented are representative of a
minimum of three independent experiments.
FIG. 5. JAK2- and c-Src-dependent C3G tyrosine 504 phospho-
rylation is required for GH-stimulated Rap1 and Rap2 activa-
tion. A and B, GH stimulates tyrosine phosphorylation of C3G in a
time-dependent manner. NIH-3T3 cells were treated with 50 nM GH for
the indicated time period. Cell extracts were prepared and processed for
determination of tyrosine phosphorylated C3G (A). Total C3G present
in the C3G immunoprecipitates is indicated (B). The results presented
are representative of a minimum of three independent experiments.
C–F, GH-stimulated C3G tyrosine phosphorylation is both JAK2- and
c-Src-dependent. NIH-3T3 cells were transiently transfected with the
empty vector or the expression construct containing either the kinase
dead JAK2-K882E or kinase dead c-Src-K295R/Y527F or both and then
stimulated with GH. After that, the cell lysates were extracted and the
tyrosine phosphorylation of C3G was determined (C). Total C3G pres-
ent in the C3G immunoprecipitates is indicated (D). The forced expres-
sion of kinase dead JAK2 and c-Src is indicated (E, F). The results
presented are representative of a minimum of three independent ex-
periments. G–K, tyrosine 504 in C3G is required for GH-stimulated
Rap1-GTP and Rap2-GTP formation. NIH-3T3 cells were transiently
transfected with the empty vector or the expression vector containing
either wild-type C3G or tyrosine site mutant C3G-Y504F. Cells were
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However, as shown in Fig. 7, A and C, forced expression of
either wild-type or dominant-negative mutant of Ras did not
alter the ability of GH to stimulate the formation of GTP-bound
Rap1 or Rap2. We next examined whether Rap affected the
ability of GH to activate Ras. Forced expression of wild-type
Rap1 did not alter the ability of GH to stimulate the formation
of GTP-bound Ras (Fig. 7F). Concordantly forced expression of
Rap1S17N was without effect on GH-stimulated Ras activity
(Fig. 7F). Forced expression of Ras and Rap1 proteins was
demonstrated by Western blot analysis (Fig. 7, E and H).
Rap1 Inhibits GH-stimulated Elk-1-mediated Transcription
through Inactivation of RalA—RalGDS, the Rap1 effector, is
also a Ral specific GEF (38, 39) providing a potential mecha-
nism for the regulation of Ral activity by Rap1 (40). We have
previously demonstrated that GH stimulates the formation of
GTP-bound RalA required for full p44/42 MAP kinase activa-
tion by GH and subsequent Elk-1-mediated transcription (29).
We therefore examined whether Rap1 inhibition of GH-stimu-
lated Elk-1-mediated transcription was via modulation of GH-
stimulated RalA activity. GH stimulation of NIH-3T3 cells
resulted in robust formation of GTP-bound RalA as previously
reported by us (29). Forced expression of wild-type Rap1 dra-
matically inhibited the ability of GH to stimulate the activation
of RalA (Fig. 8A). Concordantly forced expression of the domi-
nant-negative Rap1S17N enhanced the ability of GH to stim-
ulate the formation of GTP-bound Rap1 (Fig. 8A). Forced ex-
pression of Rap1 and Rap1S17N was demonstrated by Western
blot analysis (Fig. 8C) and did not affect total cellular levels of
RalA (Fig. 8B). We next examined the interaction between
Rap1 and RalA for the ability of GH to stimulate Elk-1-medi-
ated transcription as an indicator of p44/42 MAP kinase activ-
ity. GH-stimulated Elk-1-mediated transcription was inhibited
by forced expression of Rap1 and dramatically enhanced
by forced expression of RalA (Fig. 8D). Forced expression
of Rap1 concommitant with RalA abrogated the ability of RalA
to enhance GH-stimulated Elk-1-mediated transcription.
Rap1S17N slightly enhanced the fold stimulation by GH of
Elk-1-mediated transcription. Dominant-negative RalA com-
pletely prevented GH-stimulated Elk-1-mediated transcription
in cells transfected either with empty vector or with Rap1S17N
(Fig. 8D). Thus, Rap1 influences the ability of GH to activate
p44/42 MAP kinase activity and subsequent Elk-1-mediated
transcription by modulation of GH-stimulated formation of
GTP-bound RalA.
C3G and Rap1 Are Utilized by CrkII to Enhance GH-stimu-
lated JNK/SAPK Activity and Subsequent c-Jun-mediated
Transcription—We have previously reported that CrkII served
as a molecular switch for the selective activation of JNK/SAPK
by GH and concomitant inactivation of GH-stimulated p44/42
MAP kinase (41). We therefore examined whether C3G and
Rap1 are required for CrkII enhancement of GH-stimulated
JNK/SAPK activity. As demonstrated in Fig. 9A, forced expres-
expression vectors for wild-type Rap1 or Rap1S17N and stimulated
with 50 nM GH for the indicated time periods. p44/42 MAP kinase
activity was determined as described under “Experimental Procedures.”
GH-stimulated p44/42 MAP kinase activity in the presence of tran-
siently transfected wild-type Rap1 or Rap1S17N are presented in A and
D, respectively. The level of the transfected Rap1 and Rap1S17N were
shown as B and E. Densitometric evaluation of the effects of Rap1 and
Rap1S17N on GH-stimulated p44/42 MAP kinase activation are pre-
sented in C and F. G, Rap1 inhibits GH-stimulated Elk-1-mediated
transcription. NIH-3T3 cells were transiently transfected with the ex-
pression vectors for wild-type Rap1 or Rap1S17N together with pFR-
Luc and pFA-Elk-1. The GH-stimulated Elk-1-mediated transcription
was determined by measuring luciferase activity as described under
“Experimental Procedures.” Data presented are mean  S.E. of tripli-
cate determinations. Experiments were repeated three times.
FIG. 6. Rap1 inhibits GH-stimulated p44/42 MAP kinase activ-
ity and Elk-1-mediated transcription. A–F, effect of Rap1 and Rap1
dominant-negative mutant (Rap1S17N) on GH-stimulated p44/42 MAP
kinase activity. NIH-3T3 cells were transiently transfected with the
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sion of either CrkII or C3G enhanced GH-stimulated JNK/
SAPK activity. Forced co-expression of both CrkII and C3G
further enhanced both basal and GH-stimulated JNK/SAPK
activity (Fig. 9A). Expression of the inactive C3G-Y504F mu-
tant did not affect GH-stimulated JNK/SAPK activity in NIH-
3T3 cells. It could, however, prevent the enhanced GH-stimu-
lated JNK/SAPK activity observed upon forced expression of
CrkII (Fig. 9A). Forced expression of CrkII, C3G, and
C3GY504F was demonstrated by Western blot analysis (Fig. 9,
B and C). We next examined the effect of forced expression of
CrkII and C3G on the ability of GH to stimulate c-Jun-medi-
ated transcription. GH stimulation of NIH-3T3 cells resulted in
minimal stimulation of c-Jun-mediated transcription (Fig. 9D).
Forced expression of either CrkII or C3G enhanced the ability
of GH to stimulate c-Jun-mediated transcription (Fig. 9D).
Concordant with JNK/SAPK activity, forced co-expression of
both CrkII and C3G enhanced both basal and GH-stimulated
c-Jun-mediated transcription. Again, similar to the effect ob-
served with JNK/SAPK activity, the C3G-Y504F mutant did
not affect GH-stimulated c-Jun-mediated transcription per se
but did prevent the enhanced GH-stimulated c-Jun-mediated
FIG. 7. Ras and Rap are activated by GH independent of the
other. A–E, NIH-3T3 cells were transiently transfected with the ex-
pression vectors for wild-type Ras or dominant-negative RasS17N and
stimulated with 50 nM GH for 2 min. The GST-linked probe Ral-GDS-
RBD recognizing only the GTP-bound form of Rap was used to separate
Rap-GTP from Rap-GDP. GTP-bound Rap1 (A) and Rap2 (C) were
visualized by Western blot analysis. Total cellular Rap1 (B) and Rap2
(D) were also determined in total cell lysates by Western blot analysis
as protein loading control. The forced expression of Ras is indicated (E).
F–H, NIH-3T3 cells were transiently transfected with the expression
vectors for wild-type Rap1 or dominant-negative Rap1S17N and stim-
ulated with GH. The GST-linked probe Raf1-RBD recognizing only the
GTP-bound form of Ras was used to separate Ras-GTP from Ras-GDP.
GTP-bound Ras (F) was visualized by Western blot analysis. Total
cellular Ras (G) was also determined in total cell lysates by Western
blot analysis as protein loading control. The forced expression of Rap1
is indicated (H). The results presented are representative of a minimum
of three independent experiments.
FIG. 8. The inhibitory effect of Rap1 on GH-stimulated p44/42
MAP kinase is mediated through inhibition of RalA activity.
A–C, NIH-3T3 cells were transiently transfected with the expression
vectors for wild-type Rap1 or dominant-negative Rap1S17N and stim-
ulated with 50 nM GH for 2 min. The GST-linked probe RLIP76-RBD
recognizing only the GTP-bound form of RalA was used to separate
RalA-GTP from RalA-GDP. GTP-bound RalA (A) was visualized by
Western blot analysis. Total cellular RalA (B) was also determined as
protein loading control. The forced expression of Rap1 and Rap1S17N is
indicated (C). The results presented are representative of a minimum of
three independent experiments. D, Rap1 inhibits GH-stimulated Elk-
1-mediated transcription by inhibition of RalA activity. NIH-3T3 cells
were transient transfected with the expression vectors for either Rap1
or a dominant-negative form of Rap1 (Rap1S17N) in the presence or
absence of the expression vectors for RalA or a dominant-negative form
of RalA (RalAS28N) together with pFR-Luc and pFA-Elk-1. GH-stim-
ulated Elk-1-mediated transcription was determined by measuring lu-
ciferase activity as described under “Experimental Procedures.” Data
presented are mean  S.E. of triplicate determinations. Experiments
were repeated three times.
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transcription observed upon forced expression of CrkII (Fig.
9D).
We next examined whether Rap1 is required for CrkII en-
hancement of GH-stimulated JNK/SAPK activity. As demon-
strated in Fig. 9E, forced expression of either CrkII or Rap1
enhanced GH-stimulated JNK/SAPK activity. Forced co-ex-
pression of both CrkII and Rap1 dramatically enhanced both
basal and GH-stimulated JNK/SAPK activity (Fig. 9E). Ex-
pression of the dominant-negative Rap1S17N did not affect
GH-stimulated JNK/SAPK activity per se. It could, however,
largely prevent the enhanced GH-stimulated JNK/SAPK activ-
ity observed upon forced expression of CrkII (Fig. 9E). Forced
expression of CrkII, Rap1, and Rap1S17N was demonstrated
by Western blot analysis (Fig. 9, F and G). We next examined
the effect of forced expression of CrkII and Rap1 on the ability
of GH to stimulate c-Jun-mediated transcription. GH stimula-
tion of NIH-3T3 cells resulted in minimal stimulation of c-Jun-
mediated transcription (Fig. 9H). Forced expression of either
CrkII or Rap1 enhanced the ability of GH to stimulate c-Jun-
mediated transcription. Forced co-expression of both CrkII and
Rap1 resulted in a dramatic enhancement of GH-stimulated
c-Jun-mediated transcription (Fig. 9H). Similar to the effect
observed with JNK/SAPK activity, the dominant-negative
Rap1S17N did not affect GH-stimulated c-Jun-mediated tran-
scription per se but did prevent the enhanced GH-stimulated
c-Jun-mediated transcription observed upon forced expression
of CrkII (Fig. 9H)
DISCUSSION
In the present study we have demonstrated that cellular
stimulation with GH results in a rapid activation of the Ras-
like small GTPases, Rap1 and Rap2. To date, Ras and Ral, the
other two close relatives of Rap, together with Rac have been
reported to participate in GH signal transduction (3, 29, 42),
suggestive of a significant role for small Ras-like GTPases in
the cellular effects of GH. Rap1 has also been demonstrated to
be activated by other members of the cytokine receptor super-
family to which the GH receptor belongs, including EPO and
IL-3 (43).
It is interesting to note that cell density exerted a significant
inhibitory effect on both basal and GH-stimulated Rap activity.
This is consistent with a previous report demonstrating that
basal Rap1 activity is cell density-dependent (44). Rap1 has
also been demonstrated to be activated upon cell adhesion to
ECM and is implicated in integrin-mediated cell adhesion in
various cells in response to diverse extracellular stimuli (1).
Integrins, the transmembrane glycoproteins that usually bind
cells to ECM, may also bind cells to cells in a calcium-depend-
ent manner (45). The involved integrins are heterodimers com-
posed of both the -subunit and the 2 subunit. Although
integrins may participate in intercellular interaction, most cell-
cell adhesions are mediated by cadherin that is linked with the
actin cytoskeleton through -catenin (46). Recently, a novel
-catenin-interacting protein with a putative Rap1GEF activ-
ity has been identified (47), suggesting a role for Rap1 in the
regulation of cell-cell contact. Furthermore, the yeast Rap1
homologue, Bud1, can directly activate Cdc24, an exchange
factor for Cdc42, which is involved in the recruitment of actin
cytoskeleton to the bud site (48). Rap2 has been demonstrated
CrkII or in the presence of the expression vectors for C3G, tyrosine site
mutant C3G-Y504F, Rap1, or dominant-negative form of Rap1
(Rap1S17N) together with pFR-Luc and pFA-c-Jun. GH-stimulated
c-Jun-mediated transcription was determined by measuring luciferase
activity as described under “Experimental Procedures.” Data presented
are mean  S.E. of triplicate determinations. Experiments were re-
peated three times.
FIG. 9. CrkII-dependent hGH-stimulated JNK/SAPK activa-
tion and subsequent c-Jun-mediated transcription is via C3G
and Rap1. A–C and E–G, NIH-3T3 cells were transiently transfected
with the expression vectors for wild-type CrkII in the presence or
absence of wild-type C3G, tyrosine site mutant C3G-Y504F, wild-type
Rap1, or dominant-negative Rap1S17N, and stimulated with 50 nM GH
for the indicated time periods. JNK/SAPK kinase activity was deter-
mined as described under “Experimental Procedures.” The phosphoryl-
ation level of c-Jun fusion protein indicative of JNK/SAPK is shown in
A and E. The level of expressed CrkII, C3G and Rap1 are shown in B,
F, C, and G, respectively. The results presented are the representative
of at least three independent experiments. D and H, C3G and Rap1
mediate CrkII-enhanced GH-stimulated c-Jun-mediated transcription.
NIH-3T3 cells were transient transfected with the expression vector for
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to bind specifically with actin filaments to interact with cy-
toskeletal components (49). We have also observed a GH-de-
pendent association between Rap1 and actin by co-immunopre-
cipitation.2 Proliferation of NIH-3T3 cells is known to be highly
sensitive to contact inhibition (50). In this regard it is interest-
ing that we have observed that autocrine production of GH in
human mammary carcinoma cells results in disassembly of
adherens junctions and loss of intercellular contact.3 How this
phenomenon relates to the inability of GH to activate Rap1 in
confluent cells remains to be determined.
We have demonstrated here that full activation of Rap1 and
Rap2 by GH requires the combined activity of both JAK2 and
c-Src, although c-Src is the predominant kinase utilized by GH
for this purpose. We have therefore described another JAK2-
independent mechanism by which GH affects cellular function.
In addition, our findings have determined that JAK2 and c-Src
activate Rap through tyrosine phosphorylation and activation
of C3G, a Rap-specific GEF. These results are concordant with
our recent observation that GH-stimulated formation of both
GTP-bound RalA and RalB also required both c-Src and JAK2
(29). We have previously demonstrated that GH activates
JAK2 and c-Src independent of, and parallel to, each other (29).
The two kinases obviously converge for joint phosphorylation of
C3G required for Rap activation by GH and the relative con-
tribution of each kinase may simply depend on the relative
expression of JAK2 or c-Src in a particular cell type. Both JAK
and c-Src have previously been demonstrated to be utilized for
activation of Rap1 (51, 52). One example of JAK-dependent
activation of Rap1 is the requirement of JAK1 and Tyk2 for
Rap1 activation in type I IFN signaling (52). Src-dependent
Rap1 activation is essential for integrin-mediated cell adhesion
and formation of focal adhesion structures (53). The adaptor
protein CrkII has been identified to mediate Src-dependent
Rap1 activation (54). We have previously demonstrated that
CrkII is constitutively associated with C3G (21), and GH-stim-
ulated Rap activation is CrkII-C3G-dependent (this study).
CrkII possesses a pivotal role in GH signal transduction (41)
and is central to the formation of a large multiprotein signaling
complex upon GH stimulation of cells (21). Thus, CrkII may
recruit C3G to the vicinity of JAK2 to facilitate C3G tyrosine
phosphorylation by JAK2. FAK may act as a bridge between
CrkII and JAK2 since GH can stimulate the association of FAK
with both JAK2 and CrkII (21, 22). c-Src activated by GH also
forms part of the multi-protein complex centered around CrkII
(21). Interestingly, an increased association stimulated by GH
is also observed between FAK and c-Src (21) and therefore
CrkII may facilitate the formation of this triple kinase complex
together with C3G. In any case, cellular stimulation with GH
results in the tyrosine phosphorylation of C3G. It has been
reported that the phosphorylation of tyrosine residue 504 (Tyr-
504) in C3G is critical for C3G-dependent Rap1 activation,
presumably as phosphorylation of Tyr-504 in C3G represses
the negative regulation of C3G activity by its N-terminal do-
main (17). Consistent with this observation, the C3G-Y504F
mutant, in which Tyr-504 is replaced by the nonphosphorylable
residue phenylalanine, prevented GH-stimulated formation of
GTP-bound Rap. Both JAK2 and c-Src must therefore phospho-
rylate this same residue to achieve activation of Rap1 by GH.
CrkII-C3G-dependent activation of Rap1 therefore constitutes
another JAK2-independent pathway utilized by GH.
We have demonstrated here that the forced expression of
wild-type Rap1 prevented the prolonged activation of p44/42
MAP kinase activity observed after cellular stimulation with
GH. Concordantly, forced expression of the dominant-negative
mutant of Rap1 prolonged the activation of p44/42 MAP kinase
by GH. Several studies have previously demonstrated that
Rap1, or mutants thereof, can inhibit the p44/42 MAP kinase
pathway (1). For example, a constitutively active mutant of
Rap1 was reported to inhibit LPA or EGF induced p44/42 MAP
kinase activity and Ras-p44/42 MAP kinase stimulated IL-2
expression (55–57). IL-1-stimulated activation of Rap1 was also
observed to repress Ras-mediated activation of p44/42 MAP
kinase signaling (43). These observations support a model of
Rap function stating that Rap1 is a functional antagonist of
Ras activity; originating from the demonstration of Rap1 re-
version of the K-ras transformed phenotype in NIH-3T3 cells
(6). There are therefore two possible mechanisms for Rap1 to
inhibit Ras signaling. First, Ras and Rap1 may possess a reg-
ulator and effector relationship in the same pathway. However,
it has been demonstrated that Rap1 is not upstream of Ras
(57), which is also observed in this study and here we report
that GH-stimulated Rap activation is not Ras-dependent.
Therefore, a more plausible mechanism is that Ras and Rap1
are involved in distinct pathways while competing for the same
effector(s). Due to the striking structural similarity in the
effector domain of Rap1 and Ras (58), it has been proposed that
Rap1 interferes with Ras signaling pathway by sequestering
the Ras substrate Raf-1 kinase. However, although Rap1 binds
to Raf-1 in vitro and in vivo (8, 55, 59), there is still no dem-
onstration to date that Rap1 inhibits Raf-1 kinase activity (1).
Furthermore, Raf kinase-independent regulation of p44/42
MAP kinase by Rap1 has been identified recently (44). GH-
stimulated p44/42 MAP kinase activation has been demon-
strated to require both Ras and Raf-1 activity (3). However, we
observed no association between Rap1 and Raf-1 in NIH-3T3
cells either in the quiescent or GH-stimulated state.2 We have,
however, demonstrated here that Rap1 inhibits GH-stimulated
formation of GTP-bound RalA. We have previously reported
that forced expression of RalA prolongs GH-stimulated p44/42
MAP kinase activity (29). The inhibition of the GH-stimulated
formation of GTP-bound RalA by Rap1 is presumably mediated
by RalGDS, a putative effector shared by Ras and Rap1. As a
member of the RalGEF family, RalGDS contains RBDs that
bind to activated Ras or Rap1 in vitro and in vivo (38). Ras-de-
pendent Ral activation has been demonstrated to be inhibited
by Rap1 due to the retention of RalGDS to the compartment
where Rap1 is located, instead of being recruited by Ras to the
site of Ral (40). Subcellular localization of Rap1 is mainly at
cytosol and the perinuclear compartment, different to that of
Ras and Ral localized at the plasma membrane. RalGDS is
found in the cytosol and can be recruited to plasma membrane
by Ras in order to activate Ral (40). It has been reported for
some time that co-localization of Ras and Ral on the plasma
membrane is necessary for Ral activation in COS cells (60).
Furthermore the localization of RalGDS to the plasma mem-
brane is sufficient for Ral activation (40). Both Ras and Rap1
have the binding domain specific for RalGDS, however, Rap1
has higher affinity to RalGDS than Ras and promotes the
translocation of RalGDS to the compartment where Ral is not
found, providing a mechanism that Rap1 sequesters RalGDS to
prevent Ral activation (61).
We have previously reported that GH-stimulated formation
of GTP-bound RalA and RalB occurs in a biphasic manner (29).
It is therefore interesting to note that GH-stimulated activa-
tion of RalA occurs earlier than that of Rap1 and the trough of
GH-stimulated RalA activity is coincident with the sustained
phase of GH-stimulated Rap1 activation. Furthermore, when
GH-stimulated formation of GTP-bound Rap1 decreased at 30
min, GH-stimulated RalA activity peaked simultaneously for
2 L. Ling and P. Lobie, unpublished observations.
3 S. Mukhina, H. Mertani, K. Guo, and P. E. Lobie, manuscript in
preparation.
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the second time. Rap1 is therefore presumably involved in a
cellular mechanism to limit the ability of GH to maintain
elevated p44/42 MAP kinase activity but without interference
in the initial activation of p44/42 MAP kinase by GH. It is also
noteworthy that GH can activate RalA even at a concentration
as low as 0.005 nM whereas full activation of Rap1 by GH is
observed at concentrations of 5–50 nM. Secretion of GH is
sexually dimorphic in most species to date (62) and is respon-
sible for male specific growth patterns. The sexually dimorphic
pattern of secretion is characterized in males by consecutive
peaks and troughs in GH serum concentration (62, 63). In rats,
the peak values of GH can be greater than 200 ng/ml (about 8
nM) and trough values are less than 1 ng/ml (about 0.05 nM)
(63). Our results suggest that Rap1, unlike RalA, would be
activated by GH only when the pulsatile GH secretion reaches
the peak which would subsequently attenuate RalA activity
and subsequent p44/42 MAP kinase activity. How the differen-
tial activation of RalA and Rap1 relates to the sexually dimor-
phic response of mammals to GH needs to be determined.
p44/42 MAP kinase activity is also pertinent to aberrant sig-
naling in human cancer and constitutive activation of this
kinase has been observed in some tumors (64). Attenuation of
GH-stimulated p44/42 MAP kinase activity by Rap1 would
therefore limit the oncogenic potential of GH. The limiting
effect of Rap1 on GH-stimulated p44/42 MAP kinase activity is
consistent with previous reports concerning the ability of Rap1
to reverse oncogenic transformation (6). In agreement with our
findings, other groups have also demonstrated that both LPA
and EGF can induce a substantial Rap1 activation and
Rap1V12 (constitutive Rap1-GTP) attenuates the activation of
p44/42 MAP kinases by those mitogens (44, 57, 65). Further-
more, CrkII, identified in this report as an upstream activator
of Rap1, has also been demonstrated previously to inhibit
p44/42 MAP kinase activation by GH (41). Therefore we have
identified a pathway mediated through CrkII-C3G-Rap1,
which modulates GH-stimulated p44/42 MAP kinase activity
by suppression of RalA. This negative regulatory pathway may
be pivotal to ensure precise regulation of GH-stimulated p44/42
MAP kinase signaling.
We have previously demonstrated that CrkII is utilized by
GH for activation of JNK/SAPK (21). Here we have further
demonstrated that C3G-dependent activation of Rap1 is re-
quired for CrkII enhancement of GH-stimulated JNK/SAPK
activation. C3G has previously been reported to be upstream of
JNK/SAPK and a CrkII-C3G complex is believed to activate
JNK/SAPK through a pathway involving the MLK family pro-
teins (66, 67). However, neither the dominant-negative
Rap1S17N nor functionally deficient C3G-Y504F can prevent
hGH-stimulated JNK/SAPK activation in NIH-3T3 cells sug-
gesting that there must also exist CrkII-C3G-independent
pathways for the activation of JNK/SAPK by GH (see Fig. 10).
One possible molecule is via the adaptor protein Nck, and we
have previously demonstrated that Nck is phosphorylated by
cellular stimulation with GH (21). Nck connects to the JNK/
SAPK pathway by association with SH3 domain-associated
protein serine/threonine kinases such as PAK or NIK (68, 69).
One recent report has also demonstrated that gastrin-stimu-
lated JNK/SAPK activation is Src-dependent but CrkII-inde-
pendent (70). It has been proposed multidomain scaffold pro-
teins, such as JIP, axin, and arrestin regulate JNK activation
in response to different stimuli (70). A SHP-2-dependent JNK/
SAPK activation by insulin has also been identified (71). This
pathway is mediated by H-Ras and not CrkII, because Rac,
known as the major downstream effector for CrkII-dependent
JNK/SAPK activation, is not required for insulin-stimulated
JNK/SAPK activation (71). Thus, GH may utilize the CrkII-
independent pathways described above for the activation of
JNK/SAPK, in addition to CrkII-C3G-Rap1 pathway described
herein, in cells where the endogenous level of CrkII is minimal
such as NIH-3T3 cells utilized for this study. CrkII may also
utilize other effector molecules to activate JNK/SAPK in re-
sponse to GH, such as Rac and R-Ras, which are required for
v-Crk-dependent JNK/SAPK activation (72). However as the
CrkII enhancement of GH-stimulated JNK/SAPK activity is
largely inhibited by C3G-Y504F or Rap1S17N (this study), it is
likely that C3G-Rap1 is the major pathway downstream of
CrkII required for activation of JNK/SAPK by GH. The activa-
tion of JNK/SAPK by GH provides another pathway by which
GH may affect cellular function. JNK/SAPK is involved in
many cellular processes, including transcriptional regulation,
proliferation and apoptosis (73) and it is likely that GH utilizes
JNK/SAPK for some of these purposes. Although there is con-
siderable evidence demonstrating that activation of JNK/SAPK
and c-Jun can trigger apoptosis, reports have also accumulated
that JNK/SAPK signaling to c-Jun can inhibit apoptosis and
promote proliferation dependent on cell type and stimulus (74).
In fibroblasts, the replacement of Ser-63 and Ser-73 of c-Jun by
nonphosphorylable alanines results in defective proliferation
and loss of protection from apoptosis induced by UV irradiation
(75). The phosphorylation of c-Jun on Ser-63 and Ser-73 by
JNK/SAPK increases its transcriptional activity (76, 77). Thus,
GH may utilize JNK/SAPK to execute its documented prolifer-
ative and anti-apoptotic effects (19) in a CrkII-dependent or
-independent manner, determined by the expression level of
CrkII in a specific cell line.
FIG. 10. Schematic diagram of GH-stimulated pathways lead-
ing to either Elk-1 or c-Jun-mediated transcription. The demon-
strated pathways are indicated by solid lines and the potential path-
ways by dotted lines.
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In summary, we have demonstrated here that GH stimulates
the formation of GTP-bound Rap1 and Rap2 in NIH-3T3 cells.
GH-stimulated activation of Rap is predominantly mediated by
c-Src-dependent tyrosine phosphorylation of C3G. GH utilizes
the inhibitory effect of Rap1 to limit activation of p44/42 MAP
kinase pathway via inhibition of RalA. In addition, we have
demonstrated that the CrkII-C3G-Rap1 pathway is utilized by
GH as a molecular switch from p44/42 MAP kinase signaling to
JNK/SAPK signaling. A diagram summarizing GH utilization
of the Ras-like small GTPases to regulate MAP kinase path-
ways is provided in Fig. 10. The identification of another JAK2-
independent signaling pathway by GH will dramatically in-
crease our understanding of the mechanisms utilized by GH to
achieve its pleiotropic cellular effects.
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Identification of a JAK2-independent Pathway Regulating
Growth Hormone (GH)-stimulated p44/42 Mitogen-activated
Protein Kinase Activity
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We have demonstrated here that growth hormone
(GH) stimulates the formation of the active GTP-bound
form of both RalA and RalB in NIH-3T3 cells. Full acti-
vation of RalA and RalB by GH required the combined
activity of c-Src and JAK2, both kinases activated by GH
independent of the other. Activation of RalA and RalB
by growth hormone did not require the activity of JAK2
per se. Ras was also activated by GH and was required
for the GH-stimulated formation of GTP-bound RalA
and RalB. Activation of RalA by GH subsequently re-
sulted in increased phospholipase D activity and the
formation of its metabolite, phosphatidic acid. GH-stim-
ulated RalA-phospholipase D-dependent formation of
phosphatidic acid was required for activation of p44/42
MAPK and subsequent Elk-1-mediated transcription
stimulated by GH. Thus we report the identification of a
JAK2-independent pathway regulating GH-stimulated
p44/42 MAPK activity.
Due to lack of intrinsic kinase activity, members of the
cytokine receptor superfamily, including the growth hormone
(GH)1 receptor, recruit and activate non-receptor tyrosine ki-
nases of the JAK family to relay their cellular signals (1). JAK2
has been reported to be the predominant JAK required for the
initiation of GH signal transduction upon ligand binding to the
GH receptor (2–4). To date, all identified downstream signaling
pathways utilized by GH apparently require JAK2 activity
(2–4). The only reported JAK2-independent effect of GH is
Ca2 entry via L-type calcium channels (5), although this has
been disputed (6, 7). However, it is likely that other, as yet
uncharacterized, signal transduction pathways stimulated by
GH are activated independent of JAK2 activity.
The major groups of signaling molecules thus far identified
to be activated by GH include the following: 1) other receptor
(EGF receptor) (8) and non-receptor (c-Src, c-Fyn (9), and FAK
(10)) kinases, although as in the case of the EGF receptor it
may be used simply as an adapter protein; 2) members of the
MAP kinase family including p44/42 MAP kinase (11, 12), p38
MAP kinase (13), and c-Jun N-terminal kinase/stress-activated
protein kinase (9) and the respective downstream pathways; 3)
members of the insulin receptor substrate (IRS) group includ-
ing IRS-1, -2, and -3 which may act as docking proteins for
further activation of signaling molecules including phosphati-
dylinositol 3-kinase (14); 4) small Ras-like GTPases (15); and 5)
STAT family members including STATs 1, 3, 5a, and 5b (16,
17), which constitute one major mechanism for transcriptional
regulation by GH.
Ras is a member of the Ras-like GTPase family (18, 19). This
family is characterized by similarities in the effector domain
which Ras utilizes to interact with downstream target mole-
cules. The Ras-like GTPases play a critical role in multiple
signaling pathways leading from various cell-surface receptors.
The activation and inactivation of the Ras-like GTPases are
controlled by conformational change because of a GTP-GDP
binding cycle that is controlled by the following three different
regulatory proteins: guanine nucleotide exchange factors
(GEFs), GTPase-activating proteins, and guanine nucleotide
dissociation inhibitors. In its GTP-bound state, Ras in turn
interacts with distinct downstream effectors and initiates mul-
tiple signaling pathways, which include at least three down-
stream signaling cascades mediated by the Raf protein kinase
(i.e. A-Raf, B-Raf, and Raf-1), RalGEF (i.e. RalGDS, Rlf, and
Rgl), and phosphatidylinositol (PI) 3-kinases (18–20).
Recent reports (20, 21) suggest that two other members of
the Ras-like small GTPase family, namely RalA and RalB,
possess pivotal roles in the control of cell proliferation, migra-
tion, differentiation, cytoskeletal organization, vesicular trans-
port, and receptor endocytosis. Ral is also the member of the
Ras-like GTPases family, and its activity is regulated by cy-
cling between active GTP-bound and inactive GDP-bound
states controlled through the direct binding of active Ras to
Ral-specific GEFs. However, additional Ras-independent
mechanisms also exist to stimulate the formation of GTP-
bound Ral. For example (22, 23), RalA can be activated inde-
pendently of Ras activation via its direct binding to Ca2 alone
(24) or to Ca2-bound calmodulin in response to the elevated
level of intracellular calcium (23). Moreover, PI 3-kinase (25)
and Src-like kinases (25, 26) have also been implicated in Ral
activation. Once activated, Ral further interacts with several
other proteins that may function as its downstream effectors.
RalA has been demonstrated to associate directly with phos-
pholipase D1 (PLD1) via its N-terminal sequence and operates
synergistically with another PLD1-interacting small GTPase,
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Arf, to activate PLD1 activity (27). Phospholipase D (PLD,
including PLD1 and PLD2) is a widely expressed phospholipid-
specific phosphodiesterase that hydrolyzes phosphatidylcho-
line, a major phospholipid in the cell membrane, to form phos-
phatidic acid (PA) and choline. PA can be further converted to
diacylglycerol (DAG) and lyso-PA, both of which are the well
known intracellular mediators and extracellular messengers of
multiple biological activities (28, 29). Two other proteins have
also been reported that are to known to interact with the
GTP-bound form of RalA, leading to RalA-dependent cellular
effects. The first is Ral-binding protein 1 or RalBP1 (also called
RLIP76) (30), which is involved in receptor-mediated endocy-
tosis (30, 31). RalBP1 is also a GTPase-activating protein for
Cdc42, a Rho family member involved in actin cytoskeleton
organization and filopodia formation in fibroblasts (30). The
second is filamin, which serves as a downstream intermediate
in Cdc42-mediated filopod production by its association with
RalA (32).
We have demonstrated here that GH stimulates the forma-
tion of the active GTP-bound form of both RalA and RalB in
NIH-3T3 cells. Activation of RalA and RalB by growth hormone
did not require the activity of JAK2 per se. However, full
activation of RalA and RalB by GH required the combined
activity of both c-Src and JAK2, both kinases activated by GH
independent of the other. Activation of RalA by GH subse-
quently resulted in the activation of PLD and the formation of
phosphatidic acid that was required for activation of p44/42
MAP kinase by GH. Thus we report the identification of a
JAK2-independent pathway regulating GH-stimulated p44/42
MAP kinase activity.
EXPERIMENTAL PROCEDURES
Materials—Recombinant human growth hormone (hGH) was a gen-
erous gift of Novo Nordisk (Singapore). Src kinase inhibitors PP1 and
PP2 and phosphatidic acid were obtained from Biomol Research Labo-
ratories (Plymouth Meeting, PA). The JAK2 inhibitor tyrphostin
AG490, negative control of Src kinase inhibitor PP3, and brefeldin A
(BFA) were purchased from Calbiochem. RalA monoclonal antibody and
RalB polyclonal antiserum were purchased from Transduction Labora-
tories (Lexington, KY). c-Src polyclonal antiserum, HA monoclonal an-
tibody, and protein A/G plus-agarose were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). JAK2 polyclonal antiserum, anti-
JAK2 IgG covalently coupled to protein A-agarose, Ras monoclonal
antibody, and the Src kinase assay kit were purchased from Upstate
Biotechnology, Inc. (Lake Placid, NY). Secondary anti-IgG antibodies,
the ECL kit, [-32P]ATP, and [3H]palmitic acid were purchased from
Amersham Biosciences. The PLD assay kit was obtained from Molecu-
lar Probes (Eugene, OR). The p44/42 MAP kinase assay kit was pur-
chased from New England Biolabs (Beverly, MA). The transfection
reagent Effectene was purchased from Qiagen (Hilden, Germany). All
other reagents were purchased from Sigma.
pGEX4T3-GST-RalBD construct for GST-RLIP-RBD (33) containing
amino acids 397–518 of human RLIP76 and pGEX 2T  RBD construct
for GST-Raf1-RBD (34) containing amino acids 51–131 of Raf1 were the
generous gifts of Dr. Johannes L. Bos (Utrecht, Netherlands). The wild
type and dominant negative RalA plasmids were kindly provided by Dr.
Yasutaka Ohta (Boston, MA). The wild type and dominant negative
c-Src expression plasmids were obtained from Dr. Joan S. Brugge
(Boston, MA). The dominant negative JAK2 expression plasmid was a
kind gift of Dr. Olli Silvennoinen (Tampere, Finland). The wild type and
dominant negative PLD1 and PLD2 plasmids were generously provided
by Dr. Michael Frohman (Stony Brook, NY). The fusion trans-activator
plasmid (pFA2-Elk-1) consisting of the DNA binding domain of Gal4
(residues 1–147) and the trans-activation domain of Elk-1 were pur-
chased from Stratagene (La Jolla, CA). pFC2-dbd plasmid is the nega-
tive control for the pFA plasmid to ensure the observed effects are not
due to the Gal4 DNA binding domain and was also obtained from
Stratagene (La Jolla, CA). The dominant negative Ras plasmid was
purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). All
plasmids were prepared with the plasmid megaprep kit from Qiagen
(Hilden, Germany).
Cell Culture and Treatment—NIH-3T3 cells were cultured at 37 °C
in 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with
10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100
g/ml streptomycin, and 2 mM L-glutamine. Prior to treatment, cells
were deprived of serum for 12–16 h in serum-free medium. Unless
otherwise indicated, the final concentration of the PP1 was 50 M; PP2
was 20 M; PP3 was 50 M; AG490 was 100 M; and hGH was 50 nM.
This concentration of GH is within the physiological range for circulat-
ing rodent GH.
Ral and Ras Activation Assay—NIH-3T3 cells were grown to sub-
confluence, incubated for 16 h in serum-free medium, washed once in
serum-free medium, and incubated with 50 nM hGH for the indicated
times. After stimulation with hGH and lysis with 1 Ral buffer (10%
glycerol, 1% Nonidet P-40, 50 mM Tris-HCl, pH 7.4, 200 mM NaCl, 2.5
mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1 M leupeptin, 10 g
of soybean trypsin inhibitor per ml, and 0.1 M aprotinin), samples were
put on ice for 10 min and centrifuged at 14,000 rpm at 4 °C for 10 min.
Glutathione-Sepharose beads that had been precoupled to recombinant
glutathione S-transferase (GST)-RalBP1-RBD or GST-Raf1-RBD were
prepared as described (33, 34). After preclearance of the lysates with
glutathione-agarose, 15 g of GST-RalBP1-RBD or GST-Raf-1-RBD-
agarose precoupled to glutathione beads was added to 500 g of cell
lysate per assay with gentle rocking at 4 °C for 45 min. Samples were
washed 3 times in lysis buffer, and bound proteins were eluted in 20 l
of Laemmli sample buffer. Samples were separated by SDS-PAGE
(12.5% polyacrylamide), immunoblotted, and probed with the respective
antibodies.
JAK2 Immunoprecipitation—Cells were lysed at 4 °C in 1 ml of lysis
buffer (50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 0.5% Nonidet P-40,
0.1% phenylmethylsulfonyl fluoride) for 30 min with regular vortices.
Cell lysates were centrifuged at 14,000 g for 15 min, and the resulting
supernatants were collected, and protein concentration was deter-
mined. 800 g of protein was used for each immunoprecipitation. Im-
munoprecipitations were performed by incubating lysates with 20 l of
gel slurry of anti-JAK2/protein A-agarose. The reaction mixture was
gently rocked at 4 °C for 1 h. Immunoprecipitations were washed 3
times with ice-cold lysis buffer. The pellet was resuspended in 1 SDS
sample buffer containing 50 mM Tris, pH 6.8, 2% SDS, 2% -mercapto-
ethanol, and bromphenol blue, boiled for 10 min, and centrifuged at
14,000  g for 5 min. The supernatant was collected and subjected to
8% SDS-PAGE. Proteins were transferred to nitrocellulose membranes
using standard electroblotting procedures.
Immunoblotting—After preincubation with inhibitors for the indi-
cated times and/or incubation with the indicated concentration of hGH
for the appropriate duration, the cells were washed once with ice-cold
PBS and lysed at 4 °C in an appropriate amount of lysis buffer. Cell
lysates were dissolved and denatured in 1 SDS-PAGE sample buffer,
and separation was achieved on 8–12% SDS-polyacrylamide gels and
transferred to nitrocellulose membranes. The membranes were blocked
with 5% non-fat dry milk in phosphate-buffered saline with 0.1% Tween
20 (PBST) for 1 h at 22 °C. The blots were then treated with the primary
antibody in PBST containing 1% non-fat dry milk at 4 °C overnight.
After three washes with PBST, immunolabeling was detected by ECL
according to the manufacturer’s instructions. For reblotting, mem-
branes were stripped by incubation for 30 min at 50 °C in a solution
containing 62.5 mM Tris-HCl, pH 6.7, 2% SDS, and 0.7% mercaptoeth-
anol. Blots were then washed for 30 min with several changes of PBST
at room temperature. Efficacy of stripping was determined by re-expo-
sure of the membranes to ECL. Thereafter, blots were reblocked and
immunolabeled as described above.
Src Kinase Assay—Src kinase assays were performed as described
according to the manufacturer’s instructions (Upstate Biotechnology,
Inc.). In brief, supernatant containing 150 g of protein per sample
derived from cells stimulated with hGH was incubated with 1 g of Src
polyclonal antibody at 4 °C for 2–4 h in a final volume of 500 l.
Immunocomplexes were collected by incubation with 20 l of protein
A/G plus-agarose for 1 h. Immunoprecipitates were washed 3 times
with ice-cold lysis buffer. 10 l (150 M final concentration) of the
substrate peptide, 10 l of Src reaction buffer, and 10 l of [-32P]ATP
stock were added to a microcentrifuge tube and incubated for 10 min at
30 °C with agitation. 20 l of 40% trichloroacetic acid was then added to
precipitate peptides, and a 25-l aliquot was transferred onto the center
of a numbered P81 paper square. The assay squares were washed 5
times for 5 min each with 0.75% phosphoric acid and once with acetone.
The assay squares were transferred to a scintillation vial, and 5 ml of
scintillation mixture was added, and the level of radioactivity was
determined in a scintillation counter. The sample that contains no
enzyme serves as the background control.
p44/42 MAP Kinase Assay—p44/42 MAP kinase assays were per-
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formed according to the manufacturer’s instructions. In brief, cells were
lysed at 4 °C in lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1
mM glycerol phosphate, 1 mM Na3VO4, 0.1% phenylmethylsulfonyl flu-
oride, 1 g/ml leupeptin). The lysates were centrifuged at 15,000 g for
15 min at 4 °C. The supernatant containing 200 g of protein per
sample was incubated overnight at least 4 h with an immobilized
phospho-specific p44/42 MAP kinase (Thr202/Tyr204) monoclonal anti-
body (1:300 dilution) in a final volume of 500 l in 1 lysis buffer. The
pellets were washed twice with 500 l of lysis buffer containing 1 mM
phenylmethylsulfonyl fluoride and twice with 500 l of kinase buffer
(25 mM Tris, pH 7.5, 5 mM glycerol phosphate, 2 mM dithiothreitol, 0.1
mM Na3VO4, 10 mM MgCl2). The kinase reactions were performed in the
presence of 2 g of Elk-1 fusion protein and 200 M ATP at 30 °C for 30
min. Elk-1 phosphorylation was selectively detected by Western immu-
noblotting using a chemiluminescence detection system and a specific
phospho-Elk-1 (Ser383) antibody (1:1000 dilution).
Measurement of Phosphatidic Acid and PLD Activity—Subconfluent
cells were serum-starved and labeled overnight with [3H]palmitic acid
(5 Ci/ml) in Dulbecco’s modified Eagle’s medium. After cells were
stimulated with 50 nM hGH for the indicated time, the samples were
placed on ice, rinsed with cold PBS, and the lipids extracted by the
method of Bligh and Dyer (35). The dried samples were resuspended in
chloroform/methanol (2:1) and developed by TLC on Silica Gel 60 plates
(Merck) using chloroform/methanol/acetic acid (90:10:10, v/v/v) as the
solvent with the unlabeled PA and phosphatidylethanol as lipid stand-
ards (Avanti Polar Lipids). For PLD activity assays, cells were stimu-
lated with hGH in the presence of 1% ethanol to determine the total
activity of PLD by the standard transphosphatidylation assay. The
plates were air-dried, treated with EN3HANCE (PerkinElmer Life Sci-
ences), and exposed to a Kodak X-Omat AR film. The appropriate lipid
spots were marked and scraped from the TLC plates and counted via
liquid scintillation. Levels of PA or phosphatidylbutanol were normal-
ized to total fatty acid label incorporated into lipid. PLD activity assays
were also performed by use of the amplex red phospholipase kit from
Molecular Probes (Eugene, OR). In brief, cells were lysed in the 1
reaction buffer with 1% Triton X-100 by several quick freeze-thaw
cycles at80 °C (10–15 min each). 100 l of diluted samples containing
20 g of total whole lysate was used to perform the assay. The fluores-
cence in a fluorescent microplate reader was measured using excitation
detection at 540 nm and emission detection at 595 nm. Each point was
triplicated, and the reading was corrected by subtracting the values
derived from the non-PLD controls.
Transient Transfection and Elk-1 Reporter Assay—NIH-3T3 cells
were cultured to 60–80% confluence for transfection experiments in
6-well plates (16). 0.2 g of pCMV and 0.2 g of reporter plasmid
pFR-Luc were transfected together with 4 ng of the respective fusion
trans-activator plasmid (pFA-Elk-1 or pFC2-dbd). For each well, 10–20
l of Effectene for each g of DNA was used as per the manufacturer’s
instructions. DNA-lipid complex was diluted to a final volume of 2 ml
(for triplicate samples) with 2% fetal bovine serum medium and cells
allowed to grow for 12–16 h. 50 nM hGH was added for an additional
24 h. The cells were washed in PBS and lysed with 200 l of 1 lysis
buffer (25 mM Tris-phosphate, pH 7.8, 2 mM EDTA, 2 mM dithiothreitol,
10% glycerol, 1% Triton X-100) by a freeze-thaw cycle, and lysate was
collected by centrifugation at 14,000 rpm for 15 min. The supernatant
was used for the assay of luciferase and -galactosidase activity. The
luciferase activities were normalized on the basis of protein content as
well as on the -galactosidase activity of pCMV vector. The -galac-
tosidase assay was performed with 20 l of precleared cell lysate ac-
cording to a standard protocol (13).
Statistical Analysis and Presentation of Data—All experiments were
performed at least 3 times. Numerical data are expressed as mean 
S.D. Data were analyzed using the two-tailed t test or analysis of
variance.
RESULTS
hGH Stimulation of NIH-3T3 Cells Increases the Level of
GTP-bound RalA and RalB—We employed the GST-linked
probe RLIP76-RBD (33), which recognizes only the active GTP-
bound form of RalA and RalB and not the inactive GDP-bound
form of these molecules, to determine the level of RalA-GTP
and RalB-GTP in lysates of NIH-3T3 cells stimulated by GH.
hGH stimulation of NIH-3T3 cells resulted in the rapid forma-
tion of GTP-bound RalA and RalB which could be observed
within 30 s of cellular stimulation with hGH (Fig. 1, A and C).
The hGH-stimulated formation of both RalA-GTP and RalB-
GTP was biphasic, with the first peak of activity observed at
1–2 min after stimulation with hGH, followed by a decline to 15
min, and a second peak of GTP-bound RalA and RalB observed
at 30 min, again followed by a decline to 60 min. hGH stimu-
lation of NIH-3T3 cells did not alter RalA or RalB protein levels
over the examined period of stimulation (Fig. 1, B and D). The
hGH-stimulated formation of both RalA-GTP and RalB-GTP
was also dose-dependent with stimulation of the GTP-bound
forms of RalA and RalB first observed at 0.005 nM hGH and
maximal stimulation from 5 to 50 nM hGH (Fig. 1, E and G).
Thus RalA and RalB are two signaling molecules utilized by
hGH to exert its effect on cellular function.
hGH-stimulated Activations of JAK2 and c-Src Are Inde-
pendent—We next wished to determine the upstream kinases
responsible for the hGH-stimulated conversion of RalA and
RalB to the GTP-bound form. It was necessary, however, to
first examine the potential interdependence between two GH
activated kinases, namely JAK2 and c-Src (9, 36), after cellular
stimulation with hGH. Neither the generic Src family kinase
inhibitor PP1, nor the more specific Src kinase inhibitor PP2,
nor the structurally related non-inhibitory PP3 affected JAK2
tyrosine phosphorylation stimulated by hGH (Fig. 2A). Simi-
FIG. 1. hGH stimulates the formation of GTP-bound RalA and
RalB in NIH-3T3 cells in both a time- and dose-dependent man-
ner. NIH-3T3 cells were stimulated with the indicated doses of hGH for
the indicated time periods, and the GST-linked probe RLIP76-RBD,
which recognizes only the active GTP-bound form of RalA and RalB,
was used to separate RalA-GTP and RalB-GTP from the inactive GDP-
bound form of these molecules. GTP-bound RalA (A and E) and RalB (C
and G) were visualized by Western blot analysis. Total cellular RalA (B
and F) and RalB (D and H) were also determined in total cell lysate by
Western blot analysis as protein loading control. The results presented
are representative of a minimum of three (usually five) independent
experiments.
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larly, forced expression of either wild type c-Src or a kinase-
deficient c-Src by transient transfection of the respective
cDNAs into NIH-3T3 cells did not alter the level of hGH-
stimulated JAK2 tyrosine phosphorylation (Fig. 2C). Such a
result was obtained despite marked overexpression of the re-
spective c-Src molecules (Fig. 2E). Both PP1 and PP2 inhibited
hGH-stimulated c-Src kinase activity (Fig. 2F) under the con-
ditions in which it failed to affect tyrosine phosphorylation of
JAK2. As expected, PP3 did not affect c-Src kinase activity.
Forced expression of the kinase-deficient c-Src in NIH-3T3 cells
also inhibited c-Src kinase activity (Fig. 2G). Therefore, hGH-
stimulated tyrosine phosphorylation of JAK2 in NIH-3T3 cells
is independent of the activity of c-Src.
We next examined whether the activity of JAK2 was re-
quired for hGH-stimulated activation of c-Src. We therefore
first utilized the JAK2-specific inhibitor AG490. AG490, even
when utilized at a high concentration more than sufficient to
that reported to inhibit JAK2 activity (100 M was utilized even
though 20 M is sufficient to inhibit hGH-stimulated activation
of JAK2), failed to inhibit hGH-stimulated c-Src kinase activ-
ity. To demonstrate the efficacy of AG490, we also examined
the effect of the same concentration of AG490 on the ability of
hGH to stimulate tyrosine phosphorylation of JAK2. Pretreat-
ment of NIH-3T3 cells with AG490 before hGH stimulation
completely prevented hGH-stimulated tyrosine phosphoryla-
tion of JAK2 (Fig. 2H). Similarly, forced expression of a kinase-
deficient JAK2 (K882E) (37) also failed to inhibit c-Src kinase
activity (Fig. 2F), despite the ability of this kinase-deficient
JAK2 to abrogate hGH-stimulated JAK2 tyrosine phosphoryl-
ation under the same conditions. Thus, hGH-stimulated acti-
vations of JAK2 and c-Src kinases are two independent and
parallel events.
Full Activation of RalA and RalB by hGH Requires Both
JAK2 and c-Src—We proceeded to determine which of the two
independently activated kinases described above were respon-
sible for hGH-stimulated conversion of RalA and RalB to the
GTP-bound form. We therefore first examined the effect of the
JAK2 kinase inhibitor AG490 on hGH-stimulated conversion of
RalA and RalB to the GTP-bound form. AG490 treatment of
NIH-3T3 cells decreased the basal level of both RalA-GTP and
RalB-GTP without alteration in the total cellular level of either
RalA or RalB (Fig. 3, A–D). Treatment of NIH-3T3 cells with
AG490 slightly diminished, but did not prevent, RalA-GTP and
RalB-GTP formation stimulated by hGH. In contrast, AG490
FIG. 2. HGH-stimulated activation of JAK2 and c-Src are independent and parallel. A–E, hGH-stimulated activation of JAK2 is
independent of c-Src activity. NIH-3T3 cells were stimulated with hGH after pretreatment and in the continued presence of vehicle, PP1, PP2, or
PP3 as indicated, and cell extracts were prepared and processed for determination of tyrosine-phosphorylated JAK2 (A). Total JAK2 present in the
JAK2 immunoprecipitates is indicated (B). NIH-3T3 cells were transiently transfected with the empty vector or an expression vector containing
either wild type c-Src or kinase-dead c-Src (c-Src-KD) and stimulated with hGH, and cell extracts were prepared and processed for determination
of tyrosine-phosphorylated JAK2 (C). Total JAK2 present in the JAK2 immunoprecipitates is indicated (D). The efficacy of wild type c-Src and
kinase-dead c-Src overexpression is indicated by Western blot (E). F and G, hGH-stimulated activation of c-Src is independent of JAK2 activity.
NIH-3T3 cells were stimulated with hGH after pretreatment and in the continued presence of vehicle, PP1, PP2, PP3, or AG490 as indicated, and
cell extracts were prepared and processed for determination of Src kinase activity (F). NIH-3T3 cells were transiently transfected with the empty
vector or an expression vector containing either kinase dead c-Src (c-Src-KD) or kinase-dead JAK2 (K882E) and stimulated with hGH, and cell
extracts were prepared and processed for determination of Src kinase activity (G). H–K, AG490 and dominant negative JAK2 inhibit hGH-
stimulated JAK2 tyrosine phosphorylation. NIH-3T3 cells were stimulated with hGH after pretreatment and in the continued presence of vehicle
or AG490 as indicated, and cell extracts were prepared and processed for determination of tyrosine-phosphorylated JAK2 (H). Total JAK2 present
in the JAK2 immunoprecipitates is indicated (I). NIH-3T3 cells were transiently transfected with the empty vector or an expression vector for
dominant negative JAK2 (K882E) and stimulated with hGH, and cell extracts were prepared and processed for determination of tyrosine-
phosphorylated JAK2 (J). Total JAK2 present in the JAK2 immunoprecipitates is indicated (K). The results presented are representative of a
minimum of three (usually five) independent experiments.
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completely prevented hGH-stimulated tyrosine phosphoryla-
tion of the JAK2 substrate STAT5 (data not shown). Similarly
forced expression of a kinase-deficient JAK2 slightly dimin-
ished, but did not prevent, RalA-GTP and RalB-GTP formation
stimulated by hGH. Thus JAK2 is not required for hGH-stim-
ulated conversion of RalA and RalB to the GTP-bound form. We
next examined the effect of the generic Src family kinase in-
hibitor PP1, the more specific Src kinase inhibitor PP2, and the
structurally related non-inhibitory PP3 on RalA-GTP and
RalB-GTP formation stimulated by hGH. Both PP1 and PP2
abrogated, but did not completely prevent, RalA-GTP and
RalB-GTP formation stimulated by hGH (Fig. 3E). PP3 did not
affect hGH-stimulated RalA-GTP and RalB-GTP formation.
The effect of PP1 and PP2 on inhibition of RalA-GTP and
RalB-GTP formation stimulated by hGH was more potent com-
pared with the effect of AG490 on hGH-stimulated GTP-bound
RalA and RalB (compare Fig. 3, E and G to A and C). Forced
expression of kinase-inactive c-Src also diminished, and to a
greater extent than kinase-inactive JAK2, RalA-GTP, and
RalB-GTP formation stimulated by hGH (Fig. 3, I and K).
Because removal of the kinase activities of either JAK2 or c-Src
only partially inhibited the formation of GTP-bound RalA and
RalB stimulated by hGH, we therefore examined whether com-
bined inhibition of JAK2 and c-Src would completely prevent
RalA-GTP and RalB-GTP formation stimulated by hGH. Tran-
sient transfection of both kinase-inactive JAK2 and kinase-
inactive c-Src cDNAs completely prevented hGH-stimulated
RalA-GTP and RalB-GTP formation (Fig. 3, I and K). Thus, full
activation of RalA and RalB by hGH required the combined
activities of JAK2 and c-Src kinases.
Ras Activity Is Required for hGH-stimulated RalA-GTP and
RalB-GTP Formation—Activation of RalA and RalB has been
demonstrated previously (23, 38) to require Ras-dependent ac-
tivation of RalGEFs thereby defining Ral as a Ras effector
FIG. 3. Full activation of RalA and RalB by hGH requires both JAK2 and c-Src. A–D, AG490 partially inhibits hGH-stimulated formation
of GTP-bound RalA and RalB. NIH-3T3 cells were stimulated with hGH after pretreatment and in the continued presence of vehicle or AG490 as
indicated. The GST-linked probe RLIP76-RBD, which recognizes only the active GTP-bound form of RalA and RalB, was used to separate
RalA-GTP and RalB-GTP from the inactive GDP-bound form of these molecules. GTP-bound RalA (A) and RalB (C) were visualized by Western
blot analysis as indicated. Total cellular RalA (B) and RalB (D) was also determined in total cell lysate by Western blot analysis as protein loading
control. E–H, PP1 and PP2 partially inhibit hGH-stimulated formation of GTP-bound RalA and RalB. NIH-3T3 cells were stimulated with hGH
after pretreatment and in the continued presence of vehicle, PP1, PP2, or PP3 as indicated. The GST-linked probe RLIP76-RBD, which recognizes
only the active GTP-bound form of RalA and RalB, was used to separate RalA-GTP and RalB-GTP from the inactive GDP-bound form of these
molecules. GTP-bound RalA (E) and RalB (G) were visualized by Western blot analysis as indicated. Total cellular RalA (F) and RalB (H) was also
determined in total cell lysate by Western blot analysis as protein loading control. I–M, kinase-dead JAK2 and kinase-dead c-Src partially inhibit
hGH-stimulated formation of GTP-bound RalA and RalB. NIH-3T3 cells were transiently transfected with the empty vector or an expression vector
containing either kinase dead c-Src (c-Src-KD) or kinase-dead JAK2 (K882E) or both and stimulated with hGH. The GST-linked probe RLIP76-
RBD, which recognizes only the active GTP-bound form of RalA and RalB, was used to separate RalA-GTP and RalB-GTP from the inactive
GDP-bound form of these molecules. GTP-bound RalA (I) and RalB (K) were visualized by Western blot analysis as indicated. Total cellular RalA
(J) and RalB (L) was also determined in total cell lysate by Western blot analysis as protein loading control. Densitometric evaluation of
hGH-stimulated activation of RalA and RalB are presented (M). The results presented are representative of a minimum of three (usually five)
independent experiments.
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molecule. We therefore first examined the ability of hGH to
stimulate the formation of Ras-GTP in NIH-3T3 cells. hGH
stimulation of NIH-3T3 cells resulted in the rapid appearance
of the GTP-bound form of Ras, maximal at 2 min and followed
by a decline in the level of Ras-GTP such that at 30 min after
stimulation with hGH the level of Ras-GTP returned to basal
activity (Fig. 4A).
We next proceeded to determine the kinase dependence of
the hGH-stimulated conversion of Ras to the GTP-bound form.
We first examined the effect of the JAK2 kinase inhibitor
AG490 on hGH-stimulated conversion of Ras to the GTP-bound
form. AG490 treatment of NIH-3T3 cells completely prevented
hGH-stimulated activation of Ras without alteration in the
total cellular level of Ras (Fig. 4C and Fig. 4D). The Src kinase
inhibitors PP1 and PP2 used above were without effect on the
ability of hGH to stimulate the formation of GTP-bound Ras
(Fig. 4E). Concordantly forced expression of a kinase-deficient
JAK2 prevented Ras-GTP formation stimulated by hGH,
whereas kinase-inactive c-Src was without effect on hGH-stim-
ulated Ras activation (Fig. 4G). Thus, Ras activation by GH is
JAK2-dependent.
To determine whether Ras activity was required for hGH-
stimulated formation of RalA-GTP and RalB-GTP, we exam-
ined the ability of hGH to stimulate RalA-GTP and RalB-GTP
formation in the presence of forced expression of RasN17.
RasN17 forms a nonproductive complex with RasGEFs (22, 23)
and therefore inhibits endogenous Ras activity. Forced expres-
sion of RasN17 abrogated the ability of hGH to stimulate the
formation of both GTP-bound RalA and RalB (Fig. 4, K and M).
Thus hGH-stimulated formation of RalA-GTP and RalB-GTP is
Ras-dependent.
RalA Is Required for hGH-stimulated p44/42 MAP Kinase
Activity and Elk-1-mediated Transcription—p44/42 MAP ki-
nase has been demonstrated previously (15, 39) to be activated
by GH in a Ras-dependent manner. Because activation of RalA
and RalB by GH is also Ras-dependent, we reasoned that Ral
FIG. 4. HGH-stimulated formation of GTP-bound RalA and RalB is Ras-dependent. A and B, human GH stimulates the formation of
GTP-bound Ras in NIH-3T3 cells. NIH-3T3 cells were stimulated with 50 nM hGH, and the GST-linked probe (GST)-Raf1-RBD, which recognizes
the active GTP-bound form of Ras, was used to separate Ras-GTP from the inactive GDP-bound form of Ras. GTP-bound Ras visualized by Western
blot analysis as indicated (A). Total cellular Ras was also determined in total cell lysate by Western blot analysis as protein loading control (B).
C–F, AG490 but not PP1, PP2, and PP3 inhibits hGH-stimulated formation of GTP-bound Ras. NIH-3T3 cells were stimulated with hGH after
pretreatment and in the continued presence of vehicle or AG490, PP1, PP2, PP3, and GTP-bound Ras were visualized by Western blot analysis as
indicated. Total cellular Ras (D and F) was also determined in total cell lysate by Western blot analysis as protein loading control. G–J, kinase-dead
JAK2 but not kinase-dead c-Src inhibits hGH-stimulated formation of GTP-bound Ras. NIH-3T3 cells were transiently transfected with the empty
vector or an expression vector containing either kinase-dead c-Src (c-Src-KD) or kinase-dead JAK2 (K882E) and stimulated with hGH. GTP-bound
Ras (H) were visualized by Western blot analysis as indicated. Total cellular Ras (H) was also determined in total cell lysates by Western blot
analysis as protein loading control. K–O, dominant negative Ras (RasN17) inhibits hGH-stimulated formation of the GTP-bound form of RalA and
RalB in NIH-3T3 cells. NIH-3T3 cells were transiently transfected with either empty vector or the expression vector for RasN17 and stimulated
with hGH as described under “Experimental Procedures.” The GST-linked probe RLIP76-RBD was used to separate RalA-GTP and RalB-GTP from
the inactive GDP-bound form of these molecules. GTP-bound RalA (K) and RalB (M) were visualized by Western blot analysis as indicated. Total
cellular RalA (L) and RalB (N) were also determined in total cell lysates by Western blot analysis as protein loading control. The results presented
are representative of a minimum of three (usually five) independent experiments.
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may be upstream of, and influence, p44/42 MAP kinase activity
stimulated by GH. We therefore examined the effect of forced
expression of either wild type RalA or a dominant negative
form of RalA (RalA28N) on the ability of hGH to activate p44/42
MAP kinase activity. As reported previously (40), hGH stimu-
lation of NIH-3T3 cells resulted in a rapid time-dependent
increase in the activity of p44/42 MAP kinase. Thus maximal
activation of p44/42 MAP kinase activity was observed between
5 and 15 min after stimulation with hGH followed by a decline
in activity to 60 min (Fig. 5A). Forced expression of wild type
RalA slightly increased the basal activity of p44/42 MAP kinase
activity and resulted in a prolonged activation of p44/42 MAP
kinase activity in response to hGH. Thus, little or no dimuni-
tion in p44/42 MAP kinase activity was observed 30–60 min
after stimulation with hGH in comparison to the vector-trans-
fected control (Fig. 5A). Forced expression of RalA at the dif-
ferent time points was demonstrated by the appearance of RalA
at a slightly higher molecular weight (due to the presence of a
FLAG tag) than endogenous RalA on Western blot analysis for
RalA on the same whole cell lysates used for estimation of
p44/42 MAP kinase activity (Fig. 5B). Forced expression of
RalA28N resulted in decreased basal p44/42 MAP kinase ac-
tivity, significantly less activation of p44/42 MAP kinase activ-
ity after GH stimulation, and shorter duration of the hGH-
stimulated p44/42 MAP kinase activity (Fig. 5C). Similarly,
forced expression of RalA28N at the different time points was
demonstrated by the appearance of RalA28N at a slightly
higher molecular weight (due to the presence of a FLAG tag)
than endogenous RalA on Western blot analysis for RalA on the
same whole cell lysates used for estimation of p44/42 MAP
kinase activity (Fig. 5D). Thus, RalA is required for full acti-
vation of p44/42 MAP kinase activity by hGH in NIH-3T3 cells.
GH has been reported previously (13, 41) to stimulate tran-
scription via Elk-1 in a p44/42 MAP kinase-dependent manner
(13, 42). Furthermore, it has been reported that sustained
activation of p44/42 MAP kinase is required for activation of
Elk-1-mediated transcription (43). Because RalA overexpres-
sion resulted in sustained activation of GH-stimulated p44/42
MAP kinase, we examined the effect of forced expression of
RalA and a RalA dominant negative mutant (RalA28N) on the
ability of hGH to stimulate Elk-1-mediated transcription in
NIH-3T3 cells. Forced expression of RalA increased the basal
level of Elk-1-mediated transcription and dramatically in-
creased the ability of hGH to stimulate transcription via Elk-1
(Fig. 5E). Forced expression of RalA28N reduced the basal level
of Elk-1-mediated transcription and completely prevented
hGH-stimulated Elk-1-mediated transcription (Fig. 5E). Thus
RalA is required for full p44/42 MAP kinase activation by hGH
and subsequent Elk-1-mediated transcription.
hGH Activates Phospholipase D—One of the proteins pro-
posed to mediate the effects of Ral on cellular function is
phospholipase D (27, 38, 44). We therefore examined whether
hGH stimulation of NIH-3T3 cells would also result in an
increase of phospholipase D activity. For determination of the
effect of hGH on PLD activity, cells were stimulated with hGH
in the presence of 1% ethanol, and PLD activity measured by
the standard transphosphatidylation assay (27, 38, 44). hGH
stimulation of NIH-3T3 cells resulted in a rapid rise in PLD
activity, maximal at 5 min, and followed by a decline in activity
to 60 min (Fig. 6A). We also measured the effect of cellular
stimulation with hGH on PLD activity by use of the commer-
cially available amplex red phospholipase D kit. As observed in
Fig. 6, A and B, hGH stimulated an increase in PLD activity
similar to that observed by use of TLC to determine PLD
activity. Thus cellular stimulation with hGH resulted in an
increase in PLD activity.
PLD catalyzes the hydrolysis of phosphatidylcholine and
phosphatidylethanolamine to form phosphatidic acid (28, 29).
We consequently next examined the effect of hGH stimulation
of NIH-3T3 cells on PA production. Cells were serum-deprived
and concomitantly incubated with [3H]palmitic acid before
stimulation with hGH. The migration of PA in thin layer chro-
matography was identified against lipid standards, and the
appropriate spot was removed and radioactivity determined.
As is observed in Fig. 6C, hGH stimulation of NIH-3T3 cells
resulted in a rapid rise in the level of PA with peak levels of PA
observed at 5 min after stimulation. A sustained increase in the
level of PA was observed to at least 60 min after stimulation
FIG. 5. RalA is required for hGH-stimulated p44/42 MAP ki-
nase activity and Elk-1-mediated transcription. A–D, effect of
RalA and RalA dominant negative mutant (RalA28N) on hGH-stimu-
lated p44/42 MAP kinase activation. NIH-3T3 cells were transiently
transfected with the expression vectors for wild type RalA or dominant
negative RalA (RalA28N) and stimulated with hGH for the indicated
times. p44/42 MAP kinase activity was determined as described under
“Experimental Procedures.” hGH-stimulated p44/42 MAP kinase activ-
ity in the presence of transiently transfected wild type RalA or RalA28N
are presented in A and C, respectively. The level of endogenous RalA
and the transfected RalA (either RalA (B) or RalA28N (D)) in NIH-3T3
cells was detected by Western blotting for RalA (transfected RalA is
epitope-tagged and hence exhibits less electrophoretic mobility). E,
RalA is required for hGH-stimulated Elk-1-mediated transcription.
NIH-3T3 cells were transiently transfected with the expression vectors
for wild type RalA or dominant negative RalA (RalA28N) together with
pFR-Luc and pFA-Elk-1 for determination of hGH-stimulated Elk-1-
mediated transcriptional activity. Luciferase activities were deter-
mined as described under “Experimental Procedures.” Data presented
are mean  S.E. of triplicate determinations. Experiments were re-
peated a minimum of 3 (usually 5) times.
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with hGH. Thus hGH stimulates PA production in NIH-3T3
cells (Fig. 6C).
hGH Activation of PLD Is RalA-dependent—To determine
whether hGH-stimulated activation of phospholipase D is Ral-
dependent, we determined the effect of forced expression of
either wild type RalA or a dominant negative form of RalA
(RalA28N) on the ability of hGH to activate PLD. As observed
in Fig. 6D, transfection of wild type RalA cDNA did not signif-
icantly alter the basal level of PLD activity but significantly
enhanced the hGH-stimulated increase in PLD activity. Con-
versely, transfection of NIH-3T3 cells with a dominant nega-
tive form of RalA, although not altering the basal level of PLD
activity, abrogated the ability of hGH to stimulate increases in
PLD activity (Fig. 6D). Thus hGH-stimulated activation of PLD
is RalA-dependent.
PLD Activity Is Required for hGH-stimulated p44/42 MAP
Kinase Activity and Elk-1-mediated Transcription—PLD1 has
been demonstrated to exist in a complex with RalA and the
small G protein ADP-ribosylation factor-1 (ARF1) (27). Inhibi-
tion of ARF1 with the fungal metabolite BFA has been demon-
strated to prevent the activation of PLD by extracellular stim-
uli (28, 29, 46). We therefore first examined the effect of BFA on
the ability of hGH to stimulate p44/42 MAP kinase activity. As
observed in Fig. 7A, BFA in concentrations ranging from 1 to 50
g/ml effectively inhibited the activation of p44/42 MAP kinase
by hGH. To demonstrate that the inhibition of hGH-stimulated
p44/42 MAP kinase by BFA was specifically due to inhibition of
PLD-dependent PA production, we added exogenous PA at the
same time as BFA and examined p44/42 MAP kinase activity in
response to cellular stimulation with hGH. Exogenously added
PA, in the presence of 50 g of BFA which effectively prevented
p44/42 MAP kinase activation by hGH, restored hGH-stimu-
lated p44/42 MAP kinase activity (Fig. 7B). Thus BFA inhibi-
tion of hGH-stimulated p44/42 MAP kinase activity by hGH
was specifically due to inhibition of PA production.
To verify the results obtained with BFA, we therefore exam-
ined the effect of forced expression of PLD1, an enzymatically
inactive form of PLD1 (PLD1-K898R), PLD2, and an enzymat-
ically inactive form of PLD2 (PLD2-K758R) on hGH-stimulated
p44/42 MAP kinase activity. Forced expression of PLD1 in-
creased the basal level of p44/42 MAP kinase activity and also
increased hGH-stimulated p44/42 MAP kinase activity (Fig.
7C). The enzymatically inactive form of PLD1 unexpectedly
also increased basal p44/42 MAP kinase activity but prevented
any stimulation of p44/42 MAP kinase activity by hGH (Fig.
7C). Forced expression of PLD2 did not significantly alter the
basal activity of p44/42 MAP kinase but significantly enhanced
p44/42 MAP kinase activity stimulated by hGH (Fig. 7C). The
enzymatically inactive form of PLD2 did not significantly alter
basal p44/42 MAP kinase activity and prevented the hGH-
stimulated increase in p44/42 MAP kinase activity (Fig. 7C).
The forced expression of PLD1, PLD1-K898R, PLD2, and
PLD2-K758R was verified by Western blot analysis (Fig. 7D).
We next examined the effect of forced expression of PLD1, an
enzymatically inactive form of PLD1 (PLD1-K898R), PLD2,
and an enzymatically inactive form of PLD2 (PLD2-K758R) on
hGH-stimulated Elk-1-mediated transcription. Forced expres-
sion of PLD1 increased both basal and hGH-stimulated Elk-1-
mediated transcription (Fig. 7F). Similar to the result observed
with the effect of PLD1-K898R on basal p44/42 MAP kinase
activity, forced expression of this enzymatically inactive PLD1
also increased the basal level of Elk-1-mediated transcription
and prevented an hGH-stimulated increase in Elk-1-mediated
transcription. Forced expression of PLD2 did not increase the
basal level of Elk-1-mediated transcription but substantially
enhanced hGH-stimulated Elk-1-mediated transcription when
compared with the vector-transfected control. Forced expres-
sion of PLD2-K758R completely prevented hGH-stimulated
Elk-1-mediated transcription (Fig. 7G).
A RalA-PLD Pathway Is Required for hGH-stimulated Acti-
vation of Elk-1-mediated Transcription—We have demon-
strated above that forced expression of RalA dramatically en-
hanced the ability of hGH to stimulate Elk-1-mediated
transcription and that activation of PLD in response to cellular
stimulation with hGH was RalA-dependent. It was therefore
required to demonstrate that the RalA enhancement of hGH-
stimulated Elk-1-mediated transcription was PLD-dependent.
We therefore tested whether the enzymatically inactive PLD2
(PLD2-K758R) could inhibit the increase in hGH-stimulated
Elk-1-mediated transcription consequent to forced expression
of RalA. As observed above, transfection of RalA cDNA dramat-
ically enhanced both the basal and hGH-stimulated Elk-1-
mediated transcription, and PLD2-K758R prevented any hGH-
stimulated increase in Elk-1-mediated transcription. When
both RalA and PLD2-K758R were transfected together, an
increase in the basal level of Elk-1-mediated transcription was
evident as is observed for forced expression of RalA alone, but
no hGH-stimulated increase in Elk-1-mediated transcription
was observed (Fig. 8). Thus, RalA enhancement of hGH-stim-
FIG. 6. hGH activates phospholipase D and stimulates phos-
phatidic acid production. A and B, hGH activates phospholipase D
activity in NIH-3T3 cells. NIH-3T3 cells were stimulated with hGH for
the indicated times and processed for determination of PLD activity by
either the standard transphosphatidylation assay (A) or by use of the
commercially available amplex red phospholipase D kit (B). C, hGH
stimulates phosphatidic acid production. NIH-3T3 cells were serum-
deprived and concomitantly incubated with [3H]palmitic acid before
stimulation with hGH. The migration of PA in thin layer chromatogra-
phy was identified against lipid standards, and the appropriate spot
was removed and radioactivity determined. D, hGH activation of PLD is
RalA-dependent. NIH-3T3 cells were transiently transfected with the
expression vectors for wild type RalA or dominant negative RalA
(RalA28N), stimulated with hGH, and processed for PLD activity as
indicated under “Experimental Procedures.” Data presented are
mean  S.E. of triplicate determinations. Experiments were repeated a
minimum of 3 (usually 5) times.
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ulated Elk-1-mediated transcription requires the activity of at
least PLD2.
DISCUSSION
We have demonstrated here that hGH stimulation of NIH-
3T3 results in a rapid and biphasic activation of the small
Ras-like GTPases RalA and RalB. Similar biphasic activation
of Ral (30) and other small Ras-like GTPases including Ras (25,
47) and Rap1 (48) has been reported in other systems. It has
been postulated that this phenomenon is due to the differential
input dynamics of upstream signals and/or differential feed-
back from downstream effector molecules. For example, it has
been reported that biphasic activation of Ras by endothelin-1
was linked to the sequential activation of two downstream
pathways, p44/42 MAP kinase and PI 3-kinase (47). The de-
crease in Ras activity following the first peak of Ras activity
stimulated by endothelin-1 elicits a negative feedback through
p44/42 MAP kinase-dependent Sos1 phosphorylation, whereas
the second peak of Ras activation by endothelin-1 is facilitated
by persistent tyrosine phosphorylation of SHC (47). The impli-
cation of such a bipartite activation of Ral and its potential
contribution to GH signal transduction requires further
investigation.
We have demonstrated here that hGH-stimulated activation
of c-Src is independent of the activity of JAK2. This is the first
reported example that a kinase utilized by GH does not require
the activity of JAK2. Other kinases utilized by GH, such as
focal adhesion kinase, have been reported to associate with and
require the activity of JAK2 (10). We have reported previously
(9) that GH also activates another Src kinase, c-Fyn, although
the dependence of its activation on JAK2 was not investigated.
It is also likely that other members of the Src family of kinases
activated by GH, such as c-Fyn, are activated independent of
FIG. 7. PLD activity is required for hGH-stimulated p44/42
MAP kinase activity and Elk-1-mediated transcription. A and B,
brefeldin A inhibition of hGH-stimulated p44/42 MAP kinase activity is
reversed by addition of phosphatidic acid. NIH-3T3 cells were stimu-
lated with hGH after pretreatment and in the continued presence of
vehicle or brefeldin A at the indicated concentration as indicated, and
p44/42 MAP kinase activity was determined (A). Phosphatidic acid was
also added concomitantly with BFA as indicated, and p44/42 MAP
kinase activity was determined (B). Experiments were repeated a min-
imum of 3 (usually 5) times. C–E, effect of overexpression of wild type
PLD1, dominant negative PLD1 (PLD1-K898R), wild type PLD2, and
dominant negative PLD2 (PLD2-K758R) on hGH-stimulated p44/42
MAP kinase activity. NIH-3T3 cells were transiently transfected with
the expression vectors for either wild type PLD1, dominant negative
PLD1 (PLD1-K898R), wild type PLD2, and dominant negative PLD2
(PLD2-K758R), stimulated with hGH, and p44/42 MAP kinase activity
was determined (C). The expression of the transiently transfected PLDs
was demonstrated by Western blot analysis for the hemagglutinin
epitope tag (D). Densitometric evaluation of hGH-stimulated p44/42
MAP kinase activity with the transiently transfected PLDs is presented
in E. F and G, effect of overexpression of wild type PLD1, dominant
negative PLD1 (PLD1-K898R), wild type PLD2, and dominant negative
PLD2 (PLD2-K758R) on hGH-stimulated Elk-1-mediated transcrip
tional activity. NIH-3T3 cells were transiently transfected with the
expression vectors for either wild type PLD1, dominant negative PLD1
(PLD1-K898R) (F), wild type PLD2, and dominant negative PLD2
(PLD2-K758R) (G) together with pFR-Luc and pFA-Elk-1 for determi-
nation of hGH-stimulated Elk-1-mediated transcriptional activity. Lu-
ciferase activities were determined as described under “Experimental
Procedures.” Data presented are mean  S.E. of triplicate determina-
tions. Experiments were repeated a minimum of 3 (usually 5) times.
FIG. 8. A RalA-PLD pathway is required for hGH-stimulated
activation of Elk-1-mediated transcription. NIH-3T3 cells were
transiently transfected with the expression vectors for wild type RalA,
dominant negative PLD2 (PLD2-K758R), or both wild type RalA and
dominant negative PLD2 together with pFR-Luc and pFA-Elk-1 for
determination of hGH-stimulated Elk-1-mediated transcriptional activ-
ity. Luciferase activities were determined as described under “Experi-
mental Procedures.” Data presented are mean  S.E. of triplicate
determinations. Experiments were repeated a minimum of 3 (usually 5)
times.
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JAK2. The related hormone prolactin, which also utilizes JAK2
for its signal transduction, has also been demonstrated previ-
ously (6) to stimulate c-Src-independent activation of JAK2.
Other examples of JAK-independent activation of kinases by
members of the cytokine receptor superfamily includes inter-
leukin-3 activation of Src (49) and erythropoietin activation of
Lyn (50). Interestingly it has been reported (51) that angioten-
sin II stimulates an association between the N terminus of
JAK2 and the SH2 domain of c-Src which is dependent on the
activity of JAK2. Whether such an association was also re-
quired for activation of Src by angiotensin II was not demon-
strated (51). In any case such an association would allow JAK2
and c-Src to be spatially co-located and may facilitate synergis-
tic interactions where common signaling molecules are in-
volved. In this regard it is relevant to note that GH stimulates
the association of JAK2 and FAK, and FAK is one component of
a multiprotein signaling complex centered around CrkII and
also including c-Src (9). FAK has also been reported to be a Src
substrate (10). In this case, however, at least the activity of
JAK2 was not required for GH-stimulated activation of c-Src.
We cannot exclude the possibility that the JAK2 molecule
itself, and not JAK2 kinase activity, may be required for the
activation of c-Src. However, prolactin is able to activate c-Src
in the absence of the proline-rich Box1 region of the prolactin
receptor required for the activation of JAK2, and therefore
JAK2 association with the prolactin receptor is not required for
prolactin-stimulated Src activity (6). Thus, there may exist
multiple independent parallel pathways by which GH could
affect cellular function. It remains to be determined what the
contribution of JAK2-independent signaling pathways will be
to the final cellular effects of GH. Analysis of the genetic
targets of the different signaling pathways by cDNA microar-
ray may prove useful in this regard and is in progress.
We have demonstrated here that full activation of RalA and
RalB by GH requires the combined activity of both c-Src and
JAK2. It is interesting to note however that the impairment in
Ral activation by inhibition of c-Src is considerably greater
than that observed by inhibition of JAK2. This phenomenon
was observed with utilization of both pharmacological inhibi-
tors and cellular expression of the respective kinase-deficient
molecules. It is therefore apparent that formation of GTP-
bound Ral by GH is predominantly mediated by GH-stimulated
c-Src activity. The requirement for JAK2 activity for full GH-
stimulated activation of RalA and RalB is apparently due to the
exclusive JAK2-dependent activation of Ras by GH (see below).
Thus we have identified two signaling molecules (RalA and
RalB) that can be activated by GH, albeit to a lesser extent, in
the absence of JAK2 activity. Both fMet-Leu-Phe and platelet-
activating factor activation of Ral in neutrophils have also been
demonstrated to be partially dependent on c-Src (25). Further-
more, RalA has been demonstrated previously (44, 58) to me-
diate activation of PLD in v-Src-transformed cells. It is inter-
esting to note that Ral has also been demonstrated to regulate
the activity of c-Src in response to cellular stimulation by EGF
(52). It is therefore possible that Ral participates in regulating
the final “output” of the GH-stimulated multiprotein signaling
complex centered around CrkII and containing c-Src (9) in
addition to functioning in the linear pathway we have de-
scribed here. Further support for a role of c-Src in GH signal
transduction is the ability of Csk (Src-inactivating kinase) to
inhibit GH-stimulated p44/42 MAP kinase activity (53), and
this observation is likely to be mediated by the Src-Ral-PLD
pathway we have described here (also see below for discussion).
Another small GTPase, Ras, has been demonstrated previ-
ously (15, 39) to be activated by GH, and we have also observed
here that GH stimulates the rapid formation of GTP-bound Ras
in NIH-3T3 cells. Ral proteins are activated by RalGEFs which
are themselves activated by direct binding to Ras (18, 20).
Transient transfection of the dominant negative Ras mutant
RasN17 attenuated GH-stimulated formation of GTP-bound
RalA and RalB suggestive that GH activation of RalA and RalB
is also Ras-dependent. Ral has further been demonstrated to be
activated by Ras-independent pathways (22–24), and the fail-
ure of RasN17 to inhibit completely GH-stimulated formation
of RalA-GTP and RalB-GTP indicates that GH also utilizes
Ras-independent pathways to participate in Ral activation. Ral
has been reported to be activated by Rap1 (33). In addition,
both Rap1 (54) and RalA (23, 24, 33) can be activated in re-
sponse to an elevated level of intracellular calcium. It has been
reported that Src-like kinase activity is required for GH-stim-
ulated calcium influx (7, 55). As GH-stimulated Ral activation
is also Src kinase-dependent, it would be reasonable to propose
that GH-stimulated Ral activity might also be mediated via
Ca2 influx. By use of calcium channel inhibitors, we have
indeed demonstrated that GH activation of RalA and RalB is
also dependent on Ca2 influx via L-type calcium channels.2
Whether Rap1 is also involved in GH-stimulated Ral activation
requires further investigation. We have observed that GH stim-
ulation of Chinese hamster ovary cells stably transfected with
GH receptor cDNA (CHO-GHR-(1–638)) results in a potent ac-
tivation of Rap1, whereas minimal activation of Rap1 by GH is
observed in NIH-3T3 cells.3 We have also observed a similar
preferential activation of c-Jun N-terminal kinase by GH in
CHO-GHR-(1–638) cells in comparison to NIH-3T3 cells due to a
relative deficiency of CrkII (9, 40), and Rap1 activation has
been demonstrated previously (56) to be CrkII-dependent. In
any case, it remains to be determined if Rap1 will participate in
the activation of RalA or RalB in NIH-3T3 cells. Other Ras-
related molecules such as TC21 have also been demonstrated to
activate Ral (57). Further work should delineate the signaling
2 T. Zhu, L. Ling, and P. E. Lobie, unpublished data.
3 L. Ling, T. Zhu, and P. E. Lobie, manuscript in preparation.
FIG. 9. Diagrammatic summary of the mechanism of p44/42
MAP kinase activation by GH in NIH-3T3 cells. Actual demon-
strated pathways are indicated by the solid lines and a potential path-
way by the dotted line.
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molecules downstream of JAK2 and c-Src utilized by GH to
stimulate the formation of GTP-bound RalA and RalB.
It is interesting to note in this study that the overexpression
of wild type RalA resulted in an extended activation of p44/42
MAP kinase activity but did not increase the maximal level of
GH-stimulated p44/42 MAP kinase activity. An analogous sit-
uation has been described for nerve growth factor-stimulated
activation of p44/42 MAP kinase in PC12 cells (43). In that
example, Ras was required for the initial activation of p44/42
MAP kinase by nerve growth factor, and the small GTPase
Rap1 maintained the activation of p44/42 MAP kinase (43).
Similarly, the Rap1-sustained activation of p44/42 MAP kinase
by nerve growth factor was required for full activation of Elk-
1-mediated transcription (43). We also observed that overex-
pression of RalA resulted in dramatically increased Elk-1-me-
diated transcription stimulated by GH indicative that RalA is a
pivotal component in the mediation of the effects of p44/42
MAP kinase activation by GH. Analogously, the decreased GH-
stimulated activation of p44/42 MAP kinase observed upon
overexpression of the dominant negative RalA28N may simply
be due to the inability of the cell to maintain p44/42 MAP
kinase in an activated form rather than any deficit in activa-
tion. In any case, overexpression of dominant negative
RalA28N resulted in the absence of GH-stimulated Elk-1-me-
diated transcription. Thus RalA regulation of p44/42 MAP ki-
nase activity to produce sustained high level activation would
be required for the full transcriptional program initiated upon
activation of p44/42 MAP kinase by GH.
We have demonstrated here that GH stimulation of NIH-3T3
cells results in the activation of PLD and the subsequent gen-
eration of phosphatidic acid in the cells. RalA has been dem-
onstrated previously (44) to mediate activation of PLD in v-Src-
transformed cells. Thus, overexpression of RalA potentiated
PLD activation by v-Src, and dominant negative RalA inhibited
PLD activity in both v-Src- and v-Ras-transformed cells (55).
We have analogously demonstrated that hGH stimulates the
activation of RalA in both a c-Src- and Ras-dependent manner
and that the hGH-stimulated activation of PLD is indeed RalA-
dependent. The association of RalA and Arf has been demon-
strated previously (27) to be required for increased PLD activ-
ity. PLD-catalyzed hydrolysis of phospholipids results in the
generation of PA. The generation of PA by GH was demon-
strated to be essential for GH-stimulated p44/42 MAP kinase
activation as BFA (which prevents PLD activation and subse-
quent PA production by inhibiting Arf GTP-GDP exchange)
dramatically diminished GH-stimulated p44/42 MAP kinase
activation. Furthermore, the pretreatment of cells with PA
significantly reversed the inhibition of GH-stimulated p44/42
MAP kinase activation by BFA. Transfection of dominant neg-
ative mutants of PLD (PLD1-K898R or PLD2-K758R) also pre-
vented GH-stimulated p44/42 MAP kinase activation and Elk-
1-mediated transcription. It is therefore apparent that PA
serves as an effector generated as a result of PLD activation for
p44/42 MAP kinase activation by GH. It has been proposed that
PLD and its PA product mediate agonist-dependent Raf-1
translocation to the plasma membrane and the subsequent
activation of the p44/42 MAP kinase pathway (46). The recruit-
ment of Raf-1 to membranes is mediated by direct interaction
of Raf-1 with PA and is independent of association with Ras
(46, 59). It remains to be determined whether the requirement
of PA for GH-stimulated p44/42 MAP kinase activation is due
to a similar mechanism. It is possible that Ral and Raf-1 may
independently activate the p44/42 MAP kinase pathway as
both Raf and RalGDS signaling independently stimulate hTBP
promoter activity in a mitogen-activated protein kinase/extra-
cellular signal-regulated kinase kinase activation-dependent
manner (60). Other GH-stimulated direct PA-dependent cellu-
lar events remain to be determined. PA has been proposed to be
a potent activator of signaling molecules such as tyrosine ki-
nases, GTPase-activating protein, PI 4-kinase (which produces
the PLD cofactor phosphatidylinositol 4,5-bisphosphate), in ad-
dition to Raf (61). PA has further linked to Ca2 signaling (62)
and to superoxide anion production through NADPH oxidase
(63).
Alternatively, once produced, PA may be hydrolyzed by PA
phosphohydrolase to produce DAG with resultant activation of
PKC (28, 29, 61). Although PKC has been demonstrated to be
required for GH-stimulated activation of p44/42 MAP kinase in
other cellular systems (3), we have observed no PKC depend-
ence of GH-stimulated p44/42 MAP kinase activation here.4
Thus, Ral is unlikely to regulate GH-stimulated p44/42 MAP
kinase activity by DAG generation from PA and subsequent
PKC activation. PA can also be converted to lyso-PA and
arachidonic acid (AA) by the action of phospholipase A2 (28,
29). GH has been demonstrated previously (64) to activate
PLA2, and activation of PLA2 by GH increases the level of AA
and subsequent formation of AA metabolites. Inhibition of
PLA2 partially inhibits GH-stimulated p44/42 MAP kinase ac-
tivation,2 suggestive that the catalytic action of PLA2 on PA is
involved in the Ral-PLD-p44/42 MAP kinase pathway de-
scribed here.
Ral has been implicated in the control of cell proliferation
and Ras-mediated oncogenic transformation (19, 44, 57). For
example, expression of RalGEFs or activated Ral proteins can
cooperate with activation of other Ras effector cascades to
result in cellular transformation (65). Although GH stimula-
tion of NIH-3T3 cells results in a marked increase in p44/42
MAP kinase activity, there is little increase in cell number in
response to exogenous GH. Thus activation of Ras and Ral per
se will not necessarily result in mitogenesis nor oncogenic
transformation. In other cellular systems, such as the mam-
mary carcinoma cell, both autocrine and exogenously added
hGH result in p44/42 MAP kinase-dependent mitogenesis (66,
67). In this regard it is interesting that autocrine hGH produc-
tion by mammary carcinoma cells results in a dramatic in-
crease in cyclin D1 transcription (68), and Ral has been dem-
onstrated previously to regulate cyclin D1 gene transcription
through NF-B (65). Furthermore, overexpression in NIH-3T3
cells of a Ras effector mutant that activates RalGEF but not
Raf or PI 3-kinase resulted in the formation of a metastatic and
invasive phenotype (69). We have observed that autocrine pro-
duction of hGH in mammary carcinoma cells also results in an
invasive phenotype,5 and it is likely that Ral may be required
for such an effect. PLD1 has also been demonstrated to con-
tribute to cellular proliferation as transfected PLD1 results in
the oncogenic transformation of 3Y1 cells overexpressing the
EGF receptor (45).
In conclusion, we have demonstrated that GH stimulation of
NIH-3T3 cells results in JAK2-independent formation of GTP-
bound RalA and RalB with subsequent regulation of GH-stim-
ulated p44/42 MAP kinase activity through PLD. A diagram-
matic summary of this pathway is provided in Fig. 9. The
identification of JAK2-independent activation of specific sig-
naling pathways by GH will dramatically increase our under-
standing of the repertoire of signaling molecules utilized by GH
to achieve its pleiotropic cellular effects.
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